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ABSTRACT 
A number of chemical agents are reported to be antigenotoxic in 
human lymphocytes both in vitro and in vivo. Some of these are 
vitamins and enzymes, besides natural products, which act like 
antioxidants and can mop reactive oxygen species in damaged 
cells. These agents are used,as-prophylactics and as therapeutic 
agents in various types of cancers apd degenerative disease. Some 
anticancer drugs like cyclophosphamide themselves act as 
genotoxic agents and their us6 ffas been either stopped or are being 
reconsidered for therapy. Steroids too are used as therapeutic 
agents, for anti-allergic, anti-inflammatory, anti- depressant role, 
besides their specific hormone action. However, steroids have also 
been reported to be toxic under prolonged exposure. Therefore, 
their therapeutic use cannot be withdrawn and ameliorative 
strategies have to be adopted for checking these drawbacks. 
Vitamin and natural products fill this requirement. 
It is with this aim that the present study has been undertaken to 
show the antigenotoxic action of vitamins and some natural 
products in human lymphocytes exposed to genotoxic agents viz; 
cyclophosphamide and hydrocortisone, a hormone used widely for 
stress. The antigenotoxic principles are vitamins of B-complex, 
and C besides carotenoids and flavonoids used separately and in 
combination. The results points to their effective role in this 
regard. The percentage of clastogeny, sister chromatid exchange 
and cell cycle kinetics have been used as parameters for genotoxic 
damage and reduction in these parameters points to their 
antigenotoxic action. 
The design of the experiment included two genotoxic agents, viz -
hydrocortisone (50 )ig/ml) and cyclophosphamide (1 x 10" M) as 
positive control; where as DMSO (5 |ig/ml) and normal culture 
have been used as negative control. About 6ml of RPMI-1640 
culture medium containing 20% of foetal calf serum and treated 
with PHA and antibodies were taken in sterile culture vial to which 
about 0.2ml of heparinized blood was added through sterile pipette 
under laminar flow. The above chemicals were added in desired 
concentrations in one set; in the other set, antimutagens, were 
added to each viz. carotenoids, flavonoids, vitamins of B- complex 
and vitamin C, separately as increasing concentrations of each. For 
example, four concentrations of carotenoids were used viz 0.3|iM 
(Cao), 0.5 i^M (Cal), 0.6 i^M (Ca2) and 0.8 i^M (Ca3). Flavonoids 
were also used in four concentrations 15 juM (FO), 25|iM (Fl), 40 
jiM (F2) and 50 ^M (F3). The concentrations of B-Complex were 
lO i^g/ml (BO), 20 ng/ml (Bl), 40 jig/ml (B2) and 60 jig/ml (B3). 
The concentrations of vitamin C used were 50 |iM (CO), 60fiM 
(CI), 80|LiM (C2) and lOO^M (C3). The cultures were put for 
incubation for 24, 48, and 72hrs of incubation and adding 
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colchicine one and half hour before the scheduled time did 
harvesting. Cells were fixed in carnoy's fixative and kept over 
night, They were given three washing, and slides were prepared by 
flame dry method kept over night and stained in 5% Giemsa with 
6.8 phosphate buffer. The cells were observed under oil immersion 
and 300 plates were counted for noticing breaks gaps and other 
abnormalities. The experiment was repeated with metabolic 
activation by adding S9 fraction prepared from rat livei 
homogenate by Phenobarbital administration. The abnormalities 
were recorded as usual, the side being coded prior to recording in 
each case. 
The effect of Hydrocortisone on lymphocytes is clastogenic, 
raising aberrations form 2 percent to 19 percents through 54 
percent at 24 to 72h of duration. The carotenoid brings down the 
effect to 13.0 percent at 24h and 37 percent at 72h. with S9 mix, 
the clastogeny level is increased to 41% and with carotenoid it is 
brought down to 30%. The effect of carotenoid on SCE frequency 
shows similar trend, from 6.0 to 3.5 per cell. The replication index 
which is 1.78 in normal case is lowered to 1.48; carotenoid 
improve this to 1.58. Vitamin of B-complex similarly lowers 
clastogeny form 28 percent to 24 percent without S9 and with S9, 
it is brought from 41 to 34 percent. The negative control is used 3 
percent. The effect on SCE due to B-complex is reduction from 
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4.40. to 3.40 (-S9), and 7.42 to 4.80 (+S9). The replication index, 
which is 1.79 under normal condition, is lowed to 1.46. B-complex 
raises it to 1.61. All the effects are statistically significant. Vitamin 
C brings down clastogeny from 24 percent to 20 percent and from 
52 percent to 40 percent. The effects are repeated with S9 
administration 39 percent to 31.5 percent. Aberrations per cell is 
brought down from 0.27 to 0.04, the effect is significant. The level 
of SCE is brought down from 4.10 to 2.94 per cell. In case of S9 
the effect of vitamin C is to lower the value from 6.64 to 5.40. The 
effect on replication index is again pronounced, from 1.81 in 
normal, it is lowered to 1.51,and by mutagens vitamin C brings it 
to 1,65. 
The natural product flavonoids are also found effective in 
antigenotoxic action. The percentage level of aberrations is 21.5 to 
55.0 due to hydrocortisone, while normal level is 2.0 for 72h. Due 
to flavonoids, the percent aberration is brought down to 19.0 
percent. The enhanced values of S9 mix also get reduced from 42 
percent to 28.0 percent. The SCE values which are 1.54 without 
S9, get increased to 1.80, with S9 the hydrocortisone treatment 
increases it to 6.30. Flavonoids reduce these figures to 3.60 
(without S9) and to 4.00 (with S9). The flavonoids raise the RI 
from 1.46 to 1.58. 
The anticancer drug cyclophosphamide was used to induce 
genotoxic damage. The antimutagenic agents were also found 
effective against these damages. The normal level of aberrations is 
2.0 percent while the C.P induced level is 35 to 61 percent for 
different durations to 24.5 percent. The S9 activation increases 
clastogeny from 51 to 61 percent. The carotenoids reduce the level 
to 38 percent. The SCE level is highly increased form 1.6 to 7.6 
per cell; the carotenoids bring it down to 5.20 without S9 and3.60 
with S9 activation. The replication index from 1.83 of normal is 
lowered to 1.37; the carotenoids treatment keeps the level in 
between 1.61 to 1.68. 
The vitamin B-complex, on clastogeny, follow similar trend, and 
the effects are significant. Without S9 mix the control is 2.0 
percent with S9, the values are 2.0, 61.0 and 46 percent 
respectively. The sister chromatid exchange in control is 1.64, with 
C.P it is 7.0 and with B-complex the intermediate one 5.70 (-S9) 
and 6.0 (+S9). The replication indices are increased to 1.52, which 
are reduced due by C.P (1.41). 
Ascorbic acid treatment similarly shows the values to lye in 
betv^een 2.0 percent (control) and 32.0 percent ( of C.P); it.is 20.50 
(with C3). The effect is repeated after S9 treatment also. The SCE 
level also follows t he same trend, 1.50 (normal), 6.40 (C.P) and 
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4.0 (ascorbic acid). Replication index, which is 1.81 in normal, is 
brought down to 1.40 by C.P and with vitamin C the effect is 1.61. 
Flavonoids also show similar effects; from 2.5 in normal control to 
33.50 with C.P and 26.0 with flavonoids with S9 mix; the 
clastogeny values are enhanced with S9 but brought down by the 
flavonoids. The sister chromatid exchanges also are brought down 
from 6.20 to 4.20. Replication index lowered down to 1.41 due to 
C.P is raised to 1.47 by flavonoids. 
The combined action of antimutagenic agents is also effective in 
countering genotoxicity. The combinations used are carotenoids + 
B-complex, carotenoids+ Ascorbic acid, carotenoids + Flavonoids, 
Flavonoids + B-complex,. Flavonoids + Ascorbic acid and B-
complex + Ascorbic acid. All these principles were tested against 
clastogeny, sister chromatid exchange and cell cycle kinetics, both 
with and without metabolic activation. The effects produced are 
additive, not synergistic. 
Carotenoids and B-Complex reduce clastogeny from 30 percent to 
20 percent under 24h; for 72h this comes down from 67 percent to 
lower level The SCE level is also reduced from 7.82 to 5.32 in case 
of metabolic activation (+S9) and 7.44 to 5.10 without metabolic 
activation. (-S9). The replication index similarly is lower by C.P 
to 1.40 and raised by carotenoids and B-complex to 1.54, again S9 
treatment has higher values than without S9 treatment. 
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The combination of carotenoid and ascorbic acid lowers 
aberrations form 31 percent to 23 percent for 24h and from 67 
percent to 47 percent for 72h. The metabolic activation enhances 
clastogeny form 49 to 60 and the reduced levels due to carotenoids 
and ascorbic acid is 33.50 to 43.0. The SCE values are brought 
from 7.00 and 7.20 to 4.90 and 4.80. Replication indices are 
lowered by C.P to 1.38 and get increased to 1.52 by antimutagen. 
The B-complex and vitamin C combination is also more effective 
agent than when used separately. The level of clastogeny in control 
is 2 percent, which is increased to 67 percent. It is brought down to 
42.5 percent; the metabolic activation effects are also visible. The 
SCE values that are 1.44 in control and 7.40 with C.P are brought 
down to 4.74 (-S9) and 4.80 (+S9). The replication index of 1.76 
in control is reduced to 1.40 in C.P treatment and again contained 
up to 1.58 in the combined action of the principles. 
The combination of vitamin C and flavonoids result in reduction of 
aberration from 68 percent to 44 percent for 72h; the control level 
is 2 percent. The S9 activation varies from 50 to 61; for C.P it is 
reducible by 33 to 40 percent. The SCE value similarly gets 
reduced from 7.52 to 4.88 per cell. The replication index under 
nonrial condition is 1.81, for C.P it is reduced to 1.37; the 
combination of vitamin C and flavonoids raises it up to 1.60. 
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The combination of carotenoids and flavonoids reduce 
chromosomal aberrations figure from 28 percent to 20 percent 
under 24h, for 72h this is 67.0 percent to 47 percent. 
Metabolic activation is also effective; the change is from 50 
percent (-S9) to 62 percent (+S9) for C.P and 35.0 (-S9) to 44.0 
(+S9) for the carotenoids and flavonoids. The SCE value for 
normal control is 1.48; for C.P it is 7.52 and the combined effect is 
exhibited at the level of 5.20 per cell. The replication index in 
normal case is 1.75; the C.P treated value is 1.35. where as the 
combination of antimutagenic effect of carotenoids and flavonoids 
is 1.54. 
The combination of B-complex and flavonoids are also effective in 
controlling genotoxicity. The effect on clastogeny, SCE and 
replication index, all follow the same pattern and the effects are 
significantly different from that of control. The chromosomal 
aberrations under control. The chromosomal aberrations under 
control are 2.30, with C.P this value is 28.50 and the combined 
action of antimutagens is 18 percent at 24h. where as the same is 
brought from 67.5 to 43 percent at 72h. 
The metabolic activation (+S9) values are higher than that of 
without S9. The SCE counts are as low as 1.64 under control; 
increased to 7.3 for C.P and 4.86 for antimutagens in combination. 
The replication index to reach is 1.59. 
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The difference between the highest and lowest values of genotoxic 
parameters can be used to find the percent reduction in 
genotoxicity due to antimutagnes. Thus carotenoids, are most 
effective (i.e. 32%) against hydrocortisone induced toxicity while 
vitamin C finds the place for C.P (33%), the effect being equal. In 
hydrocortisone with S9, flavonoids and vitamin C have highest 
action (34%), while B-compIex has maximal action against both 
hydrocortisone and C.P. without S9 mix, vitamin C is most 
effective against C.P. 
In combination of two antimutagenic agents, carotenoids + vitamin 
C has the highest action (37.7) without S9, while B-complex and 
vitamin C has higher effect (408) with S9. For SCE, without S9 
flavonoids and vitamin C and with S9, B-complex and vitamin C 
have the highest activity. For reporting R.I, highest action is that of 
B-complex for hydrocortisone and for C.P, it is 15 percent. For 
combination, flavonoids and vitamin C has the highest action both 
without S9 and with S9 mix. The results are represented in tables 
and groups. 
The present findings can be taken as antigenotoxic action of 
carotenoids, flavonoids, vitamin B-complex and vitamin C in 
hydrocortisone and C.P exposed human lymphocytes measured by 
clastogeny, sisterchromatid exchange and replication indices. 
These can be used as therapeutic and prophylactic strategy for 
countering genotoxicity especially against anticancer drug C.P or a 
steroid hydrocortisone. These agents are widely known 
antioxidants, also acting as scavengers of free oxygen radicals 
produced by genotoxic stress. The results have been discussed 
extensively against this backdrop and future work is suggested to 
explain the molecular and biochemical basis of steroid 
genotoxicity and antigenotoxic action of these chemicals at sub 
cellular level. More screening can also be done with human 
fibroblasts and cancer cell lines to validate these findings and 
explain mechanism of action. 
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PREFACE 
Amelioration of genotoxic damage by certain chemical agents in human 
lymphocytes. 
Quite a large number of chemical agents have been found to have 
antimutagenic and countergenotoxic effects among laboratory animals 
and humans, and their reaction mechanisms have been worked out at 
cellular level. A large number of chemical mutagens find their way into 
humaii bodies, essentially through drugs and necessary constituents of 
dietary regimens, having little or no alternative left there off for their 
withdrawal. Correction of damage, if any, induced by these chemicals, 
therefore, ought to be of utmost concern as is their proper pharmacology. 
Some of the protective chemicals are vitamins, some enzymes 
(superoxide dismutase, catalase) and other modifiers of metabolic 
toxicity in cells, which usually act as scavengers of free oxygen radicals 
and other molecular reactive oxygen species. We, therefore, propose to 
evaluate the protecfive action of given chemicals in human blood 
lymphocytes in vitro in controls as well as in anticancer and steroid 
induced-damaged cells exhibiting clastogeny, restitution of chromosome, 
aneuploidy, sister chromatid exchange, altered cell cycle kinetics and 
other indicators of genotoxic damage. The peripheral blood culture 
method of healthy donors has been used assay system for amelioration of 
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the damage against using natural products like vitamins, carotenoids and 
flavonoids damage induced by anticancer drugs amd natural products. 
The methodology followed was as follows: 
(i) Mitomycin, bluomycin and retinone are well-known 
anticancer agents, long administered for inducing genotoxic 
damage in lymphocytes in peripheral blood culture. Here 
cyclophosphamide has been used as mutagen. The steroid 
tested for mutagenicity is hydrocortisone. 
(ii) Cell cycle kinetics, SCE and clastogeny have been measured 
as per standard protocol. 
(iii) Vitamin C, B-Complex, carotenoids and flavonoids have 
been administered at different dosage as antimutagenic agent 
along with the anticancer drugs and the response noted in 
place of super oxide dismutase, flavonoids and arotenoids 
has been used. 
(iv) Comparison with control cases (without antimutagenic 
agents being added) has been attempted to highlight the 
significance. 
(v) Findings have been discussed and new lights is thrown on 
the reaction norms besides suggesting the therapeutic value 
of these scavengers in controlling the adverse effects of 
anticancer drugs. 
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A number of chemical agents either natural or synthetic and their 
derivatives induce a plethora of changes in hereditary material either, 
directly or indirectly, which are generally termed as mutation. It does not 
mean either that we are swimming in a sea of mutagens or carcinogens, 
so to say, and are being bombarded ceaselessly by their uncontrolled 
number, yet we must recognize the potential that many factors from our 
environment could be cancerous or contribute to the mutagenic risk. Most 
of these chemicals have already exhibited carcinogenic and mutagenic 
properties in animal models for varieties of short terms tests (lARC 
1982; Wynder, 1982). 
The heritable nature of both the preneoplastic and the neoplastic states 
has given rise to the speculation that the pathogenesis of cancer involves 
permanent alterations in gene expression, accompanied perhaps, by 
permanent alterations in gene structure. These concepts are now clumped 
under the somatic mutation theory (Florey, 1962). Since, a large 
proportion of human cancer may arise from chemical agents, cancer 
prevention will depend to a large extent upon the recognition and possible 
elimination of environmental and endogenous exposure to carcinogenic / 
mutagenic agents (Doll and Peto, 1981) and a judicious formulation for 
prevention and, hence, control of cancers can be attempted for wider use. 
1.1 Mechanisms of Action of the Carcinogenic / Mutagenic Agents; 
A high proportion of human cancers are attributed to environmental 
agents, brought about by xenobiotics. Epidemiological evidences strongly 
suggest that there could be strong environmental factors behind the real 
occurrence of cancer. Such factors, rightly speaking, are a combination of 
all aspects of our life styles. 
Most chemical carcinogens are alkylating or acylating agents 
(electrophilic reagents) and produce such compounds following 
metabolism in the body. This means that they have electron deficient 
centre and will combine with electron rich centre within the cell. 
Reaction with DNA is the most important process in the initiation of 
mutagenesis and carcinogenesis although reaction with certain amino 
acids in proteins will also occur (Farmer, 1982). Alkylating agents are 
able to react at many sites in DNA, in particular at the nitrogen ring and 
the exocyclic oxygen atoms of the phosphate inter nucleotide linkages 
(Margison and O'Connor, 1979; Singer and Kusmierek, 1982). 
Substitution at the N-7 position of guanine in DNA is usually the major 
reaction product with alkylating carcinogens and mutagens although 
many other products such as 3- alkyl adenine, 3- alkyl guanine, 0^-alkyl 
guanine, alkyl thymidine, 3- alicyl cytosine and exocyclic N - alkyl 
guanine are also formed (Farmer, 1982). 
From Brookes and Lanley's discovery (1964) of correlation between 
carcinogenic and mutagenic potency of alkylating agents, on one side, 
their ability to bind to DNA on the other, considerable proof has now 
accumulated to show that this, intact, signifies a general biological 
principle. Miller and Miller (1977) concluded that most carcinogens and 
mutagens are electrophilic reagents or they, in majority of cases, can give 
rise to electrophilic reagents through metabolism (bioactivation) or 
through various chemical changes. 
1.2 Cytogenetic Studies for the Assessment of Mutagenicity and 
Antimutagenecity: 
Chromosomal damage indicates a biological effect on the genome, the 
implication of which for carcinogenesis and mutagenesis are still 
unknown. It is generally believed that increased rates of chromosomal 
aberration in the organism may indicate an increased cancer risk for the 
individual (Forni, 1984). 
1.3 Heritable Cytogenetic Damage: 
Human cytogenetics began in the mid 1950s with the development of 
human tissue culture technique (Hsu, 1952; Tjio and Levan, 1956; and 
Moorhead et al 1960). The improvement of this technique, which 
analyses the numeric chromosome aberration (Lejuene et al, 1963) in 
human beings, initiated a new branch of human genetics called clinical 
cytogenetics. The work done on chromosome analysis in adults, 
newborns and abortuses, permits an estimate of the load of chromosome 
mutations in man. The direct evidence of induced germ cell mutations, 
the selection of various stages of prenatal development, and the outcome 
of chemically induced mutations were experimentally examined using 
mitomycin C (Easier, 1980), and 2,3,5-triethylene iminobenzoquinone-
1,4 (Trenimon) (Easier et al, 1976). Thus around 43% of the zygotes 
showed induced chromosomal abeiTations, which provided impetus for 
further toxicological studies. 
1.4 Carotenoids: Uses and AppUcation: 
The fact that mutagenic events seem to be of critical importance in 
carcinogenecity suggests that certain human cancers might be prevented 
by identification of mutagens in the environment. However, many 
experiments are currently underway in order to detect agents, which can 
suppress cellular mutagenesis and carcinogenesis. During the past decade 
a large number of compounds that can inhibit the development of cancer 
has been identified. Many of these compounds are found to occur 
naturally in food or elsewhere in Nature. Carotenoids are widespread in 
nature, but particularly among the organisms that are exposed to light. 
Because of their extensive conjugated double bond system, carotenoids 
absorb light in the 400-500 nm region, that is, they show a yellow to 
orange colouration. They have attracted the attention of biologists and 
chemists for over two centuries. More than 600 carotenoids have thus 
far been characterized, and each of them has a variety of cis-isomers. 
Many treatises have been devoted to carotenoids of which the most 
comprehensive one is that edited by Isler (1971). Approximately 50 
carotenoids serve as precursors of vitamin A in mammals (Simpson and 
Tsou, 1986). Indeed, the conversion of carotenoids into vitamin A is of 
crucial significance in human nutrition in as much as most of the vitamin 
A obtained from the diet in less industrialized countries is derived from 
carotenoids. 
1.4.1 Biosynthesis: 
Carotenoids, which are polyisoprenoids, are synthesized in 
nature from acetyl coenzyme A via (3-hydroxyl P-methyl glutaryl 
coenzyme A, mevalonic acid and geranyl pyrophosphate. Carotenoid 
formation is induced by light and inhibited by a variety of natural and 
synthetic compounds. Much attention is now being given to the cloning 
of carotenoid gene clusters and to elucidating the mechanisms of their 
control (Armstrong et al, 1990; Misawa et al, 1990). 
1.4.2 Metabolism: 
Owing to its nutritional importance, the cleavage of (3- carotene 
into vitamin A has been extensively studied (Olson, 1988, 1989). The 
compound P-carotene is oxidatively cleaved at the 15, 15 central double 
bond to yield two molecules of retinal by a cytosolic enzyme found in 
intestinal mucosa, the liver and other tissues. In plants and in some 
microorganisms, carotenoids are excentrically cleaved to give (3-
apocarotenals, (3-ionone and other products. In mammals, excentric 
cleavage has only recently been shown (Wang et al 1991). The relative 
importance of central and excentric cleavage in the conversion of 
carotenoids into vitamin A among humans is yet not clear. The 
metabolism of other carotenoids in mammals is not yet well defined. 
Xanthophylls, however, may be biologically acylated or may form sugar 
conjugates, and a variety of epoxides and other oxidation products may 
result from interactions with various oxidants in vivo and in vitro. In a 
more physiological context, the intestinal absorption of dietary 
carotenoids depends on several factors namely, its bioavailability from 
foods, its structure, the concomitant presence of fats and oils in the diet, 
and the total amount ingested. For example a - and P- carotene from raw 
and sliced carrots are very poorly absorbed (5 - 10%). Upon cooking, its 
absorption increases to 40 - 50% in the presence of dietary fat. 
Carotenoids in oil are much better absorbed than those bound in other 
foods. As the intake of carotenoids increases, the absorption efficiency 
declines. 
After absorption, carotenoids are transported in chylomicron into the 
general circulation and then, in the steady state, in lipoproteins of plasma. 
The pattern of carotenoids in human plasma generally reflects that of the 
diet. Major plasma carotenoids are lutein, lycopene, cryptoxanthin, the (3-
carotene in plasma and in adipose tissue are closely related (Parker, 
1989). The absorption, metabolism and plasma clearance of carotenoids 
in humans is very much dependent on their structure. Thus ethyl |3-apo-
8-carotenal is absorbed very well, is not detectably metabolized and 
shows slow plasma clearance, where as |3-apo-8-carotenal is absorbed 
less well, is rapidly metabolized and its products are quickly removed 
from the circulation (Zeng et al, 1991). 
1.4.3.1. Actions and Associations: 
Carotenoids serve as antioxidants at low p02, quench singlet 
oxygen, enhance the immune response, reduce photo-induced neoplasm, 
inhibit mutagenesis, reduce tumor development in vivo, lower the cell 
transformations in vitro, prevent sister chromatid exchange and reduce 
so-called "precancerous" changes such as leukoplakia and micronuclei 
prevalence in buccal epithelia (Bendich and Olson, 1989). Carotenoids 
also reduce lipid peroxidation in low-density lipoproteins (Esterbancer et 
al, 1989), an observation of possible significance in the genesis of 
atheromas. The chronic administration of P-carotene in large doses 
possibly causing the benign condition of carotenosis is not known to 
cause toxic manifestations. 
In epidemiological studies, relating to dietary patterns with chronic 
diseases and particularly with cancer, vitamin A and its precursor 
carotenoids were quite early identified as showing a protective effect, i.e. 
tne higher the intake, the lower the risk of cancer (Ziegler, 1989, 1991). 
Most, though not all, studies showed a significant relationship between 
carotenoid intake and reduced risk of lung cancer (Ziegler, 1989, 1991). 
The P - carotene, one of the most widespread natural carotene, has been 
reported to have cancer preventive activity (Peto et al, 1981). Hasegawa 
and Nishino (1987) examined biological activities of P-carotene in vitro. 
Some studies have suggested that the P-carotene has an inhibitory effect 
on the genotoxic activity of several compounds. Raj and Katz (1985), 
using benzo[a]pyrene and mitomycinC, reported positive anticlastogenic 
activity of P-carotene in mouse bone marrow cells for induction of 
chromosome breaks. Abraham et al (1986) showed that carrot juice has 
an inhibitory effect on the induction of chromosome damage detected as 
micronuclei, induced by cyclophosphamide in mouse bone marrow cells. 
Darroudi et al (1988) reported a reduction in the frequencies of sister 
chromatid exchange in human lymphocytes. 
The mechanisms of the protective action of (3-carotene are not well 
understood. It has been suggested that P-carotene may act as an 
£:ntioxidant, functioning as an effective radical trapping agent (Burton 
and Ingold, 1984) and is remarked as efficient quencher of singlet oxygen 
(Krinsky and Deneke, 1982). The possibility that P - carotene exerts its 
antimutagenic effect by affecting the process of enzymatic activation of 
promutagens / carcinogens was also suggested by Darroudi et al (1988) 
and De Flora (1990). 
Besides p-carotene, a-carotene, lycopene, lutein and cryptoxanthine are 
detectable in the human blood and tissues. (Parker, 1989; Katrangi et 
fl/,1984; Kaplan et al, 1990). In the present study, we have investigated 
whether carotenoids act as an antimutagenic, and anticlastogenic agent 
modulating the frequency of chromosomal aberrations, sister chromatid 
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exchanges or cell cycle kinetics in different doses and durations of 
carotenoids treatment with and without the presence of (±)S9 mix in 
hydrocortisone and cyclophosphamide induced genotoxicity in vitro. 
Cyclophosphamide is well known chemotherapeutic drug, indirectly 
acting as mutagen and clastogen (Mahn and Ellenberger, 1976). 
1.5. Flavonoids: 
Flavonoids are ubiquitously distributed in vascular plants. They are 
benzo-y-pyrone derivatives and are usually responsible for the myriad 
bright colours found in plant tissues. These colors are easily changed to 
different shades and tones when the surrounding pH of the medium is 
altered (Brouillard and Cheminat, 1988). Animals cannot synthesize 
flavonoids, which enter into the animal systems through their diets. It is 
estimated that humans consume about Ig/day of flavonoids from the 
intake of foods, containing plant tissues such as vegetables, fruits, cereals, 
tea, cocoa, coffee, wine, beer, cola and peanuts (Kuhnau, 1976; 
Wollenwever and Dietz, 1981). Flavonoids are abundant in legumes; 
within plant tissues, they exist as sugar derivatives called glycosides and 
concentrations vary widely depending on stressors such as viral, bacterial, 
fungal, or heribivorous attack. These compounds undergo hydrolysis in 
the human gut, yielding aglycones. Like the lignans, these aglycones 
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meet one of the three fates; they may be excreted or absorbed from the 
gut or undergo further metabolism. The four most common flavonoids 
are formononetin, diadzein, genistein and biochanin. Products of 
flavonoid metabolism may be either excreted or absorbed. If absorbed, 
the phytoestrogens undergo conjugation in liver with glucuronic acid or 
to a lesser extent, sulfate and are excreted in urine or in the bile. 
Food polyphenols and especially flavonoids, which have long been 
thought to be nonessential for human health, may be one among such a 
group of food ingredients (Stich and Rosin, 1984; Birt and Bresnick, 
1991). Recently it has been suggested that flavonoids might be useful as 
new chemopreventive agents in human carcinogenicity (Gabor, 1988). 
Estimates for the average daily intake of flavonoids in the western diet 
varies from 50 mg to about Ig/person (Pierpoint, 1986). Quercetin and 
K.aempferol are the two most abundant flavonoids in our diet. 
1,5.1. Biological Effects: 
Since the flavonoids were generally considered to be nontoxic, 
"inert"or"semi-essential" components of diet, till recently little attention 
had been devoted to their potential nutritional, biochemical and 
physiological or pharmacological role in human health. 
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There lies well-documented experimental evidence (Birt and Bresnick, 
1991; Stich, 1991), mainly from the in vitro assays, that many flavonoids 
may activate or inhibit enzymatic processes of the liver and other 
organs. Certain flavonoids have been found to inhibit protein 
phosphorylation by protein kinases in human neutrophils and platelets. 
Protein phosphorylation is involved in the activation of these cells during 
inflammation (Wallace et al, 1990). Similarly, quercetin inhibits protein 
kinase, an enzyme involved in the transduction of growth factor signals 
to the nucleus, an effect that has been suggested as a "novel therapeutic 
target for anticancer agents" (Hoffman etal, 1988). Flavonoids have also 
been shown, by both in vitro and in vivo experiment, to inhibit platelet 
aggregation (Gryglewski et al, 1987), and to modify the activity of 
enzyme involved in arachidonic acid metabolism (Alcaraz and Ferrandiz, 
1987) thereby acting as anti-inflammatory agents (Alcazar and Jimenez, 
1988). Flavonoids inhibit the activities of hyaluronidase enzymes, as they 
are involved in a number of processes including allergic reaction 
inflammation, migration of cancer cells and malignant cell proliferation 
(Kuppusamy et al, 1990). The ability of rutin and quercetin to react with 
superoxide anion and lipid peroxyradicals as well as to form iron 
complexes that are unable to catalyze the formation of active oxygen 
radicals makes them useful for possible therapy in combating cellular 
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(damage caused by radicals, "free radical pathologies" (Afanas'ev et al, 
1989). 
Flavonoids are i<:nown to have a number of biological effects, which have 
piharmacological significance. For a long time it has been thought that 
flavonoids can maintain or restore the normal integrity of blood vessel 
walls. This is the main reason for clinical applications of flavonoids for 
treatment of decreasing capillary fragility (Havsteen, 1983). Quercetin 
and rutin can reduce the level of serum triglycerides and are 
antithrombatic (Kato. etal, 1983). 
In the present study, the antigenotoxic effects of flavonoids in terms of 
reduction in CAs, SCE frequencies and enhancement of RI, in different 
doses and durations of treatment, have been noticed either singly or in 
combination with other antimutagenic agents, and with and without the 
presence of S9 mix against hydrocortisone and cyclophasphamide induced 
damage of lymphocytes in culture. The results show a positive effect. 
As a result of the above findings there is considerable interest and effort 
in research on the therapeutic potential of flavonoids as drugs for the 
prevention and treatment of certain human diseases (Singleton 1981; 
Parkas et al, 1986). In addition, some flavonoids are used as "model" 
compounds for developing more efficient pharmacological effects. Some 
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enzymatic effects of flavonoids on cell physiology are being explored as 
novel therapeutic targets of anticancer agents. It has been also observed 
in in vitro tests, that the combination of the protein kinase inhibition 
achieved by quercetin with the activity of busulphan (an antileukaemia 
chemotherapeutic agent), acts synergistically in inhibiting the 
proliferation of human leukemia cells (Hoffman et al, 1988). 
1.6 Ascorbic Acid: 
In the mid-18^ *^  century, James Lind demonstrated that the juice of fresh 
citrus fruits cures scurvy.The active agent was the enolic form of 3-Keto-
L-gulofuranlactone and was named ascorbic acid or vitamin C which was 
later isolated in the late 1920's by Albert Syzent-Gyorgyi (1928). 
Ascorbic acid is a a-ketolactone whose empirical formula is C6H806. 
Ascorbic acid contains a double bond between a and P carbon atoms and 
an acid ionizing group. 
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Fig: Ascorbic acid and some of its metabolites. A, ascorbic acid; B, 
ascorbate anion; C, ascorbyl radical; D, dehydro ascorbic acid. 
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Thii present recommended dietary allowance of the Food and Nutrition 
Board of the United States National Academy of Sciences-National 
Research Council is 45 mg/ day for an adult. This amount is adequate to 
prevent scurvy in almost all normal adults. There is a possibility that a 
large intake could lead to better health and a greater control of disease. 
This question was raised as soon as the pure compound became freely 
available. However, administration of larger amounts of vitamin C to 
biological systems has led to discovery of genotoxic effects in several 
different test systems. 
Kenyon and Andress (1980) have studied the effects of vitamin C on the 
induction of X-linked recessive lethal mutations in Drosophila 
melanogaster. They used the base (Muller-5) test to screen X-
chromosome transmitted by wild-type males that had been fed for 8,13 or 
29 days on instant medium either supplemented or not supplemented with 
a single dose of ascorbic acid. Males reared on medium with no added 
ascorbate had 116 non-lethal and no lethal X-chromosome. However, 
males reared on medium with ascorbate had 455 non-lethal and four 
lethal X-chromosomes. When Chinese Hamster Ovary (CHO) cells were 
exposed to solutions of ascorbic acid (2-5x1 0"''M), somatic mutations 
resulted at the hypoxanthineguanine-phosphoribosyl transferase(HGPRT) 
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locus (Rosin et al 1980). In the same experiments mutant cells were 
resistant to 6-thioguanine (6-TG) and sensitive to a medium containing 
hypoxanthine, and aminopterin and thymidine. Mutants were identified 
by their ability to grow in the presence of toxic purine analogue 6-
thioguanine. Doses of ascorbate, which were mutagenic, were also toxic. 
If catalase were added to these high ascorbic acid concentrations, both 
mutagenicity and toxicity were prevented. These results suggest that 
mutagenic metabolites of ascorbate probably involve peroxide radicals. 
Catalase also reduces the chromosome and DNA damaging capacity of 
ascorbate (Stich et al, 1979). 
There is a possibility that the mutagenic and chromosome-breaking 
ability by ascorbate in mammalian cells may represent a possible health 
hazard. The potential hazard of ascorbic acid is increased by the fact that 
se^/eral transition metals [Cu'^ ^ Mn"*"^  Fe"^ ^ and Fe"^ "'] greatly enhance the 
mutagenic action of ascorbate (Stich et al, 1976; Stich et al, 1979). 
Ascorbic acid is also a potent antimutagen in various test systems. 
Shamberger et al (1979) have observed that ascorbic acid as well as 
several other antioxidants including butylated hydroxytoluene, vitamin E 
and Selenium, prevented mutagenesis caused by malonaldeyhyde, when 
several varieties of Salmonella strains were tested with the antioxidants. 
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Lee et al (1979) homogenized 7 species of raw fish commonly eaten by 
Koreans and subjected them to in vitro nitrosation under stimulated 
gas:ric condition with and without ascorbic acid after homogenization 
and then tested them with the Salmonella Ames test. Ascorbic acid in an 
amount 3 to 5 fold equimolar to the nitrate used almost completely 
blocked the formation of the mutagenic principle. 
Volatile mutagens were produced from normal human and animal faeces 
upon incubation with sodium nitrite in saline at 37°C for 48h (Rao et al, 
1981). The mutagens were detected using the Ames' Salmonella tester 
strain TA 1535 without microsomes. Sodium ascorbate and a-tocopherol 
each reduces the mutagenicity by about 30%. 
Daily doses of 1.0 g ascorbic acid were given to a group of 35 coal tar 
workers occupationally exposed to polycyclic aromatic hydrocarbons and 
benzene during the processing of coal tar (Sram et al 1983). Genetic 
analysis of peripheral blood lymphocytes revealed a significant drop in 
the frequency of aberrant cells. 
Benedict et (3/(1980) have observed that ascorbic acid at the noncytotoxic 
concentration of 1 |Lig/ml can completely inhibit the transformation of 
mouse C3H/IOT 1/2 cells, when induced by 3-methylcolenthrene (MCA) 
added daily as late as 3 weeks after a 24h exposure to MCA. Gol-Winkler 
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et al (1980) and Rosin et al (1980) have also observed that ascorbic acid 
added to the culture medium suppresses the MCA transformation 
Csl^lGT Vi cells. This indicates that ascorbate could influence cellular 
transformation at a level beyond the initiation step. Transformed cells, 
however, become resistant to the effect of ascorbate if they were initially 
sub-cultured several times without ascorbate and then were exposed to 
the vitamin. 
Large doses (100 mg/kg body weight daily for 4 months) of vitamin C 
have been found to promote the induction of sarcomas by a single 
injection of 20 mg of methylcholanthrene (Banic, 1981). Tumors were 
seen to appear earlier in a group of guinea pigs when treated with vitamin 
C after injection of methylcholanthrene. 
Fukushima et al (1983) have studied the promoting effect of sodium 
ascorbate on two- stage urinary bladder carcinogenesis in F344 rats 
initiated with N-butyle-N-(4-hydroxybutyl) nitrosamine. Administration 
of 5.0%, but not 1% of the chemical in the diet significantly increased the 
incidence and number of preneoplastic lesions, papillary or nodular 
hyperplasia, induction of papilloma as well as cancer of the urinary 
bladder. 
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1.6.1 Anti carcinogenic Effects: 
Ramirez et al (1980) have studied the direct effects of ascorbic acid and 
deiiydroascorbic acid in vitro on human lymphocyte proliferation to 
phytohaemagglutinin (PHA) and concavalin (con A) stimulation when the 
cells were exposed to physiologic and high concentrations of ascorbic and 
dehydro ascorbic acid, the cells showed more dose dependent and poor-
tritiated thymidine incorporation than the controls without the vitamin. 
Even if supra optimal concentrations were used, there was no return of 
the mitogen response, indicating that ascorbic acid did not inhibit the 
response by direct competition. Viability studies of cells in culture 
showed that concentrations of ascorbic acid and dehydro ascorbic acid 
which had inhibited the mitogenic stimulation of lymphocytes, were not 
toxic throughout the period of culture. 
The mitotic activity of the transplantable mouse tumors, sarcoma 37, 
Krebs-2 and Ehrlich carcinomas, in the ascites form, were inhibited after 
treatment with a mixture of vitamin C and Bn (Poydock et al, 1979). 
However, when the vitamins were administered alone, at the same 
dosage, they did not show any apparent effect on mitosis or cell 
morphology. 
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Ascorbic acid has been shown preferentially to inhibit cancer cells in 
tissue culture. This inhibition may be due to either a toxic effect of or an 
anti-carcinogenic effect. The compound L-ascorbic acid has been shown 
to suppress the growth of bone marrow cells from patients with acute 
non-lymphocyte leukemia (Park et al 1980). The effect of vitamin C on 
cell proliferation and DNA synthesis has been studied using two tumor 
lines, Hep and KB (Bishun et al, 1978). Increases in the ratio of dead to 
live cells and a decrease in the rate of DNA synthesis have been 
observed. 
Vitamin C prevents carcinogenesis through a variety of mechanisms. 
Vitamin C may prevent tumorigenesis through its antioxidant action. The 
antioxidant effect may be exacted through the prevention of peroxidation, 
which produces free-radical damage to various cellular components. 
Se '^eral studies have suggested that there is an increased relationship 
between vitamin C intake from fresh fruits, vegetables and salads and 
several types of cancer. Weisburger et al (1980) have suggested that the 
prevalence of gastric cancer was greater in the northern part of the world 
or mountainous regions, having relatively little everyday access to fresh 
fruits, vegetables and salads. Vitamin C also blocked experimental 
nitrosation of the Japanese Sanma fish consumed in a Japanese region 
22 
with high risic of gastric cancer and completely blocked the formation of 
mutagens in the reaction mixture. 
1.7 Vitamin B-Complex: 
In our study among the vitamins, which showed antimutagenic activity 
towards C.P induced mutagenicity, were vitamins of B complex. The 
same were tested at different dose ranges. When treated this way, 
riboflavin and cyanocobalamin were found to possess exceptional 
inhibitory ability on a molar basis. These results were in line with the 
previous experiment of Bhattacharya et al (1987), whose experiment 
showed that the inhibitory ability of these vitamins against the mutagen 
Aflatoxin B were 15 to 40 fold in excess of vitamins over the exposed 
Aflatoxin B i doses, and therefore could negate the mutagenic activity by 
50*>o, such a potential effect of these vitamins has never been reported 
earlier. 
The exact mechanism by which the vitamins of B-complex inhibit 
mutagenicity is not clearly understood. It may include events such as 
chemical quenching of enzymatically generated reactive electrophiles, 
irreversible binding with active sites of microsomal enzymes, or even a 
direct attack on the membrane-bound phospholipid or cytochrome P.450 
which are required for bioactivation of cyclophosphamide and 
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hydrocortisone. A comparison of the effect of riboflavin and retinal 
reve:als a remarkable similarity between the degree of inhibition produced 
by them on Aflatoxin B mutagenicity as observed by Bhattacharya et al, 
(1987) and on Aflatoxin B|-DNA adduct formation (Bhattacharya et al, 
1984) and metabolic activation of AFBl (Firoze et al, 1986) as observed 
earlier. It is seen that the inhibition by riboflavin is of a non-competitive 
type while that of Retinal is of a competitive type, like wise 
cyanocobalamin showed non-competitive inhibition. These results 
suggest that all these vitamins may be interacting with some component 
(s) of the microsomal enzyme system. Although riboflavin has been 
shown to have a role in chemical carcinogenesis (Miller et al, 1948), no 
report is available on the role of other components of vitamin of B-
complex. It is presumed that the capacity of riboflavin, cyanocoblamin 
and other components of vitamin B- complex to inhibit C.P and 
hydrocortisone induced mutagenicity can have a reflection on their 
ability to afford protection against generation of C.P-induced neoplasia in 
susceptible species. While riboflavin was found to be very effective 
inhibitor, its physiological derivatives, FMN and FAD, were not. On the 
other hand Wood et al (1982) observed that FMN very effectively 
antagonized the mutagenic activity of bay- region diol-epoxides of 
polycyclic aromatic hydrocarbons. 
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This antimutagenic property may also hold true for several other food 
components, both nutrient as well as non-nutrient in nature. Hence 
screening of a wide variety of dietary factors through in vitro 
mutagenicity test may help in identifying potential candidates for 
anti carcinogenic activity. 
1.8 Methadological Considerations: 
1.8,1 In vivo and in vitro evaluation: 
It is natural to study the effect of chemicals directly on person exposed to 
these chemicals or drug (Gebhart, 1982,1984). But ethical reasons 
preclude the experimental approach on evaluation of genotoxicity and 
antigenotoxicity on humans. The in vivo study is possible only in specific 
cases when individuals have already been exposed to these agents either 
as a chemotherapeutic necessity (e.g. medicines) or occupational 
inevitability (e.g. exposure to styrene, aniline, polyvinyl chloride) or for 
accidental reasons (e.g. exposure to radiation, atom bomb explosions 
etc.). The genotoxicity as well as antigenotoxicity evaluation among 
patients on therapy is difficult. Patients may be on multiple therapies so 
that effect observed might either be additive, synergistic or antagonistic 
to each other. 
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The in vivo cytogenetic evaluation also has its shortcomings. The 
cytogenetic abnormalities found in exposed persons represent the most 
drastic and obvious expression of genotoxic damage while the frequent 
and subtle genetic change like mutations are not detected. Another 
limitation is that the peripheral lymphocytes, which are cultured, are not 
in the dividing cell stage at the time the chemicals exert their influence in 
vivo. Drug which can cause primary genetic lesions in the Gl phase only, 
can manifest their detrimental effects while agents that cause genetic 
damage in the S-phase may not exhibit cytogenetic damage in 
lymphocyte cultures of individuals exposed to these agents (Gebhart, 
1982). 
These shortcomings of the in vivo evaluations can be overcome by in 
vitro treatment of peripheral blood lymphocytes in culture. The 
experimental approach can be used as well as the effect of chemicals can 
be evaluated at different concentrations and compositions on 
lymphocyte cultures of healthy individuals. This method also permits the 
evaluation of the effects at different time exposure of the test chemical 
and fate of lesions after consecutive cell divisions as well as the effect of 
test chemicals during the 01 along with S-phase of the cell cycle. These 
in vitro tests, however, have their own shortcomings because there is no 
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metabolizing system of tiie drugs and chemicals on it. On the other hand, 
lymphocytes have been known to metabolize quite a few compounds viz; 
activation of polycyclic hydrocarbon eg. benzo[a]pyrene (Whitlock et al, 
1972, Okano et al, 1979). The presence of erythrocytes in cultures is also 
known to aid in metabolizing compounds like aniline, HCl(Wilmer et al, 
1984), Sodium selenite (Ray and Altenberg, 1978) and Styrene and its 
analogues (Norppae/'a/, 1983. Norppa and Tursi, 1984.) 
In the present study two mutagens, Hydrocortisone and 
Cyclophosphamide are selected for their known property of induction of 
genotoxicity (Ahmad et al, 2000, Gebhart, 1984) whereas the test 
ch(2micals are vitamins of B-complex and C and phytoproducts like 
carotenoids and flavonoids, tested for their antigenotoxic effects on 
human lymphocytes chromosome in peripheral blood culture in vitro. All 
the test chemicals were also tested in the presence of metabolic activation 
(S9 mix). 
1.8.2 Chromosomal Aberrations: 
Chromosomal aberration assessment serves as a good indicator of the 
clastogenic effects of chemical agents (Gebhart, 1970; Buckton and 
Evans, 1982; Hsu, 1982). The aberration can be classified into chromatid 
type aberrations, which result in the latest Go or G2 phase of cell the 
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cycle, and the chromosome type aberration, which are caused by damage 
to i:he chromosome materials in the Gi or early S-Phase. The chromatid 
type aberrations include chromatid gaps, breaks and deletions. The 
chromosome type aberrations include, isochromatic gaps and breaks, 
inter-chromosomal exchanges resulting in ring chromosome and acentric 
fragments, and interstitial deletions resulting in acentric fragments (Hsu, 
1982). Inclusion of gaps in the quantitation of chromosomal damage 
following exposure to drugs and chemicals is controversial. Many 
workers ignore gaps in their analysis (Buckton and Pike, 1964; Goetz et 
al, 1975). However, others suggest that since increase in the frequency of 
gaps is related to mutagen exposure, they should be included in the 
analysis (Gebhart, 1970; Anderson and Richardson, 1981; Hsu, 1982 
Brogger, 1982). 
The distinction between chromatid gap and break is very arbitrary. A gap 
cytogenetically is distinguished form a break, depending on the length of 
the non-staining region in the chromosome. If the attenuated region is 
shorter than the width of the chromatid, it is classified as gap and if 
longer than the width, it is a break. But the problem in this classification 
is that chromosome at prometaphase are elongated with a small width of 
chromatid, while at late metaphase they are condensed with larger width. 
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Th) s results in classification of more brealcs in early metaphase and more 
gaps in late metaphase. 
Various studies have been done to look into the nature of gaps and 
breaks. A combination of studies with light microscopy, transmission 
electron microscopy and scanning electron microscopy of X-ray induced 
aberration in Vicia showed that gaps and breaks are different 
manifestations of the same events and that gaps may be only completed 
breaks (Brecher, 1977) Breaks for example, are thought to be a complete 
loss of material at the non staining region with displacement of the distal 
fragment, while gaps are thought to have chromatid bridges. Thus 
electron microscopic studies (Brecher, 1977) demonstrated that few 
breaks had chromatin material bridging the space while same gaps had 
no such chromatin bridges. Hence, the distinction between the two is 
arbitrary, at the light microscopy level and both are apparently different 
manifestations of the same phenomenon. 
Comings, (1974) offered a hypothesis regarding the nature of gap. 
According to him gaps and breaks represent the same basic lesions 
though differ in the period at which the lesion was induced. If a break in 
chromatin fiber occurs when the chromatin is fully extended e.g. Gi, S or 
early G2 phase; subsequent condensation of chromosome results in 
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chromatid break. But if the chromosome is already partially condensed 
(e.g. G2 phase) and a break occurs, a few fibers still hold the chromosome 
together, resulting in gap appearance. This has also been observed in our 
case. 
Silver staining technique of the chromatid core has also shown that the 
chromatid core is not continuous in case of chromatid gaps (Satya 
Prakash et al, 1981). Some authors suggest that gaps are produced due to 
loss of de-spiralization of both DNA as well as chromosomes following 
meicapto ethanol exposure, suggesting that gaps may occur largely from 
damage to the protein moiety of the chromatid, causing deficient folding 
of the chromatin fiber in the metaphase chromatid (Brogger, 1975). 
However, under the influence of mutagen, the frequencies of both gaps 
and breaks increase. It has been suggested by many authors that gaps are 
indicative of toxic phenomena from genetic point of view and the 
aberrations could be useful sensitive indicators of chemically induced 
genetic damage (Anderson and Richardson, 1981), Gebhart, 1977,1982, 
1984; Goetz et al, 1975: Dipaolo and Popesen 1976; Hansteen et al, 
1984; Hsu, 1982). 
Any damage altering the normal morphology of a chromosome (be it due 
to damage to DNA and chromatin or the packing proteins of 
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chromosomes) could interfere with normal functioning of the 
chromosome causing genotoxicity. Therefore gaps were also included in 
the present study. 
1,8.3 Sister Chromatid Exchanges: 
Sister chromatid exchange (SCE) represents, the interchange of 
DNA strands between sister chromatid at apparently homologous loci. 
SCEs were first demonstrated by Taylor,(1958) through autoradiographic 
technique using tritium labeled thymidine. The detection of SCEs 
become simple and more precise with the incorporation of 
Bromodeoxyuridine (BrdU) into the DNA by culturing cells for two cell 
cycles to give a unifilary substituted and one bifilary substituted 
chromatid in a chromosome (Latt, 1973). Subsequent differential staining 
of these chromatid were obtained by fluorescent dyes (Latt, 1981) or 
fluorescent plus Giemsa stain (Perry and Wolf, 1974). 
The frequency of SCEs has been found to be greatly increased on 
exposure to mutagenic agents. Therefore, SCEs are considered to be 
sensitive indicators of DNA damage (Latt, 1974; Perry and Evans, 1975; 
Cmmoetal, l978Gebhart, 1981,1982,1984). 
A positive correlation between the frequencies of chromosome 
aberrations and SCEs has been found with most of the known mutagenic 
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chemicals (Latt, 1974). However, some mutagenic agents cause an 
increase only in aberration frequency and not in SCEs, e.g. X-rays (Perry 
and Evans, 1975), certain anti tubercular drugs in combination in vivo 
(Madhuri er a/, 1983). On the other hand there are other mutagenic 
chemicals that induce only SCEs but do not cause chromosome 
aberrations e.g. aniline (Abe and Sasaki, 1977; Ishidate and Odashima, 
1977). 
Thus SCEs and chromosome aberrations are two different end points 
depicting cytogenetic damage due to mutagenic action and their 
amelioration when treated with antimutagenic test chemicals. The 
mechanism of these end points is probably different. One system cannot 
replace the other. Therefore both the endpoint should be scored to assess 
the genetic damage and their amelioration caused by drugs and chemical 
1.8.4 Cell Growth Kinetics: 
Cell cycle kinetics analysis is based on the differential staining technique 
of sister chromatids. Scoring cell preparation at Mi, M2, and M3 
(metaphase l'^ ', 2"^ * and 3'^ '' replication cycle) is a sensitive method for 
detecting delay or stimulation in human lymphocyte cultures (Tice et al, 
1976; Crossen and Morgan, 1977; Morimoto and Wolff, 1980). 
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The rate at which mitosis occurs is measured by the mitotic index. The 
index gives an idea about the stimulation of lymphocytes for division and 
hence the mitotic activity in culture (Mellarango and Smith, 1984; Sinha 
et al, 1984). Any change in the mitotic index following drug exposure 
when compared to concurrent control, provides information on mitotic 
stimulative or mitotic depressive activity of the drugs and chemicals. 
Treatments resuhing in SCE formation have been found to induce cell 
cycle delay (Morimoto, 1983;Craig-Holmes and Shaw, 1976). However, 
the relationship between the proliferation rates as measured by cell 
growth kinetics and the induction of SCEs is controversial. Santessen et 
al (1979) found that SCE levels in B-lymphocytes (early proliferating 
cells) were significantly lower than those in T-lymphocytes from the 
same individual. Snope and Rary (1979) and Block et al (1982) also 
found a lower SCE frequency in the more rapidly dividing cell 
populations. Lindblad and Lambert (1981) found that though the 
percentage of B and T lymphocytes did not correlate with SCE frequency, 
significantly higher SCE rate was presented in slowly proliferating 
cultures. Becher e/ a/ (1981) however, found low SCE and longer cell 
cycle in leukemia cells while Heidemann et al (1983) found increased 
SCE rate and shortened cell cycle time in trisomic cells of a Down 
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syndrome mosaic. Many other workers however failed to find any 
relationship between SCE rate and cell cycle kinetics. For example, in 
second generation metaphases collected from different culture times 
(Seek and Obe, 1979). Moritomo and Wolff (1980) and Morgan and 
Crossen (1981) found no significant differences in SCE frequency. 
Giulotto et al (1980) also concluded that the incidence of SCE appeared 
to be independent of the proliferating properties of cultured lymphocytes, 
such as length of cell cycle, fast or delayed response to PHA and number 
of divisions performed in vitro. Lamberti et al (1983) set up repeated 
cultures in three tissue culture media and found a great variability in 
proliferation kinetics between tissue culture media and between donors. 
Speit et al (1986) studied the SCEs frequency and proliferation of 
cultures in repeated human lymphocyte cultures. 
MATERIALS 
AND 
METHODS 
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The in vitro evaluation of the antimutagenic and anticlastogenic 
potentials of vitamins of B-complex, and vitamin C, of carotenoids and 
flavonoids were attempted against genotoxicity induced by 
cyclophosphamide and hydrocortisone, and test were conducted on the 
blood lymphocytes obtained from the healthy volunteers. All volunteers 
were free from any known exposure to drugs, alcohol or irradiations. 
Each test chemical was tested on the lymphocytes utilizing chromosomal 
aberrations, sister chromatid exchange (SCE) and cell growth kinetics 
assays in the absence as well as in the presence of exogenous metabolic 
activation. 
2.1 Description Of Test Chemicals: 
In the present investigation, cyclophasphamide and hydrocortisone were 
taken as known mutagens while vitamins of B-complex and C, 
carotenoids and flavonoids were investigated as antimutagens. The 
properties of theses chemicals are described below. 
2.1.1 A Mutagens; 
1 - Cyclophosphamide (CP): Cyclophosphamide (endoxan) is the most 
versatile therapeutic drug, which possesses the broadest spectrum, anti 
tumor activity of all alkylating agents (Brock, 1967). It is well known to 
hiave strong mutagenic effects, which have been proved, many times on 
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different cells. Cyclophosphamide acts by forming DNA cross-links by 
the reaction of chloroethyl moieties of CP with adjacent nucleotide bases. 
Due to its potent mutagenic and clastogenic nature, it is widely used as a 
known mutagen in in vitro assays. 
P — N 
CH 
CH 
2 - Hydrocortisone (C21H30O5; Mol- wt-362-47). 
Woodward and co-workers reported first total synthesis of 
cortisone in 1951. The basic structure is a complex 
cyclopentanophenanthrene ring with various functional groups. 
Cholesterol is converted through pregnenolone to progesterone. From 
here the corticosteroids separate out. Cortisone is converted in the body to 
the more active substance hydrocortisone. It is one of the potent anti-
irflammatory agent and also recently known to be potent mutagenic as 
well as clastogenic agent in the cells. 
Properties: -White, odourless, crystalline powder, sensitive to light, bitter 
taste m.p- 212-220 °C with some decomposition. 
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CH20H 
2.1.2 B - Antimutagens: 
Vitamins ofB-complex. 
The B vitamins essential for human nutrition are. 
A- Thiamin (Vitamin Bi). 
B- Riboflavin (Vitamin B2). 
C- Niacin (nicotinic acid, Vitamin B3). 
D- pantothenic acid (Vitamin B5). 
E- pyridoxine (Vitamin B6). 
F- Biotin 
G- Cynocobalamin (Vitamin B12). 
H - Folic acid (Pteroyl glutamic acid) 
Because of their water solubility, excess of these vitamins are excreted in 
urine and so rarely accumulate in toxic concentrations. 
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Thiamin: 
Thiamin consists of a substituted pyrimidine joined by 
methylene-bridge to substituted thiazole 
N 
C C-H 
H 
C _CH2 —N+ 
C C-CH2-CH2-OH 
CH3 
Riboflavin: 
Riboflavin consists of a lieterocyctic isoalloxazine ring to the 
sugar alcohol, ribitol. It is a coloured, fluorescent pigment that is 
relatively heat stable but decomposes in the presence of visible light. 
CH20H 
H-C -OH 
H - C - OH 
H~C "OH 
H~C~H 
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' Niacin: 
Niacin is the generic name for nicotinic acid and nicotinamide, 
either of which may act, as a source of the vitamin in the diet Nicotinic 
acid is a monocarboxylic acid derivation of pyridine. 
0 
-C-NH2 
• Pantothenic Acid: 
Pantothenic acid is formed by combination of pantonic acid and (3-
alanine. 
Pantothenic acid is phospharylated by ATP to form 4-
phosphopantothenate. Addition of cysteine and removal of its carboxyl 
group results in the net addition of thioethanolamine, generating 4 -
phosphopantetheine, the prosthetic group of both Co A and ACP. The 
thiol group acts as a carrier of cycloradicals in both Co A and ACP. 
O H3C OH 0 H O H 
II I II I II I 
O-P-O-CH2-C-CH-C-N-CH2-CH2-C-N 
O- H3C CH2 
CH2 
I 
Pantothenic acid. SH 
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{-'- Vitamin-Bf^  
Vitamin 65 consists of tiiree closely related pyridine 
derivatives, pyridoxine, pyridoxal, and pyridoxamine, and their 
corresponding phosphate. Of these, pyridoxine, pyridoxal phosphate 
and pyridoxamine phosphate are the main representatives of the 
vitamins in the diet. All three have equal vitamin activity, as they can 
be interconverted in the body. 
HO 
H , C -
CH2OH 
o 
r - H 
- CH2 - 0 - P - OH 
0 -
N 
Pyridoxal phosphate 
HO rCHjOH 
3 5 
2 6 
H,C N 
H 
Pyridoxine 
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Biotin: 
Biotin is an imidazole derivative, widely distributed in natural foods as a 
large portion of the human diet. Requirement for biotin is met by 
synthesis from intestinal bacteria, biotin deficiency is caused not by 
simple dietary deficiency but by defect in its utilization. 
H - N 
H2C 
N - H 
CH - (CH2) 4 COOH 
Vitamin B^: 
Vitamin B12 (cobalamine) has a complex ring structure (corrin 
ring), similar to a porphyrin ring, to which is added a cobalt ion at its 
centre. Microorganisms exclusively synthesize the vitamin. Thus, it is 
absent from plants unless they are contaminated by microorganisms but is 
conserved in animals in the liver, where it is found as methylcobalamin, 
gdenosylcobalamin and hydroxocobalamin. Liver is therefore a good 
source of the vitamin, as is yeast. The commercial preparation is 
cyanocobalamin. 
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Folic Acid: 
Folic acid or folate, consists of the base pteridine attached to one 
molecule each of P-aminobenzoic acid (PABA) and glutamic acid. 
Animals are not capable of synthesizing PABA or of the attaching 
glutamate to pteroic acid and, therefore, require folate in their diet; yeast, 
liver and leafy green vegetables are major sources. In plants, folic acid is 
present as a polyglutamate conjugate consisting of y-linked polypeptide 
chain of seven glutamate residues. In the liver, major folate is a 
pentaglutamyl conjugate. 
N 
CH2 
3H NH 
coo-
:H2 
:H2 
t-N-C-H 
COOH 
PABA Glutamic acid 
Folic Acid 
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4. Vitamin C (Ascorbic Acid); 
The structure of ascorbic acid is reminiscent of glucose, from which 
it is derived in the majority of mammals. However in primates, including 
humans and a number of other animals e.g. birds, pigs, fishes and 
invertebrates, the absence of the enzyme L-gulonolactone oxidase 
prevents this synthesis. When ascorbic acid acts as a donor of reducing 
equivalents, it is oxidized to dehydro ascorbic acid which itself cannot act 
as source of the vitamin. Ascorbic acid is a reducing agent with a 
hydrogen potential of +0.08V, making it capable of reducing such 
compounds as molecular oxygen, nitrate and cytochromes a and c. The 
mechanism of action of ascorbic acid in many of its activities is far from 
clear, but the ascorbic acid may act as a general water soluble antioxidant 
e.g. in reducing oxidized tocopherol in membranes and may inhibit the 
formation of nitrosamines during digestion. 
0 = C 
O H - C 
O H - C 
H - C 
O H - C 
H 
H 0 
- H 
0 = C 
C-OH 
II 
- • C - O H 0 
H - C 
H O - C - H 
CH2OH CH2OH 
Gulonolactone. Ascorbic acid. 
2H 
0 = C 
c = o 
C = 0 0 
H - C 
H O - C - H 
CH2OH 
Dehydroascorbic acid. 
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5 - Carotenoids: 
Carotenoids are primarily symmetrical C-40 polyisoprenoid structures 
with extensive conjugated double bond system. Although widely 
distributed in nature, they are synthesized in photosynthetic 
microorganisms and plants, but not in animals. Hydrocarbon carotenoids 
are metabolized to a host of products; such as retinal; abscisin and 
trisporic acid, show pronounced biological activity. Carotenoids function 
as protective agents against light induced cell death in microorganisms 
and in absence of the dietary intake of pre formed vitamin A. Vitamin A 
is a major product of approximately 50 out of the roughly 600 
characterized natural carotenoids. 
All trans-P-carotene is generally considered as the reference compound 
(Df its class. Many variations of this structure occur in nature, including 
those of longer C-50 and shorter e.g. the (3-apocarotenals, abscisin and 
trisporic acid compounds and conjugated derivatives. The biological 
activity of these compounds reside in their long conjugated double bond 
system, which confers the properties of light absorption, singlet 
oxygen quenching, and antioxidant action. 
44 
a - Carotene. 
P - Carotene 
6 - Flavonoids: 
Flavonoids are ubiquitously distributed in vascular plants. They 
are benzo y-pyrene derivatives and are usually responsible for the myriad 
bright colors found in plant tissues. Animals cannot synthesizne 
llavonoids, which enter into the animal system through their diets. 
Flavonoids possess a phenolic structure, which is a feature shared by the 
commonly known natural a-tocopheral and synthetic butylated 
hydroxyanisale (BHA) and butylated hydroxytoluene (BHT). Flavonoids 
have been reported to act as antioxidants in both nonaquous lipid and 
aqueous lipid systems. Since flavonoids are natural antioxidants, they 
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play a role in preserving biologically beneficial compounds in foods, as 
well as scavenging electrophilic species and oxygen free radicals formed 
during metabolic process in humans. Apples, prunes, citrus fruits, 
cabbages, lettuce and potatoes are only a few examples of fruits and 
vegetables in which isoflavonoids are found in substantial amounts 
(lARC, 1983). Within plant tissues, isoflavones exist as sugar derivatives 
called glycosides, their concentrations vary widely. These compounds 
undergo hydrolysis in the human gut, yielding aglycones. The four most 
common isoflavones are formononatin, daidzein, genistein and biochanin 
A. Biochanin A is metabolized to P-ethyl phenol. Formononatin may be 
metabolized to daidzein, which is further metabolized to equoal. Product 
of isoflavone metabolism may be excreted or absorbed. If absorbed the 
j^hytoestrogens undergo conjugation in the liver with glucuronic acid and 
are excreted in the urine or in the bile. Some intestinal bacteria produce 
(^glucuronidases, enzyme that can deconjugate metabolites when they 
pass through the intestine setting the stage for their recirculation 
through the body. 
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OH 0 
GENISTEIN DAIDZEIN 
EQUOL 
OH 
FLAVONOIDS. 
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'ompounds Structure 
Ring A RingC RingB 
R5 R7 2' 3' 4' 5' 
Rutin OH OH 0-rutinose H O H O H H 
Quercetin OH OH 
Morin OH OH 
Myricentin OH OH 
Kaempferol OH OH 
OH 
OH 
OH 
OH 
H OH OH H 
OH H OH H 
H OH OH OH 
H OHOHH 
2.1.3 Selection of Control Chemicals: 
(a) Normal control: 
Double distilled water was used as normal control. 
(b) Negative Control (Dimethyl sulfoxide, DMSO) 
The steroids and some phytoproducts are not soluble in water. Therefore, 
the organic compound dimethyl sulfoxide (DMSO) is being successfully 
employed as a solvent control. It has been reported to be nontoxic to 
animals and human (Preston, 1987). This negative control provides the 
baseline from which the data were compared for significant effects. 
H.C 
S = 0 
H,C 
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2.2. Short Term Cytogenetic Test: 
It has now become feasible with the use of cytogenetic methods to detect 
mutagenicity of chemicals at biologically significant levels and thus help 
in considering the complexity of human exposure patterns, with their 
various interacting factors and modifying responses. 
Some of the recommended methods for the in vitro cytogenetic tests are 
structural chromosome aberrations, sister chromatid exchange (SCE), 
micronuclei and cell cycle kinetics. 
Induced chromosome aberrations in human lymphocytes were well 
developed by mid 1970s (Evans and 0'Riordan,1987). Recommended 
methodology, classification and scoring of structural aberrations and 
statistical methods have already been described (Evans, 1982, Forni, 
1979). Chromosome abeiTations consist of breakage and rearrangement 
of chromosome visualized in the metaphase plate. Chromosome 
aberrations are most sensitive to agents that can directly break DNA 
duplex. However since most chemical mutagens that cause chromatid 
type damage, are 'S' phase dependent, and the highest yield of aberration 
is likely to be seen in the first division of the metaphases (table, 1). 
Sister chromatid exchanges (SCEs) involve breakage of double stranded 
DNA in both chromatids followed by an exchange of whole DNA 
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duplexes. The SCEs, like chromosome aberrations, induced by S-
dependent agents, are formed by unrepaired tensions that are present 
when the cell passes through S-phase and the chromosome replicates. 
This is the most sensitive method to detect the mutagenic property of the 
chemical and determine which of the metabolites of a premutagenic and 
precarcinogenic agent might be the most likely ones to interact with DNA 
and cause its effect (Perry and Evans, 1975; Latt et al, 1981). 
Parameters 
Typical lesions. 
Types of chromosome 
aberration induced 
Induction of SCEs. 
Relationship to 
Repair in PL 
Ionizing radiations 
DNA double Strand 
breaks 
Go, Gi: chromosome 
type 
S; chromosome type. 
G2; chromatid type 
Ineffective as SCE 
inducer. 
Lesion repaired or 
misrepaired 
immediately 
aberrations produced 
Mutagenic 
chemicals 
Base alkylation, 
DNA 
Cross links, 
interaction 
Mostly chromatid 
type 
Effective SCE 
Inducer. 
Misrepair can be 
expressed in vitro 
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2.3 Assay System Used: 
Most of the cytogenetic studies being carried out involve the examination 
of metaphase chromosomes. The evaluation of chromosomal damage at 
metaphase helps to study a greater number of dividing figures and hence 
gives more precise and detailed picture of the clastogenic agent than that 
at the anaphase or telophase stage. Human peripheral blood lymphocytes 
being extremely sensitive indicators of the in vivo and in vitro assay 
system, the measure of induced chromosomal changes (numerical and 
structural) were utilized for investigation of the genotoxic as well as 
antigenotoxic potentiality of test chemicals. The parameters studied 
included chromosomal aberrations (CA), sister chromatid exchange 
(SCEs) and cell growth kinetics both in the presence and in the absence 
of exogenous metabolic activation. 
2.3.1 Preparation of Sg Liver/ Microsome Fraction; 
The S9 liver/ microsome fraction, so to say, formed the 
otogenous metabolic activation system utilized for the present 
investigation and was prepared as follows. 
Induction of rat liver enzyme: 
For preparing S9 fraction, the standard procedures as recommended 
by Ames et al (1973) and Maron and Ames (1983) were followed. Swiss 
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albino healthy rats (Wister strain, obtained from disease free small 
Animal house HAU, Hisar, India) each weighing about 200 g were given 
0.1% (Img/ml) of Phenobarbital in drinking water for 1 week for the 
induction of liver enzymatic activities. 
Removal of livers from the rats: 
The rats were sacrificed through cervical dislocation. In order to 
ensure the sterility of S9 preparation, the livers were removed aseptically 
using sterile surgical tools in laminar flow cabinet. Care was taken not to 
cut across the oesophagus or the intestine, which could other wise cause, 
the contamination of liver homogenate. The removed livers were 
immediately placed in chilled 0.15 M KCl. 
Preparation of liver homogenate fraction S^mix: 
The whole procedure was carried out at 0- 4C*^  using sterilized 
solutions and glassware, which had been cooled. The livers were washed 
in fresh chilled KCl several times so as to remove the traces of 
hemoglobin, which inhibits enzyme activity. The washed liver were 
transferred to a beaker containing three volumes of 0.15 M KCl (3 ml/g 
wet liver) and after mincing with sterile scissors, these were homogenized 
within a tissue homogenizer. The homogenate was centrifuged in a 
refrigeration centrifuge for 10 min at 9000 rpm. The supernatant (S9 
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fraction) was decanted and saved in 1ml aliquots in polypropylene 
storage vials and stored in liquid nitrogen till further use. 
Preparation of Sq mix; 
The Sg mix from S9 fraction was prepared fresh every time for use 
in the culture. It contained 0.04 ml/mi of S9 fraction, 8 \M NADP, 100 
(.iM Na2HP04 and Na2HP04 of buffer with 7.4 pH. About 0.8 ml of S9 
mix was added every time along with the test chemicals in the cultures. 
2.4 A- In Vitro Assay Of Chromosomal Aberrations: 
2.4.1. Preparation of culture media: 
Tissue culture medium RPMI-1640 (Flow Laboratories) with L-
glutamine and Hepes buffer without NaHCOs was prepared always in 
advance and stored at 4C° ,but the storage period never lasted longer than 
a week. About 1.574 g of medium was dissolved in 100 ml of triple 
distilled water by gentle shaking. Antibiotics, penicillin (100 lU/ml) and 
streptomycin (100 lU/ml) (Hoechst) were also added and the pH was 
adjusted from 6.8-7.2 with N/10 NaHCOs and HCl. The medium was 
then filtered, sterilized in the negative pressure millipore filtration 
assembly by using 0.45 juM millipore filters. The filtered medium was 
then stored in sterilized tightly capped glass bottles. 
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2.4.2 Collection of blood sample; 
l^eripheral blood from the healthy donors was taken fresh every time 
through veinal puncture under a septic conditions using disposable needle 
(21 gauge) and disposable syringes (Steriware). Heparin (500 lU/ml; 
Micro lab) was used as anticoagulant. The tightly capped glass vials were 
gently mixed and stored at 4C^ for half an hour to separate red blood cells 
(RBC) from plasma. 
2.4.3 Setting of the cultures: 
Lymphocyte culture was carried out by adding 0.8 ml of plasma 
containing white blood cells (WBCs) in 4.5 ml of culture medium 
supplelnented with 0.1 ml phytohaemagglutinin-P (PHA-P, Micro Lab) 
and 15% fetal calf serum (Gibco). The culture vials were then tightly 
c£ipped to avoid CO2 loss and after gently mixing their contents, these 
were incubated at 37C° in dark for 72 hours. Colchicine (0.20 p-g/ml; 
Micro lab) was added 2/4 hours prior to harvesting to arrest the cells at 
metaphase stage. 
2.4.4 Harvesting of the cultures: 
After the expiry of 72 hours, the cultures were taken out from the 
inc;ubator and their contents after gentle shaking were transferred to a 
centrifuge tube, the cells were spun down by centrifugation (10 min, 1200 
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q)m) and the button of cells saved by discarding the supernatant. 
Hypotonic treatment (0.075 M KCi) was carried out for 10-12 minutes at 
37°C and the cells were recollected by centrifugation. The cell pellet was 
suspended in 5 ml freshly prepared chilled fixative (3:1; methanol:acetic 
acid), which was added drop by drop with a Pasteur pipette while 
continuously shaking the pellet so as to avoid formation of clots. In order 
to ensure the proper fixation, the cells were kept suspended in the fixative 
for a minimum period of one hour but preferably overnight. Two or three 
changes with fresh fixative were given before preparing the slides. 
2.4.5 Slide preparation and staining: 
After giving final washing in the fixative, the cells were resuspended in 
0.2 ml of fresh fixative. Two to three drops of this cell suspension were 
dropped on clean, grease free, pre-chilled wet microscopic slides, which 
were then air-dried. 
One-day-old slides were stained in Giemsa (sigma) for 15 minutes and 
rinsed in 95% alcohol and finally in absolute alcohol for proper 
differentiation after air-drying, these slides were dipped in xylene for 5 
minutes before mounting in depex (BDH). 
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2.4.6. Analysis of the cells: 
[n order to avoid the bias in scoring of tlie chromosomal anomalies, 
iDefore and after treatment of different test chemicals, all slides were 
coded prior to scoring. A total of 300 well spread metaphase were 
analyzed for each concentration of the test chemicals and for each time 
duration to analyze various chromosome and chromatid type aberrations; 
the following method as described by Evans (1984) was followed. 
Chromatid type aberrations: 
Chromatid gap (g) 
Chromatid break (b) 
Chromatid deletion (d) 
Chromatid fragment (f) 
Minute (m) 
- The chromatid lesion appears as non-
staining region on the chromatid with its 
width being less than that of a chromatid 
arm. 
- The aligned or non-aligned broken ends 
of the chromatid with its size larger than 
the width of the chromatid. 
- A deleted portion at the terminal end of 
the chromatid. 
- Free displaced chromatid piece seen 
either in association or without 
association with the parent chromatid. 
- Single, unpaired dot like intercalary 
fragment. 
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Chromosome - type aberrations 
Chromosome gaps (ig) - The gaps involving both the chromatid, 
isochromatid; gaped arms at the same 
location. 
Chromosome breaks (ib) - The break in both the chromatid at 
almost the same location. 
Chromosome breaks (ib) ~ The break in both the chromatid at 
almost the same location. 
Acentric fragments (if) Two parallel chromatids without an 
evident centromere. 
Ring (r) - The chromosome arms joined to form 
circle with or without centromere. 
Chromosome minute (im) - A pair of dot like fragments, smaller 
Dicentric (dc) 
than the size of fragments. 
- Chromosome with two centromeres 
formed by the union of two 
chromosomes. 
Exchanges(ex) A symmetrical interchanges involving 
two chromosomes. 
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Multiple anomalies 
Polyploidy (p) 
Endoreduplication (end) 
Cell with multiple 
anomalies (cma) 
Pulverization (pu) 
An increase in the chromosome number 
in excess of diploid set or in multiple of 
the haploid set or in multiple of the 
haploid (N) number. 
The chromosome reduplication 
occurring in the absence of sister 
chromatid sepration. 
The cells with 10 or > 10 aberrations 
anomalies 
The extremes fragmentation of the 
chromatid material. 
2.5 Sister Chromatid Exchange (SCE) Analysis: 
2,,5.1.Mechanism of sister chromatid exchange (SCE) detection. 
Sister chromatid exchange is a sensitive, rapid and objective method of 
observing reciprocal exchange between sister chromatid. This method 
depends upon the phenomenon of 5-bromo-2-deoxyuridine (BrdU) 
incorporation into DNA in place of thymidine. After two rounds of cell 
division, the chromatids are labeled with BrdU and consequently these 
stain differentially with Hoechst stain. The BrdU incorporation quenches 
the fluorescence of 33258 Hoechst. Therefore, the light energy is 
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absorbed but not emitted by such dyes, which results in the reduced 
staining of chromatid with Giemsa (Latt and Wohilel, 1975; Latt, 1976). 
2.5.2 Labeling of chromosomes with BrdU; 
Sister chromatid exchange analysis was carried out following the 
standard procedure of Latt et al (1981) with suitable modifications. The 
cells in the cultures were exposed to nucleoside, BrdU (Sigma) after 24 
hours of culture initiation at the final concentration of 2|ig/ml. The 
culture vials were tightly capped and covered with tin foil to avoid light 
exposure and incubated at 37C° for another 48 hours in dark. 
2.5.3 Slide preparation and staining: 
i^ ifter IVi hour of colchicine treatment, the cultures were harvested and 
processed following the same procedure as described for the 
chromosomal aberration analysis. 
For the differential staining of SCEs the methods of Perry and Wolff 
(1974) and Latt et al {\9%\) with slight modifications were followed. 
One-day-old slides were dipped in 0.5 |dg/ml of 33258 Hoechst stain 
(Sigma) dissolved in double disfilled water in horizontal coplin jar. The 
slides were then put in flat glass dish with the layer of cells facing 
upwards. These were covered by thick layer (2-3 cm) of phosphate buffer 
(p" 6.8) and exposed to UV lamp (15 w, 254 nm. Philips) from a distance 
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of 10-15 cm for 30-45 minutes. The slides were taken out from the 
buffer, washed twice in double distilled water and air-dried. These were 
then incubated in 2xSSC (0.3 M NaCl, 0.03 M sodium citrate, p" 7.0) at 
65C° in water bath for 90 minutes using vertical coplin jars. The slides 
were taken out and rinsed in distilled water. The air-dried slides were 
ihen stained in Giemsa for 20 minutes and rinsed in 90% alcohol 
followed by rinsing in absolute alcohol. The dried slides were dipped in 
xylene for 5 minutes and mounted in Depex (BDH). 
2',.5.4 Analysis of the cells: 
All slides were coded prior to scanning so as to avoid any 
bias. Around 100 second division metaphase (50 metaphases/donor) with 
differentially stained chromatids were scored for each test chemicals 
treatment in absence of S9 and 50 metaphase (25 metaphase/donor) were 
sc;ored for each treatment in the presence of S9 mix. The interstitial 
exchanges between two sister chromatids were scored as two exchange 
and the terminal exchanges were scored as a single exchange. Student's 
't' test was applied for calculating the significance of difference between 
the treated and the controls. 
2.6 Cell Cycle Kinetics: 
The cells undergoing first (M,), second (M2) and third (M3) divisions 
were detected by studying the BrdU labeled differentially stained 
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chromosomes following the methodology of Tice et al (1976) and 
Crossen and Morgan, (1977). The cells with both the chromatids being 
darkly stained were scored as Mi cells, those with one dark and one 
lightly stained chromatid as M2 cells and those having mixture of both the 
differentially stained and uniformly stained chromatids were scored as M3 
metaphase. Around 100 well spread metaphase were scored for each 
concentration and each treatment durations from each donor in the 
absence as well as in the presence of S9 mix. The replication index (RI) 
was calculated according to the formula of Tice (1979) as given below. 
The deviation from the controls was determined by using Chi-squareX" 
test. 
(Ml, , ) + (M2,2) + (M3,3) 
R.I = 
100 
2.7 Statical Analysis: 
Standard deviation (SD) and standard error (SE) were calculated 
using the following formula. 
Zx 
MeanX = 
Z(X-ii.X') 
Variance 5 = 
11 - 1 
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S.D (5) = 
SD 
Sx'-Ti.x' 
T l - l 
SE = 
Where X = Variable 
r\ = Number of observations 
^X^ = Sum of square of individual variables. 
X = Mean of variables 
5 = Standard deviation. 
2x3 chi-square test (X )^ for homogeneity test of variance was used to 
analyses the cell growth icinetics exchange with the normal control. The 
level of significance was tested from standard statistical tables of Fisher 
and Yates (1963). 
The endoreuplication, ploidies, pulverization and cells with multiple 
anomalies were not included in the statistical analysis. Student two tailed 
't' test was used for calculating the statistical significance in SCE and 
chromosomal aberration by comparing the effect induced by different test 
chemicals with the respective control. The following formula was used 
for this purpose. 
t X) (Control)-X, (treated) 
(SE of Control)' + (SE of treated)' 
The statistical significance was calculated from Fisher and Yates table at 
(ni + n2 -2) degree of freedom (df) at 0.05% level of significance. 
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3.1 Antimutagen Chemicals; 
1 - Carotenoids: 
The treatment with hydrocortisone results in clastogenic 
abnormalities (Table-1) as observed in percent metaphase 
aberration types of aberration and aberration per cell (10.19 to 
10.54), compared with controls, the Normal or DMSO (0.02 to 
I 
0.03) at various dosage and durations. These values show linear 
iacrease with dosage Carotenoids bring down the aberrations 
from 0.17 to 0.13 at different dosages and at different durations, 
the effect being maximal at highest dose (Cas) and for highest 
duration (72 h). Even with normal controls carotenoid reduces the 
level to 0.02 from 0.03, when no carotenoid was administered. 
This is due to a basal free oxygen radical level in normal culture. 
These results are also repeated when metabolic activation system 
is used (Tab-2). The data recorded only for 48 h treatment 
duration of clastogenic levels are augmented toward higher 
frequency aberrations of (0.26 to 0.41), again the values are 
reduced following carotenoid treatment from 0.23 to 0.18 in 
absence of (-S9) mix and from 0.37 to 0.31 in presence of 
(+S9) mix. The effect is parallel with the first table, thus 
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providing evidence for lowering of damage by carotenoids. When sister 
chromatid exchanges are counted (Tab-3), the reduction is evident both 
in the absence as well as the presence of metabolic activation, there being 
El lowering of the mean range and the total. SCE(s) and SCE per cell from 
4.60 to 1.50 and from 6.0 to 1.80, for this only 48hours of cultures were 
used and 50 metaphases were scanned.The normal or control SCE is low 
in Indian population (2%, Ahmad, et al, 2000), as there is less 
consumption of beverages or smoking when compared with the foreign 
counterpart (7%). 
The effects of carotenoid on replication index (Tab- 4) show an elevated 
level when compared from the hydrocortisone treatment level (1.63 from 
1.48). Though lower than the normal level of 1.78, the effect of metabolic 
activation does not show much difference on this parameter. 
Z-Vitamin B - Complex. 
The role of vitamin B-complex in reducing metaphase aberrations 
due to hydrocortisone (table-5) is quite significant, being from 0.53 to 
0.43 at the highest dose (B3), and for highest duration (72h) followed by 
0.24 to 0.18 at the lowest dose (BQ) for lowest duration (24h) The vitamin 
B-complex also reduces basal clastogeny from 0.03 to 0.02 in untreated 
cells. The results in absence of metabolic activation shows reduction to 
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0.2 from 0.28, in the presence of S9 mix, this goes down from 0.41to 0.27 
and in case of normal the effect is a bit higher being from .03 to .04. The 
B-complex vitamin treatment lowers their respective levels at all dosage 
and durations. The effect on SCE counts are similarly reduced, however, 
the experiments were conducted only for 48 h. for all the control 
treatments and also vitamin administration. The total numbers of cells 
counted are 50, without S9 treatment and with S9 (table -7) treatment 
each. 
As for cell cycle kinetics studies, out of 200 cells scored, the cell 
appearing in M], M2 and M3 phase show lowering trend due to 
hydrocortisone administration (56 to 02) and 41 to 20 in normal controls. 
When vitamins of B-complex are used along with hydrocortisone 
treatment, the replication indices get corrected and reach from 1.46 to 
1.68, being nearly equal to control level of 1.76. The highest 
concentrations of B3 however again shows lowering trend toward 1.61. 
The metabolic activation seems not to differ from earlier results. (Table-8). 
^-Vitamin C: 
Among the soluble vitamins ascorbic acid has been the most well 
studied one in antigenotoxicity assay. The hydrocortisone level of 
perceijitage aberrations of 24 is quite magnified from the normal control 
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of 3.50; vitamin C treatment brings about reduction down to 20.5 percent 
and at the highest concentration and duration it amounts to 40 to 50. 
There has been reduction from 0. 41 aberrations per cell to 0.24; the 
control level is extremely low i.e. 0.03 per cell (Table-9) 
The effect of S9 treatment leads to higher levels of metaphase aberrations, 
v/ith hydrocortisone treatment with S9, it gives 18.50 percent from 10.0 
and vitamin treatment lowers this down to 22.00 (without S9) and 31.50 
(with S9) at the highest dose. The basal levels are 3.0% and 3.5% where 
as vitamin C treatments lowers this to 3%o and 4%). The DNA damage as 
expressed in sister chromatid exchange is quite prominent being 205 in 
hydrocortisone and 147 in vitamin treatment at maximal dose and 
duration. The control values are the least, being 85 to 95 which is further 
reduced to 75 in the presence of ascorbic acid. The range varies from 1 to 
11 in case of hydrocortisone treatments and to 0 to 8 in case of controls. 
The metabolic activation of hydrocortisone as usual pulls up exchange 
counts, yet significant reduction is achieved with ascorbic acid treatment; 
there is increasing effect with increasing dosage and concentrations. 
(Table-11). Vitamin C is potent in increasing the replication index up to 
1.59 and 1.65 at the highest levels. The normal control is 1.75 whereas 
DMSO control is 1.74; Vitamin C reduces control figure of replication 
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index having similar effect with metabolic activation; with higher dosage, 
the results are not significant (Table-12). 
4-Flavonoids: 
The flavonoids have long been used as antioxidant for combating 
\'arious degenerative actions of free oxygen radicals and reactive oxygen 
species. All the controls show aberrations around 3%, while 
hydrocortisone treatment has values ranging from 21.5 to 55.0, with 
increasing durations when flavonoids are used, the reduction varies from 
19.50 to 49.0% at lower concentration and 19.0 to 46.5% at the highest 
concentration (Table-13). When augmented with S9 mix, the percent 
aberrations are higher, and however these get reduced when flavonoids 
are used concurrently with hydrocortisone. The least values go with 
control and F2. The range and mean values of SCE get reduced with 
flavonoids in the absence as well in the presence of metabolic activation 
(Table-15). The replication indices, which are reduced due to 
hydrocortisone treatment level (1.46), is elevated to 1.61, thus bringing 
the cell proliferation nearly back to normal of 1.73. The S9 activation also 
has been noticed. (TabIe-16). 
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3.2 B Cyclophosphamide: 
Cyclophosphamide, an anticancer agent, is a known potent 
mutagen and extensively used as a positive control for genotoxicity assay. 
In order to establish the antimutagenic action of vitamins and natural 
products, C.P was used as a potent mutagen. The clastogeny level 
induced with different concentrations of the chemical vary form 35.0 to 
61.0 percent which is significantly higher (as many folds of 2.5 to 3.5%). 
When carotenoids are administered along with C.P the reduction is quite 
obvious from 29% to 43% with increasing dose and increasing duration 
of time. The reduction is prominent in case of S9 enhanced percentage 
aberrations (Table-18). The sister chromatid exchange are similarly 
brought down from 6.80 to 5.20; however the level is still higher when 
compared to 1.60 to 1.92 per cell in control cases. The effect is parallel 
with S9 activation system (Table-19). 
The cell proliferation index in case of normal controls is 1.83, which is 
reduced by C.P to 1.37; with the carotenoids the index group goes from 
1.41 to 1.76, the same tend is visible with augmentation (Table- 20). 
All the results with vitamins of B-complex and with C.P are in parallel 
w'th hydrocortisone induced changes. However, the magnitude of 
clastogeny and sister chromatid exchanges are higher than when seen 
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alone with hydrocortisone treatment (Table 21 to 24) Ascorbic acid 
(Table|25 to 28) and flavonoids (Table 29 to 32) too are effective against 
C.P induced genotoxicity. 
33 Action in Combinations; 
The combination of carotenoids and B-Complex were used against 
C.P induced genotoxicity. The reduction in terms of percent aberrations 
are quite prominent being from 30% to 20% which is higher when 
compared to the values obtained with carotenoids or B-Complex alone. 
The increased level, however, is neither additive nor synergistic though 
combined action is still clear (Table 33 to 36). The combination of 
carotenoids and ascorbic acid (Table 37 to 40), B-Complex and vitamin C 
(Table 41 to 44), also vitamins C and flavonoids together (Table 45 to 
48), carotenoids and flavonoids (Table 49 to 52) and vitamins of B-
Complex and flavonoids (Table 53 to 56) show increased effects. The 
effects are more pronounced when administered together than when 
applied alone. The results thus establish the role of natural products like 
carotenoids and flavonoids and also vitamins of B-Complex and C quite 
significantly in lowering the genotoxicity levels. 
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3.4 Percentage reduction in genotoxicity due to antigenotoxic agents: 
Comparative pictures of percentage reduction in genotoxic 
parameters reveal strange facts. Witii hydrocortisone, carotenoid has 
shown highest reduction (32%) where as with C.P, vitamin C the least, 
/igain in combination, vitamin B-complex and C have the highest impact 
(44%). With SCE, vitamin C has the highest impact (37.5%)) in case of 
both hydrocortisone and C.P, flavonoid and vitamin C have the higher 
impact (40.9%) whereas carotenoid and B-complex have the least 
(32.7%). 
The replication indices (RI) register highest reduction (15%o) with vitamin 
B-complex and C.P, again vitamins C (15.0%)) in combination with 
flavonoid have the highest impact (18.9%)). 
A comparison with S9 and without S9 condition is also given, it is lower 
being 25.6% than that without S9 (34.6%) with hydrocortisone, with C.P 
the values are 30.5%) in case of vitamin C.Again percentage reduction in 
SCE with and without S9 register lower level of reduction under S9 
treatment which is but expected. These trends are followed even in 
combined treatments of the two natural agents. Reduction is more due to 
combination of agents than when administered alone. The effect on 
re;plication indices follow the same trend, there being less reduction with 
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Sg and more reduction when combined treatment is given alone. These 
results are consistent with a mechanistic model of antigenotoxic action of 
chemical agent against genotoxicity induced by steroid or a known 
rautagen (Table 57 to 64 and graph 1 to 6). 
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The antigenotoxic effect of some test chemiSatr'tf^^itamins of B-
complex and C, and carotenoids and flavonoids have been evaluated in 
vitro in the present study. The advantages and disadvantage of the test 
systems used, the parameters assayed and the effect of the test chemicals 
evaluated on these parameters are discussed below. 
4.1 A - General considerations: 
All the results of antimutagenicity and antigenotoxicity evaluation of 
the vitamins of B-complex and C and some phytoproducts viz; 
carotenoids and flavonoids are aimed eventually at human safeguards. It 
is therefore ideal to evaluate these directly on human beings who are 
exposed to environmental mutagens or drugs directly, or indirectly and 
also to test them for antigenotoxicity on a system that has the same 
sersitivity of response as the human genome. The human peripheral 
blood lymphocyte culture system is a single system that provides us with 
a larger number of dividing cells. These can be easily cultured to yield 
large number of mitotic figures for chromosome analysis. The 
lymphocytes also contain some metabolizing enzyme systems that are 
able to a large extent, to activate certain promutagens into a 
mutagenically active state (Buckton and Evans, 1982). 
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4.6 B - Test Mutagens; 
Because of the apparent relationship between chromosome 
abnormalities, mutagenesis, and carcinogenesis (Sandberg, 1980), invivo 
and invitro screening for chromosome aberrations is an established tool in 
the evaluation of potential hazards to the genetic material due to 
environmental agent. However, the great limitations of this 
morphological approach is that only gross genetic damage is visible and 
negative findings do not exclude other types of genetic damage such as 
those resulting in point mutations. 
The phenotypic expression of genetic damage either as visible 
chromosome aberrations or single point mutations, depend on the 
developmental time when the damage occurs, namely in pre or post natal 
life, and the type of cell, somatic or germinal, in which damage occurs 
(German, 1979). If such damage occurs in somatic cells of the developing 
embryo, it can lead to malformations and abortion in extreme cases. 
The theoretical possibility of genetic damage during postnatal life will 
apply directly to the health of the drug user. Any mutational effect on 
adult somatic cells could lead to cancer (Weiss, et al 1979). 
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4.7 C - Anti-Genotoxic Test Chemicals; 
The fact that mutagenic events seem to be of critical importance in 
carcinogenesic suggests that certain human cancers might be prevented 
by identification of mutagens in the environment. However, many 
experiments are currently underway in order to detect agents that can 
suppress cellular mutagenesis and carcinogenesis. During the past decade, 
a large number of compounds that can inhibit the development of cancer 
have been identified. The modulation of genotoxicity in somatic cells 
has provided a tool for improving human health, by extending life 
expectancy and by preventing mutation related diseases, such as cancer. 
A number of dietary components have been identified as inhibitors of 
mutagenesis and carcinogenesis induced by various chemical mutagens. 
The present study was therefore, aimed at clarifying the hypothesis as to 
how carotenoids, vitamins of B-complex, C, and flavonoids protect 
against chromosomal damage induced by hydrocortisone and 
cyclophosphamide in vitro. 
4.7.1 Carotenoids: 
Our results show that carotenoids ((3- carotene) were effective in 
reducing chromosomal damage induced by C.P or Hydrocortisone, under 
certain conditions. The anticlastogenic action of carotenoids (especially 
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a- and [3-carotene) occurred with the increases of its concentration up to a 
cei1;ain level after which this effect was not observed. The higher 
concentrations did not show any protective action, on the contrary they 
increase the extent of damage (Lowe et al, 1999; Paolini et al, 1999), 
even can turn as pro-oxidant (Goodman, 2000). These antigenotoxic 
effects of carotenoids at moderate dose, support our finding that 
carotenoids reduce CA, SCE and enhanced RI. Our studies also show that 
at higher concentration (data not presented) effects were not much 
significant. 
The mechanism of action of carotenoids is not yet well understood. The 
existing literature suggests for some mechanisms by which this 
provitamin could act. Carotenoids could be acting as modulator of the 
m(Jtabolism selectively inhibiting certain forms of mixed functional 
oxidases that are involved in the metabolism of xenobiotics. Basu et al 
(1987) reported the effect of dietary supplements of {3 - carotene on 
hepatic microsomal drug metabolizing enzyme activifies in mice. This 
study showed a marked reduction in the hepatic concentration of 
cytochrome P. 450, which is one of the enzymatic systems involved in the 
metabolism of cyclophosphamide (Domeyer and Sladek, 1980). 
According to Cohen and Jao (1970), the mixed functional oxidase system 
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involved in the cyclophosphamide (C.P) metabolism can be inhibited in 
vitro by compounds also known to be metabolized by the same 
enzymatic system. Such an inhibition is of a competitive type. Thus, a P 
- carotene also requires cytochrome P.450 dependent enzyme to be 
converted into vitamin A. The protective effect of P - carotene may be 
due to a competitive inhibition of this enzymatic system, thus decreasing 
the metabolic activation of C.P. This may be the one reason in our study 
also that the carotenoids act against C.P. 
Abraham et a/(1986) and Dorroudi e? (2/(1988) reported that carrot 
juice, have an inhibitory effect on the genotoxic activity of C.P, 
possibly by interfering with the enzymatic process of its activation. 
It is known that C.P is an indirectly acting agent, which needs previous 
activation to be mutagenic. So if [3-carotene affects the enzymatic 
activation of C.P, we would expect to find a reduction in the frequency of 
chromosome damage induced by C.P, which was found in the above 
studies. Antagonistic to this, Renner (1985), using C.P, reported no 
aniiclastogenic activity of p-carotene in Chinese hamster bone marrow 
cells for induction of chromosomal aberration. He also reported that P -
carotene exhibited anticlastogenic effect on aberration induced only by 
dir3ct acting mutagen thiol TEPA, methyl methane sulfonate and 
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busulfan. Apparent differences between these results and those obtained 
by Abraham et al (1986) and Dorroudi et al (1988) could be due to the 
use; of (3 - carotene in one case, and carrot juice in the other, as well as the 
different species and route of administration of C.P. We, however, have 
not conducted here any parallel study on mode of administration. 
On the other hand, the results obtained using (3 - carotene doses above 
100 mg/ kg agree, in part with our results, we selected four different 
moderate doses in present study. Another mechanism of antimutagenesis 
proposed for {3 - carotene is through its antioxidant and free radical 
scavenging activity (Burton and Ingold, 1984: Krinsky, 1989; De Flora, 
1990; De Flora et al, 1999;Rousseau et al, 1992; Peng et al, 1995). In 
general, the antioxidants are expected to inhibit mutagenesis at some 
level by deactivating mutagens through chemical reaction and blocking 
reactive molecules through scavenging reactive oxygen species (De 
Flora and Romel, 1988). This may be the cause of anticlastogenic 
activities of carotenoids against hydrocortisone-induced genotoxicity, 
using parameters CA, SCE and RI. Thus carotenoid alone and in 
combinations with other phytoproducts, lowers CAs, SCEs and enhances 
RI significantly. Renner (1984) used the antioxidant agent, ethoxyquin, 
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and Kola et al (1989) using ascorbic acid reported a protective effect of 
these antioxidants on C.P induced chromosomal aberrations. 
According to De Flora and Ramel (1988), prevention of mutagenesis may 
be achieved at the metabolic stage either by inhibiting those biochemical 
mechanisms which are responsible for the activation of promutagens to 
e;lectrophilic metabolites, or by stimulating the enzymatic detoxification 
of chemicals, or as the mechanisms are quite often competitively or 
sequentially involved, by shifting their balance in favour of 
detoxification. Thus carotenoids act on cellular as well as chromosomal 
level, as our studies showed above, and, thus protect the integrity of 
individual cells. The (3-carotene has been found to inhibit the growth of 
some malignant cells, including human prostate cancer cells in vitro 
(William e^fl/, 2000). 
4.7.2 Vitamin s of B-complex; 
The present study demonstrates protective action of vitamins 
against steroid and cyclophosphamide induced genotoxicity in the human 
lymphocytes. This finding has a parallel with the report of Gebhart et al 
(1971) using altogether different mutagens. Vitamin B-1, with its 
antioxidant properties and reversible deficiency leads to increased cell 
mortality and condensation of chromatid (Bettendroff e^  al, 1997). High 
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concentrations of vitamin Bl were associated with a decreased risk of 
colon, rectal and prostate cancers (Du et al, 1997; Kaaks et al, 1998). 
Also vitamin B2 supplement action can reverse DNA-binding of 
carcinogens caused by deficiency; it plays a role in regulating the 
carcinogenic activity of aflatoxin B1 (Prabhu et al, 1989; Pangrekar et al, 
1993). 
Vitamjn B-2 prevents an elevation of lipid peroxides and prevents 
precancerous oesophageal lesions (Wahrendrof et al, 1988). Substantial 
reduction in tumor growth was reported in rats fed with supplemental B-2 
(Van Rensburg et al, 1986). 
These findings support our study, where vitamins of B-complex decreases 
chromatid breaks, chromosomal aberrations and sister chromatid 
exchange. This also increases cell life by reducing cell death due to test 
mutagens. 
Vitamin B3 act as coenzyme in wide range of enzymatic processes. Like 
vitamin B2, it also assists in repairing DNA breaks. When deficiency of 
folate and antioxidants exist, these are expected to act in synergy with a 
nicotinamide deficiency, which may result in DNA damage and cancer 
(Henning, 1997). 
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Vitamin B6, a precursor of pyridoxal phosphate functions as a co-enzyme 
and its deficiency results in uracil incorporation with subsequent 
chromosome breaks (Key, 1997). Thus, the vitamins of B-complex 
provide a better protection of chromatid as well as chromosome against a 
number of mutagens and carcinogens. It also decreases sister chromatid 
exchanges and enhances proliferation of cells. 
Identification of the exact mechanism (s) involved in the probable 
protective role of vitamin-B complex is not clearly understood. The 
mechanism suggested by Tazima (1984), while discussing environmental 
mutagenesis, could enumerate several factors that might affect the 
biological response of different cell line systems to chemical mutagens. 
These factors are (1) scavenging the mutagens or their metabolites out of 
the cells (2) metabolic modification and detoxification of the mutagen 
molecule themselves (3) inhibition in the path of mutagen to reach the 
target cells, (4) the auto repairability of the damaged cells or their genetic 
material, (5) selective cell killing and elimination of the damaged cells, 
and finally (6) compensatory division among the remaining resistant and 
comparatively less damaged "clear" cells. The improvement in frequency 
of chromosomal aberrations, sister chromatid exchange and cell growth 
kiretics by vitamin B- complex, may be due to vitamin mediated 
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modification and detoxification of the steroid and C.P. The vitamin B 
complex may also act as scavenger for the free radicals or elcetrophiles 
which damage DNA and other cell targets. Peroxidation of lipid and 
nullification of adriamycin induced disturbance in DNA replication have 
been found to be brought out by one of the vitamin B (Riboflavin) in 
Ehrlich cells (Okamoto et al, 1985). Therefore, this vitamin, like vitamin 
C can be deemed to bring down the cellular level of lipid, thereby 
providing less chances of formation of mutagenic steroid lipid conjugates, 
E'.hattacharya et al (1987) tested 19 vitamins including B-complex for 
their ability to suppress mutagens and concluded that such action is 
possibly mediated through interaction with microsomal activating 
enzymes. Hoda et al, (1991, 1992) tested the impact of vitamins of B-
complex as a antimutagenic against pesticide induced mitoinhibition and 
clastogeny. 
4.7.3 Vitamin C: 
Results of the subsequent experiment carried out to find out if 
ascorbic acid exerts any effect against the mutagenicity of steroid and 
C.P. showed that it has protective effect on the genotoxicity induced by 
these drugs in the human lymphocyte culture. The parameters are 
chromosomal aberration, sister chromatid exchange and cell cycle 
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kinetics which show positive effect when treated at different doses of 
ascorbic acid alone or together with other test chemicals used in the 
present study. Ascorbic acid has been shown to posses antimutagenic and 
anticarcinogenic properties against a number of chemicals in a variety of 
systems including man (Bhattacharya et al, 1984; Shamberger; 1984; 
Gebhart et al; 1985; Liotti et al 1986; Bhattacharya et al, 1987, Leafed al 
1987; Fabiani et al, 2001; Kaya, 2003). The anticlastogenic effect of 
^/itamin have been reported earlier in human lymphocytes in culture, as 
also against ionizing radiation in plant cells (Barthelmess et al, 1968). 
Antimutagenic action of vitamin C has been reported in bacteria 
(Guttenplan, 1977) as well as human cell (Dion et al, 1982; Halliwell, 
2001). Vitamin C, a water-soluble substance, has been the subject of a 
great deal of controversy due to its genotoxic as well as antimutagenic / 
anticarcinogenic effect (Shamberger, 1984). A few studies pertaining to 
ttie preventive effect of ascorbic acid against tumour induction in mice by 
3"hydroxyanthanilic acid and 7,12 dimethyle benzo (a) anthracene plus 
croton oil has been reported (Schlegal et al, 1970). With transplantable 
murine ascites tumors P^ ^ leukemia and Ehrlich demonstrated complete 
inhibition of mitotic activity after treatment with dehydroascorbic acid in 
mice (Poydock et al 1982). Ascorbic acid inhibits nitrosation of N-
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nitrosonornicotine, which is the most abundant carcinogenic nitrosoamine 
present in cigarettes by C-nitro compounds and sodium nitrite 
(Castonguay et al, 1979). Guttenplan (1977) reported the inhibitory effect 
of L-ascorbate ion on mutagenesis by N-methyl-N nitroso guanidine 
(MNNG) and dimethyl nitrosoamine (DMN) in histidine requiring S. 
\yphimurium tester strain TA 1530. Park et al (1980) reported that the 
number of evertant colonies in TA 1535 TA 100 taster strains when 
induced by methyl guanidine nitrosated with S9 and by MNNG, was 
reduced to a control level of spontaneous reversion by ascorbic acid 
treatment. The known potent frameshift mutagen-4 nitrosoquinoline-1-
cxide showed mutagenicity, only after metabolic activation by rat liver 
microsomal enzymes in TA 98 and TA 100 tester strains. An interaction 
between ascorbate and microsomal enzymes was suspected but no 
evidence for this interaction was found. Our studies also show their 
effects against C.P and hydrocortisone, may be due to this behaviors of 
ascorbic acid .It was also recorded that S9mix enhances the antigenotoxic 
activities of ascorbic acid, which is parallel to above finding. Guttenplan 
(1977) believes that ascorbate extended an antimutagenic potential either 
b>' blocking the formation of N- nitroso compounds or by nucleophilic 
deactivation of the electrophilic alkylating metabolites of the 
compounds Toshihiko et al (1980), reported the reduction of 
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mutagenicity of 1,4 dinitro-2 methyl pyrrole by treatment with ascorbic 
acid. The loss of mutagenicity was attributed to the reduction from C-
nitro to C- amino group. The mutagenic effect of nitro sodium 
methylamine and nitrosomorphiline with S9 mix was found to be 
inhibited by ascorbic acid (Khudolei, 1982). 
The protective action of vitamin in S9 induced mutagenesis has been 
underreported though data on S9 activated cyclophosphamide damage 
was shown to be enhanced with vitamin E in case of mouse bone 
marrow (Kodytkova et al, 1980) showing clastogenic activity. We also 
noticed, in previous study, the additive effects of vitamin C and E in 
human lymphocyte culture (Ahmad.S et al, 2002). Our experiment with 
vitamins of B-complex and C also shows parallel results with this 
experiment on human lymphocyte culture. The co-clastogenic activity on 
chromosome damaging action of S9 activated C.P are due more to 
unfavorable relation in the morality between clastogeny and 
anticlastogen, and better when added in distinct molar surplus (1 = 
1000 to 1: 10,000; Gebhart, 1971, 1978). Our study however, reveals 
better effect even at lower concentration of vitamin C. No study with 
vitamin B-complex has been reported earlier. This may be an 
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encouraging result for prophylactic action of vitamin B in reducing 
clastogeny and used for propiiylactic action among human population. 
The parallel results with SCE and cell growth kinetics data also show that 
difference between structural chromosome damage and SCE or cell cycle 
kinetics are not observed in the present study. Some effect of vitamin 
C on reducing SCE (by 25%) has been reported by Galloway and Painter 
(1979). The present results, do exhibit this trend, which may be due to 
prophylactic effect of vitamin C. 
However, few reports on anticlastogenic effects of ascorbic acid have so 
far been reported. Out of these the work of Sram et al (1983) is of 
great significance as they reported that prophylactic administration of 
ascorbic acid led to the reduction of SCE from 5.07 to 1.70% in 
peripheral blood lymphocytes of workers exposed to coal tar or 
halogenated ethers. Ghaskadbi and Vaidya (1989) reported in vivo 
anticlastogenic effect of ascorbic acid drug on di- iodohydroxyquinoline 
treatment in micronucleus test in Swiss albino mice. It has been suggested 
that it will be necessary to elucidate the mechanism of action of 
ascorbic acid before a practical use of ascorbic acid is contemplated for 
this purpose. Vitamin C acts as an antioxidant and hence mops cellular 
level of free oxygen radical as demonstrated invitro and cell free 
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experiments (Odin, 1997; Collins, 1999; Fabiani et al, 2001). The 
scavenging role of vitamin C against lipid peroxidation cannot be 
mooted here and may be important for invivo study. 
Vitamins can suppress mutagenic activity of certain environmental 
mutagens possibly mediated through interaction with microsomal 
activating enzymes. Our studies here bring out a correlation between 
inhibition of steroid and C.P induced damage and vitamins used in in 
vitro systems. 
4.7.4 Flavonoids: 
This section will summarize result with some flavonoids, which 
have been found to exhibit certain beneficial or protective effects in 
suppressing C.A, and SCE and in enhancing RI in human lymphocyte 
culture, separately as well as when given together with other test 
chemicals like vitamins and carotenoids, 
Flavonoids, food ingredients, have been found to exhibit antimutagenic 
or anticarcinogenic properties (Fortham, 1990; Birt and Bresnick, 1991; 
Stich, 1991;0"Brien et al, 2000; Dhawan et al, 2002). Since all 
vegetables and fruits contain flavonoids and their effects have been 
observed in humans in in vivo studies (Wattenberg ,1983; Scambia et al, 
1990; Daniel and Stoner, 1991; Kandaswami et al, 1991), there is an 
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increased interest and expectation in possible use of flavonoids as 
chemopreventive agents against human carcinogenesis (Gabor, 1988; 
Birt and Bresnick, 1991). 
Seiveral studies dealing with mice using feeding of flavonoids and known 
chemical carcinogens have produced improving results. In some 
instances, disappointing results (Nishino et al, 1984; Smart et al, 1986; 
Wattenberg et al, 1980; Hirono et al; 1981; O'Brien et a/,2000), follow. 
Our finding shows their beneficial effects on human lymphocytes in vitro, 
and our chemical can be used as chemopreventive agents against many of 
the disease including several types of cancer. Also we did not notice any 
harmful effects in this study. In other studies, for example, quercefin 
sh(Dwed an antitumor effect in mouse skin after topical application (Fujiki 
et al, 1986 Lato.R, 1983) but not after oral administration. However, 
other polyphenols, such as ellagic acid, exhibited protective effect when 
given orally (Nakadate e^a/, 1984; Mukhtar e/a/, 1986). 
Di(itary flavonoids (acidic) were found to inhibit liver and large intestine 
tumors in hamsters induced by the chemical carcinogen 
methylazoxemethanol (MAMO) (Mori et al, 1986). Flavonoids, 
especially quercetin and rutin are capable of scavenging reactive oxygen 
species and suppressing the generation of hydroxyl radicals (Kostyuk et 
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al, 1996). Medicating, myrcetin quercetin and rutin, three flavonoids 
exhibited a similar protection against H2O2" induced DNA strand breaks 
in the cell models used (OBrien, et al, 2000). Our studies exhibit 
chromatid and chromosome breaks, and also increase in sister chromatid 
exchange by potent mutagens,and may be due to the liberation of H2O2' 
and like above mentioned functions of flavonoids, the counting of 
aberrations and exchanges got significantly reduced. According to 
Decharneux et a/,(1992),it is unlikely that only the scavenging activity 
and anti-lipoperoxidant activity of the flavonoids protect cells against the 
action of reactive oxygen species. De Groot and Rauen(1998) suggested 
thai; other biological activities of the flavonoids, such as enzyme 
inhibition, including oxidases and oxygenases, may also contribute to the 
cell and tissue protective properties of the flavonoids. Possible 
mechanism in prostate cancer control by flavonoids, especially genistein 
takes place via cell arrest at the G2/M phase due to the down regulation 
of cyclinBl and up regulation of p21 proteins (Choi et al, 2000; Aronson 
et al, 1999). Similar finding is noticed in our studies, that flavonoids 
enhance cell proliferation and RI.Reports on flavonoid by other scientists 
are in plenty. 
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EUagic acid, an isoflavonoid present in many fruits and vegetables, has 
been shown to be a potent antagonist of the carcinogenic effects of 
several polyaromatic hydrocarbons (PAHS) (Wood et al, 1982, Mukhtar 
et al, 1984). Ellagic acid was reported to exert a protective effect against 
other food carcinogens. For instance, 4% of ellagic acid fed to rats 
receiving subcutaneous injections of N-nitroso-benzylmetylamine (a 
compound which induced esophageal tumors in 100% of rats) inhibited 
significantly (60 %) the formation of tumors (Doniel and Stoner, 1991). It 
has been postulated that the inhibitory effect of ellagic acid may be due to 
its interaction with hydroxylated metabolites of the xenobiotics, and like 
this, hydrocortisone may induce genotoxicity. In other instances 
flavonoids do not inhibit mutagenicity (Alldrick et al, 1986). Thus 
reduction in the chemical reactivity would diminish the capacity of the 
xenobiotic e.g. [B (a) P] to undergo covalent binding to DNA (Wood et 
al, 1982). In present work, variations in effects between the presence and 
absence of metabolic activation system were noticed. It has been 
demonstrated, clearly that in addition to the mutagen itself, the source of 
hepatic Sg mixe used in in vitro assays could play a role in the mutagenic 
response or inhibitory capacity of the individual isoflavonoids (Alldrick 
et al 1986). Another isoflavonoids, Quercetin, when fed to mice, inhibited 
[B (a) P] - induced nuclear damage in colonic epithelial cells (Wargovich 
95 
et al, 1985). Similarly, dietary quercetin significantly reduced the number 
of palpable rat mammary tumor/and also the number of rats with tumors, 
induced by intragastric instillation of 7,12 dimethylbenz(a) anthracene 
(DMBA) and by I.V. injection of N-nitrodomethyleurea, both of which 
are confirmed chemical carcinogens (Verma et al, 1988). The same 
xenobiotics, DMBA induces chromosomal aberrations in rat bone 
marrow. However, a fresh or boiled juice from vegetables significantly 
suppresses the incidence of aberrations (Ito et al, 1986). We also 
confirmed such effects to flavonoids in human lymphocytes culture, 
where it reduces aberration along with sister chromatid exchanges. 
In spite of the progress made by many investigations in the last several 
years to elucidate the mechanism by which food flavonoids exert their 
protective effect in reducing carcinogenicity, the precise mechanism of 
action is still unclear (Stich, 1991). Since many flavonoids are 
antioxidants, it is likely that the antioxidative property of flavonoids is at 
least in part, responsible for their reported anticarcinogenic potential. 
Nevertheless, overwhelming evidence from research conducted in many 
laboratories in last several years, indicates that the mode of action of 
flavonoids extends much wider than their antioxidative properties. This 
section will review the mechanisms, suggested by different studies, by 
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which food flavonoids may exhibit their "protective" action. They are as 
follows: -
(1) By their action as antioxidants, Flavonoids could protect certain 
biologically beneficial, but easily oxidizable compounds in foods (i.e. 
vitamins) by reducing their oxidative degradation (Fraga et al, 1987). 
Similarly, they exhibit a quality - preserving effect on raw or cooked 
mea': (Herrmann, 1976), and extend the shelf life of lard, edible oils and 
fruits (Dick er a/, 1985) 
(2) By their action as scavengers of free radicals formed either during 
preparation of food, or as a result of certain metabolic process in the body 
(Husain et al, 1987; Robak and Gryglewski, 1988). The deleterious 
effect of free radicals in cells is assumed to be responsible for many 
chronii diseases, including aging and cancer. However, there is a 
controversy concerning the correlation between antioxidative and 
scavenging activities of flavonoids. Some author found that the 
antioxidative properties of flavonoids are mainly due to their free radical 
scavenging capacity (Cillard et al, 1990), while others could not find that 
correlation (Yuting et al 1990). 
(3) By their action as chelating agents, flavonoids can form complex with 
transition metals e.g. with copper, thus preventing destruction of ascorbic 
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acid or with, iron or copper thus preventing the initiation of free radical 
reaction (Pincemail et al, 1990). 
(4) By inhibiting lipid peroxidation, through combining chelating and 
antioxidative properties of flavonoids.(Afanasev et al, 1989). 
(5) By blocking or trapping ultimate carcinogen electrophiles by forming 
innocuous products in a nucleophilic chemical reaction.(Newmark, 1987). 
(6) By interaction and subsequent binding to the mutagenic/ carcinogenic 
metabolites to render them ineffective to bind covalently with DNA 
(Wood etal, 1982; Mukhtav et al, 1984; Das etal, 1985). 
(7) By forming adducts with DNA, thus 'masking' binding sites and 
rendering them unavailable for reaction with mutagens or carcinogens. 
(Teel, 1986). 
(8) By inhibiting the promotion phase of carcinogenesis. Several 
investigators have observed that some flavonoids, when administered 
topically, act as anti promoters against known promoters of 
carcinogenesis (Nishino et al, 1984, Wang et al 1989, Wei et al, 1990). 
(9) By inhibiting endogenous nitrosation in the stomach of man.(Stich 
and Rosin, 1984). 
(10) By inhibiting enzymes or blocking biosynthesis of enzymes involved 
in reaction sequences required for transforming procarcinogenic 
compounds into ultimate carcinogens, e.g. by inhibiting the arachidonate 
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cascade mechanism or lipoxygenase (Wheeler and Berry, 1986). These 
effects could be ascribed to all three categories which gives further 
supjDort for the likelihood of diversified. The experimental evidence, as 
presented above, suggests that there are many plausible mechanisms of 
action by which isoflavonoids can reduce genotoxicity and 
carcinogenicity. It is expected that many of the above mentioned 
observations, mainly from in vitro experiments, may reflect the ability 
of flavonoids to counteract the adverse biological effects of mutagens 
and carcinogens (Bhattacharya, 1990). However not all modes of 
action are applicable to all isoflavonoids which may act in more than 
one way, or may not act at all. Recently, De Flora and Romel (1988) 
provided an excellent discussion of the overall mechanism of 
antimutagenesis and anticarcinogenesis. In their scheme, they classified 
the inhibitors by the possible mechanism of action into three broad 
categories: (a) those that act extracellularly either by hindering uptake of 
carcinogens, or by favoring removal or deactivation of mutagnens/ 
carcinogens, (b) those that act intracellular, modulating metabolic process 
in several different ways and by blocking DNA - mutagen/ carcinogen 
int(jraction, and (c) those that act on already initiated neoplastic cells by 
modulating tumor promotion or by preventing malignant cell invasion. 
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It appears that the mechanisms by which flavonoids, as a group, perform 
thedr mode of action on biological systems are antimutagenic. 
Conclusion: 
The results in the present study have been discussed in the light of other 
workers studies. However, there are certain limitations with the present 
work. There has been no in vivo monitoring on volunteers with matched 
control, nor there are any animal model systems used. There has also 
been no work on fibroblast, CHO or other cell lines for prolonged studies 
on these chemicals. Yet the detailed investigations with steroids, positive 
and negative controls, and the test chemicals viz. natural products 
cai'otenoids, flavonoids and few vitamins do bring out the antigenotoxic 
action of these chemicals at various dosage and duration. Of these, some 
sh(Dw greater activity than others mainly carotenoids and vitamin C, while 
others show less pronounced effect. There has been no attempt to 
mesasure free oxygen radicals or take measures, other toxicity measure, 
which could have thrown better light on the mechanism of action. Such 
attempt may be taken in future to further this study. However, the work 
points to antimutagenic and antigenotoxic action of these chemicals in 
human test system to be used for future therapeutic application and 
protection against environmental exposure of steroids. 
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CONCENTRATION OF CHEMICAL 
Hydrocortisone 
Cyolophosphamide 
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50|Lig/ml 
1 xlQ-'^M 
5|j.g/ml 
J St 
2nd 
3rd 
4th 
Carotenoids. 
Cao 
Cai 
Ca2 
Ca3 
0.3|iM 
O.Sf^ M 
0.6iiM 
O.S^M 
Flavonoids 
FO 
Fl 
F2 
F3 
15 i^M 
25|iM 
40^iM 
50|iM 
B - Complex. 
BO 
Bl 
B2 
B3 
lO^ig/ml 
20|ig/ml 
40iLig/ml 
60^g/ml 
Vitamins C. 
CO 
CI 
C2 
C3 
50|iM 
60)iM 
SOidM 
lOO^M 
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Table - 1: Analysis of C.A. after treatment with hydrocortisone 
carotenoids in human lymphocyte culture. 
and 
Treatments 
Hydrocortisone 
(50^g/ml) 
Hydrocortisone+ 
Carotenoids 
Hyd + Cao 
Hyd + Ca, 
Hyd + Ca2 
Hyd + Ca3 
Control 
Normal + Cai 
Normal 
DMS0(5^g/ml) 
Q 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
72 
T3 
o 
a 
•M 
0) 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
Perc 
aberr 
Meta] 
O 
16.00 
23.00 
39.70 
14.50 
20.00 
32.75 
14.00 
19.25 
31.20 
12.60 
17.50 
29.25 
13.00 
17.00 
27.50 
2.50 
2.80 
3.30 
,ent 
ation 
Dhase 
Cifi 
X 
15.00 
20.00 
37.50 
13.00 
18.00 
30.25 
12.00 
17.50 
30.00 
10.50 
16.00 
27.50 
11.50 
15.00 
26.00 
1.50 
2.00 
2.50 
Types of 
Aberration (%) 
B 
o 
13.33 
17.70 
30.70 
11.67 
14.50 
25.50 
11.00 
14.00 
24.25 
9.25 
12.00 
22.50 
9.00 
11.00 
21.00 
1.50 
1.70 
2.00 
B 
o 
O 
a 
o 
M 
6.00 
8.33 
23.30 
5.33 
7.50 
19.00 
5.00 
7.00 
18.50 
4.50 
6.00 
17.00 
4.25 
5.50 
15.75 
0.50 
1.00 
1.00 
"3 
o 
19.33 
26.03 
54.00 
17.00 
22.00 
44.50 
16.00 
21.00 
42.75 
13.75 
18.00 
39.50 
13.25 
16.50 
36.75 
2.00 
2.70 
3.00 
Aberration/ 
cell ± SE 
0.19 ±0.03 
0.26 ± 0.03 
0.54 ±0.03 
0.17 ±0.03 
0.22 ±0.03 
0.45 ±0.03 
0.16 ±0.03 
0.21 ±0.03 
0.43 ± 0.05 
0.14 ±0.03 
0.18 ±0.03 
0.40 ± 0.05 
0.13 ±0.03 
0.17 ±0.03 
0.37 ±0.05 
0.02 ±0.01 
0.03 ±0.01 
0.03 ±0.01 
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T a b l e - 2 : Analysis of C.A after treatment with Hydrocortisone and 
carotenoids with and without (S^mix) in vitro. In 48h 
duration. 
Treatm(jnts 
Hydrocortisone 
(50(ig/ml) 
Hydrocortisone+ 
Carotenoids 
Hyd + Cao 
Hyd + Ca, 
Hyd + Ca2 
Hyd + Cas 
Control 
Normal+Ca2 
Normal 
DMS0(5^g/ml) 
2 K3 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
00 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Percent 
aberration 
metaphase 
0 
^5 W) 
18.33 
26.50 
16.50 
22.37 
15.60 
20.50 
14.00 
18.33 
13.50 
17.00 
3.00 
3.50 
3.67 
4.00 
4.33 
4.50 
'-3 
0 ^ 
W 00 
16.67 
25.00 
14.00 
20.50 
13.00 
18.00 
12.50 
16.67 
12.00 
16.00 
1.70 
1.50 
2.33 
2.00 
1.67 
2.00 
Types of 
Aberration (%) 
B 0 
u 3 
17.00 
22.00 
14.50 
19.33 
12.75 
18.50 
10.50 
17.33 
11.00 
16.50 
2.50 
3.00 
3.00 
3.50 
3.00 
2.50 
0 
a 
0 0 
9.33 
19.00 
8.00 
17.67 
8.00 
16.00 
6.50 
14.67 
7.00 
14.00 
0.50 
0.33 
0.33 
0.50 
0.67 
1.00 
13 
H 
26.00 
41.00 
22.50 
37.00 
20.75 
34.50 
17.00 
32.00 
18.00 
30.50 
3.00 
3.33 
3.33 
4.00 
3.67 
3.50 
Aberration / 
cell ± SE 
0.26 ± 0.04 
0.41 ±0 .05 
023 ± 0.04 
0.37 ±0 .05 
0.21 ±0 .04 
0.35 ±0 .05 
0.17 ±0 .04 
0.32 ±0 .05 
0.18 ±0 .04 
0.31 ±0 .05 
0.03 ± 0.02 
0.03 ± 0.02 
0.03 ± 0.02 
0.04 ± 0.03 
0.04 ± 0.02 
0.04 ± 0.02 
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TabIt^ -3: Analysis of SCE after treatment of hydrocortisone and 
carotenoids in vitro. 
Treatment 
1 
Hydrocortisone 
50(ig/ml 
Hydrocortisone 
+Cartenoids 
Hyd + Cao 
Hyd + Ca, 
Hyd + Ca2 
Hyd + Cas 
Control 
Norm.al+ Cai 
Normal 
DMS0(5|ag/ml) 
S^ 
o 
• ^ 
V-i 
D 
48 
48 
48 
48 
48 
48 
48 
48 
2 c 
• o - 2 
-2 ^ 
^ > 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
230 
300 
205 
248 
190 
215 
170 
200 
175 
205 
75 
90 
85 
105 
90 
120 
Range 
2 - 1 1 
1-11 
1-10 
2 - 1 2 
1-9 
1-10 
2 - 1 1 
1-11 
2 - 1 0 
1-11 
0 - 5 
0 - 5 
0 - 6 
0 - 5 
0 - 5 
0 - 6 
SCE /Cell ± SE 
4.60 ± 1.20 
6.00 + 1.25 
4.10 ±0.70 
4.96 ±1.00 
3.80 ±0.60 
4.30 ±1.00 
3.40 ±0.05 
4.00 ±1.00 
3.50 ±0.05 
4.10 ±1.00 
1.50 ±0.14 
1.80 ±0.25 
1.70 ±0.14 
2.10 ±0.50 
1.80 ±0.14 
2.40 ± 0.70 
126 
Table-4; Analysis of cell cycle kinetics after treatment of 
hydrocortisone and carotenoids in vitro. 
Treatment 
Hydrocortisone 
50(j.g/ml 
Hydrocortisone + 
carotenoids 
Hyd+ cao 
Hyd+ cai 
Hyd+ ca2 
Hyd-t- ca3 
Control 
Normal + ca2 
Normal 
1 DMSO (5|ig/ml) 
o 
O 
o 
GO 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
Percent cell 
Ml 
56 
56 
54 
55 
52 
53 
50 
50 
51 
51 
42 
44 
43 
M2 
40 
40 
40 
38 
39 
37 
37 
37 
38 
40 
38 
40 
37 
in 
M3 
04 
04 
06 
07 
09 
10 
13 
13 
11 
09 
20 
16 
20 
Replication 
Index 
(RI) 
1.40 
1.48 
1.52 
1.52 
1.57 
1.57 
1.63 
1.63 
1.60 
1.58 
1.78 
1.72 
1.77 
2*3 Chi square 
Test 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Not significant 
Not significant 
Not significant 
Significant 
Not significant 
Normal 
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Table-5: Analysis of C.A after treatment of hydrocortisone and 
Vitamin of B - Complex in vitro. 
Treatments 
Hydrocortisone 
(50^g/ml) 
Hydrocortisone+ 
Vit B-complex 
Hyd + Bo 
Hyd + B, 
Hyd + B2 
Hyd + B3 
Control 
Normal + B2 
Normal 
DMSO (5^g/ml) 
.2 
Q 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
72 
si ^ 
2 00 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
Percent 
aberration 
Metaphase 
00 
5^ bO 
17.50 
22.50 
38.50 
14.33 
18.50 
32.50 
14.00 
17.00 
30.00 
12.50 
15.50 
28.50 
13.00 
16.00 
30.00 
2.70 
3.00 
3.50 
PQ bD 
16.00 
20.50 
36.00 
13.00 
17.50 
30.00 
12.50 
16.00 
28.50 
11.50 
14.00 
26.50 
12.00 
15.00 
28.00 
2.00 
2.00 
3.00 
Types of 
Aberration (%) 
S 0 
0 -d 
15.00 
18.50 
32.50 
13.00 
15.00 
30.00 
12.50 
14.00 
27.50 
11.00 
13.50 
26.00 
11.00 
14.00 
27.50 
1.50 
1.70 
2.00 
0 
en 
0 s 
0 
u 6 9.50 
10.00 
20.00 
9.00 
8.50 
17.00 
8.50 
8.00 
15.50 
7.50 
7.50 
14.00 
7.00 
8.00 
15.00 
0.67 
1.00 
1.00 
13 
-t-j 0 
24.50 
28.50 
52.50 
22.00 
23.50 
47.00 
21.00 
22.00 
43.00 
18.50 
21.00 
40.00 
18.00 
22.00 
42.50 
2.17 
2.70 
3.50 
Aberrationy 
cell ± SE 
0.25 ±0.03 
0.29 ± 0.03 
0.53 ±0.05 
0.22 ± 0.03 
0.24 ± 0.03 
0.47 ± 0.05 
0.21 ±0.03 
0.22 ± 0.03 
0.43 ±0.05 
0.19 ±0.03 
0.21 ±0.03 
0.40 ± 0.05 
0.18 ±0.03 
0.22 ± 0.03 
0.43 ± 0.05 
0.02 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
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Table 6: Analysis of C.A after treatment with hydrocortisone and 
vitamin B - Complex in presence of metabolic activation (S9-
mix) in vitro. 
1 
Treatments 
Hydrocortisone 
(50|ig/ml) 
Hydrocortisone+ 
Vit B-complex 
Hyd + Bo 
Hyd + B, 
Hyd + B2 
Hyd + B3 
Control 
Normal + B2 
Normal 
DMSO (5^ig/ml) 
3 c 
s > 
!S a 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
0) in 
B S 
"S 03 
S V) 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Percent 
aberration 
Metapl 
3 
'^  s^  
^ S) 
18.50 
24.50 
16.00 
20.50 
15.50 
18.00 
15.00 
16.50 
16.00 
19.50 
2.50 
3.00 
3.50 
4.00 
4.00 
4.50 
lase 
00 
3 
"B ^  
17.00 
23.00 
15.00 
19.00 
14.50 
17.00 
14.00 
15.50 
14.50 
18.00 
2.00 
2.50 
2.50 
3.00 
3.50 
2.00 
Types of 
Aberration (%) 
0 
^ 
0 T5 
18.00 
22.50 
16.50 
19.50 
14.50 
17.50 
13.50 
15.00 
16.00 
18.50 
2.50 
2.00 
3.00 
3.30 
3.00 
2.50 
0 
on 
0 
B 0 
^ (D 
0 B 
10.00 
18.50 
8.50 
16.50 
8.00 
14.50 
7.00 
12.00 
8.00 
16.00 
0.50 
1.00 
0.50 
1.00 
0.70 
1.00 
a 
0 
H 
28.00 
41.00 
25.00 
36.00 
22.50 
32.00 
20.50 
27.00 
24.00 
34.50 
3.00 
3.00 
3.50 
4.30 
3.70 
3.50 
Aberration/ 
cell ± SE 
0.28 + 0.04 
0.41 ± 0.05 
0.25 ± 0.04 
0.36 ±0.05 
0.23 ± 0.04 
0.32 ±0.05 
0.21 ±0.04 
0.27 ±0.05 
0.24 ±0.04 
0.35 ±0.05 
0.03 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
0.04 ±0.01 
0 04 + 0 01 
0.04 ±0.01 
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Table - 7: Analysis of SCE, after treatment with liydrocortisone and 
vitamin of B-Complex in vitro, with and without the 
presence of metabolic activation 
Treatment 
Hydrocortisone 
50|.ig/ml 
Hydrocortisone+ 
Vit B-complex 
Hyd + Bo 
Hyd + B, 
Hyd + B2 
Hyd + B3 
Control 
Normal +,62 
Normal 
DMSO (5|Lig/ml) 
/—\ 
^ 
c 
.2 
'•^-> 
Q 
48 
48 
48 
48 
48 
48 
48 
48 
.5^  c 
0 - 2 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
<^ ry-l 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
220 
317 
190 
260 
182 
242 
165 
230 
170 
240 
82 
85 
90 
110 
93 
120 
Range 
2 - 1 2 
1-11 
1-10 
1-12 
1-9 
1-11 
2 - 1 0 
0-10 
1-11 
1-11 
0 - 8 
1-7 
0 - 6 
0 - 8 
1-7 
0 - 6 
SCE /Cell ± SE 
4.40 ±1.00 
7.42 ±1.50 
3.80 ±0.50 
5.20 ±1.20 
3.64 ±0.50 
4.84 ±1.00 
3.30 ±0.50 
4.60 ±1.00 
3.40 ±0.50 
4.80 ±1.00 
1.64 ±0.14 
1.70 ±0.15 
1.80±0.15 
2.20 ±0.30 
1.86±0.15 
2.40 ±0.30 
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Table-8: Analysis of cell cycle kinetics after treatment with 
hydrocortisone and Vitamin of B -complex in vitro with and 
without metabolic activation. 
Treatment 
Hydrocortisone 
(50^g/ml) 
Hydrocortisone+ 
Vit B-complex 
Hyd + Bo 
Hyd + Bi 
Hyd + B2 
Hyd + B3 
Control 
Normal + B2 
Normal 
DMSO (5|ig/ml) 
Td 
U 
0 
0 
03 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
0 -^ a 
ro > 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
Percent cell 
Ml 
56 
56 
54 
55 
52 
53 
48 
50 
50 
51 
41 
42 
44 
M2 
42 
42 
40 
38 
39 
38 
36 
36 
39 
37 
39 
40 
40 
in 
M3 
02 
02 
06 
07 
09 
09 
16 
14 
11 
12 
20 
18 
16 
Replication 
Index 
(RI) 
1.46 
1.46 
1.52 
1.52 
1.57 
1.56 
1.68 
1.64 
1.61 
1.61 
1.79 
1.76 
1.72 
2*3 Chi 
square 
Test 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Not 
Significant 
Not 
Significant 
Not 
Significant 
Not 
Significant 
Not 
Significant 
Normal 
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Table-9: Analysis of C.A after treatment of hydrocortisone and 
vitamin C in vitro. 
Treatments 
1 
Hydrocortisone 
(SO i^g/ml) 
Hydrocortisone 
+ Vit. C 
Hyd + Co 
Hyd + Ci 
Hyd + C2 
Hyd + C3 
Control 
Normal + C2. 
Normal 
DMSO (5^g/ml) 
0 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
72 
l 2 C« 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
Percent 
aberration 
Metaphase 
16.00 
22.00 
39.50 
13.00 
17.50 
32.50 
12.50 
16.50 
31.00 
11.00 
14.00 
29.50 
12.50 
17.00 
31.00 
3.00 
3.50 
3.50 
Cifi 
. . - 4 
15.00 
20.00 
37.50 
12.00 
16.00 
30.00 
11.00 
15.00 
29.00 
10.00 
13.00 
27.50 
11.50 
15.50 
29.50 
2.50 
2.50 
3.00 
Types of 
Aberration (%) 
a 
0 
U 73 
15.00 
17.50 
33.00 
12.50 
14.50 
27.00 
12.00 
13.50 
25.50 
10.50 
13.00 
24.00 
12.00 
15.00 
25.00 
2.00 
2.50 
3.00 
0 
0 
a 0 
u a 
9.00 
10.50 
19.00 
8.00 
9.00 
17.00 
7.50 
8.00 
16.00 
7.00 
7.00 
14.50 
8.00 
8.50 
15.50 
0.50 
1.00 
1.00 
13 
0 
H 
24.00 
28.00 
52.00 
20.50 
23.50 
44.00 
19.50 
21.50 
41.50 
17.50 
20.00 
38.50 
20.00 
23.00 
40.50 
2.50 
3.50 
4.00 
Aberration / 
cell ± SE 
0.24 ± 0.03 
0.28 ±0.03 
0.52 ± 0.05 
0.21+0.03 
0.24 ± 0.03 
0.44 ± 0.05 
0.20 ± 0.03 
0.22 + 0.03 
0.42 ± 0.05 
0.18 + 0.03 
0.20 ±0.03 
0.39 ±0.05 
0.20 ± 0.03 
0.24 ± 0.03 
0.41 ±0.05 
0.03 ±0.01 
0.04 ±0.01 
0.04 ±0.01 
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Table - 10: Analysis of C.A after treatment with hydrocortisone and 
Vitamin C with and without presence of metabolic 
activation In vitro. 
Treatments 
Hydrocortisone 
(50^g/ml) 
Hydrocortisone 
+ Vit. C 
Hyd + Co 
Hyd + C, 
Hyd + Cj 
Hyd + C3 
Control 
Normal + C2' 
Normal 
DMS0(5 i^g/ml) 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Percent 
aberration 
Metaphase 
18.00 
24.00 
15.00 
20.50 
13.50 
19.00 
12.00 
17.50 
14.00 
20.00 
2.50 
2.70 
3.50 
4.00 
4.00 
4.50 
on 
XI 
16.50 
22.50 
14.00 
18.50 
12.50 
17.50 
10.50 
15.00 
13.00 
17.00 
2.00 
2.00 
2.50 
2.50 
3.00 
3.00 
Types of 
Aberration (%) 
s 
0 
17.50 
23.50 
14.00 
19.25 
12.50 
18.50 
10.00 
15.50 
14.00 
18.00 
2.70 
3.00 
3.00 
3.33 
3.00 
3.50 
0 
w 
0 S 0 
u B 
9.50 
16.50 
8.50 
14.75 
8.00 
14.00 
7.00 
12.50 
8.00 
13.50 
0.30 
0.50 
0.00 
0.67 
0.50 
0.50 
0 
H 
28.00 
41.00 
22.50 
34.00 
20.50 
32.50 
17.00 
28.00 
22.00 
31.50 
3.00 
3.50 
3.00 
4.00 
3.50 
4.00 
Aberration 
/cell ± SE 
0.27 ± 0.04 
0.40 ± 0.05 
0.23±0.03 
0.34±0.04 
0.21+0.03 
0.33+0.04 
0.17±0.03 
0.28±0.04 
0.22±0.03 
0.32±0.04 
0.03 ±0.01 
0.04 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
0.04 ±0.01 
0.04 ±0.01 
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Table - 11: Analysis of SCE, after treatment with hydrocortisone and 
vitamin C in vitro with and without metabolic activation. 
Treatment 
Hydrocortisone 
50|.ig/ml 
Hydrocortisone 
+ VitC 
Hyd + Co 
Hyd + C, 
Hyd + C2 
Hyd + C3 
Control 
Normal + C2 
Normal 
DMS0(5|ig/ml) 
S; 
0 
S-i 
Q 
48 
48 
48 
48 
48 
48 
48 
48 
'-> c 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
CO 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
205 
332 
160 
275 
150 
266 
142 
257 
147 
270 
75 
87 
85 
107 
95 
117 
Range 
1-11 
1-12 
2 - 1 2 
2 - 1 1 
0 - 1 0 
1-10 
2 - 1 2 
2 - 1 1 
0 - 1 0 
1-10 
0 - 8 
0 - 7 
0 - 6 
0 - 8 
0 - 7 
0 - 6 
SCE /Cell ± SE 
4.10 ±0.05 
6.42 ±1.20 
3.20 ±0.50 
5.50 ±1.20 
3.00 ±0.50 
5.32 ±1.20 
2.84 ±0.50 
5.14 + 1.20 
2.94 + 0.50 
5.40 ±1.20 
1.50±0.14 
1.74 ±0.14 
1.70 ±0.14 
2.14 ±0.20 
1.90 + 0.14 
2.34 ± 0.20 
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Table-12: Analysis of cell cycle kinetics after treatment with 
hydrocortisone and vitamin C in vitro with and without 
metabolic activation. 
Treatment 
Hydrocortisone 
50|ag/nil 
Hydrocortisone 
+ Vi tC 
Hyd + Co 
Hyd + C, 
Hyd + C2 
Hyd + C3 
Control 
Normal + C2 
Normal 
DMSO (S^ig/ml) 
-a 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
Percent cell 
Ml 
53 
57 
50 
54 
49 
52 
47 
49 
48 
50 
40 
42 
43 
M2 
43 
40 
41 
38 
40 
36 
38 
34 
39 
37 
39 
41 
40 
in 
M3 
04 
03 
09 
08 
11 
12 
15 
17 
13 
13 
21 
17 
17 
Replication 
Index 
(RI) 
1.51 
1.46 
1.59 
1.54 
1.62 
1.60 
1.68 
1.68 
1.65 
1.63 
1.81 
1.75 
1.74 
2*3 Chi square 
Test 
Significant 
Significant 
Significant 
Significant 
Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
Normal 
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Table-13: Analysis of C.A after treatment with hydrocortisone and 
flavonoids in vitro. 
Treatments 
o 
Q 
on 
03 
U 
Percent 
aberration 
Metaphase 
Types of 
Aberration (%) 
O 
O 13 
O 
en 
O 
s 
o M 
o 6 
03 
• I - ' 
O 
H 
Aberration/ 
Cell ± SE 
Hydrocortisone 
(50(ig/ml) 
24 
48 
72 
300 
300 
300 
16.50 
23.00 
40.50 
15.50 
20.50 
37.00 
14.00 
18.33 
31.00 
7.50 
8.67 
24.00 
21.50 
27.00 
55.00 
0.22 ± 0.03 
0.27 ± 0.03 
0.55 ±0.05 
Hydrocortisone 
+ Flavonoids 
Hyd + Fo 
Hyd + F 
Hyd + F2 
24 
48 
72 
300 
300 
300 
14.00 
18.50 
34.75 
13.00 
16.50 
32.00 
12.50 
15.00 
27.50 
7.00 
8.00 
21.50 
19.50 
23.00 
49.00 
0.20 ± 0.03 
0.23 ± 0.03 
0.49 ±0.05 
24 
48 
72 
Hyd + F, 
Control I 
Normal + F2 
Normal 
DMS0(5|dg/ml) 
24 
48 
72 
24 
48 
72 
72 
72 
72 
300 
300 
300 
12.50 
17.00 
32.25 
12.00 
16.00 
30.50 
11.50 
14.00 
26.25 
7.00 
7.50 
20.75 
18.50 
21.50 
47.00 
0.19 ±0.03 
0.22 ± 0.03 
0.47 ± 0.05 
300 
300 
300 
300 
300 
300 
300 
300 
300 
11.00 
15.50 
30.00 
10.00 
14.00 
28.50 
13.50 
17.50 
33.00 
2.50 
2.80 
3.30 
12.50 
16.00 
31.00 
1.70 
2.00 
2.50 
10.00 
12.75 
25.00 
6.50 
7.00 
18.00 
12.00 
14.50 
26.50 
1.50 
1.70 
2.00 
7.00 
8.00 
20.00 
0.50 
1.00 
1.00 
16.50 
19.75 
43.00 
0.17 ±0.03 
0.20 ± 0.03 
0.43 ± 0.05 
19.00 
22.50 
46.50 
2.00 
2.70 
3.00 
0.19 ±0.03 
0.23 ± 0.03 
0.47 ± 0.05 
0.02 ±0.01 
0.03 ±0.01 
0.03 ±0.01 
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Table - 14: Analysis of C.A after treatment with hydrocortisone and 
flavonoids in presence of S9- mix in vitro. 
Treatments 
Hydrocortisone 
(50(ig/ml) 
Hydrocortisone 
+ Flavonoids 
Hyd + Fo 
Hyd + F, 
Hyd + F2 
Hyd + F3 
Control 
Normal + F2 
Normal 
DMSO (S^ig/ml) 
r^ 
.2 
_> 
' • > - ' 
0 
_o 
'0 
-O 
• ( - > 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-0 
0 
0 
CO 
OH 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Percent 
aberration 
Meta] 
19.00 
25.25 
17.00 
23.50 
15.35 
21.00 
14.00 
18.25 
12.50 
16.50 
2.50 
3.00 
3.50 
4.20 
4.00 
4.50 
phase 
.S 
X 
17.00 
24.00 
15.50 
22.50 
14.25 
20.00 
12.75 
17.00 
12.00 
15.00 
2.00 
2.50 
2.00 
3.70 
1.50 
2.00 
Types of 
Aberration (%) 
-a 
a 
0 
17.50 
22.50 
16.00 
21.00 
14.75 
19.50 
14.00 
17.50 
12.00 
15.00 
2.50 
2.00 
3.00 
3.50 
3.30 
2.70 
B 0 
CO 
0 B 
0 
u 
9.50 
19.50 
9.00 
18.00 
8.50 
17.00 
8.00 
15.50 
7.50 
13.00 
0.50 
1.00 
0.33 
0.50 
0.70 
1.00 
13 
27.00 
42.00 
25.00 
39.00 
23.25 
36.50 
22.00 
33.00 
19.50 
28.00 
3.00 
3.00 
3.33 
4.00 
4.00 
3.70 
Aberration/ 
Cell ± SE 
0.27 ± 0.04 
0.42 ± 0.05 
0.27±0.04 
0.39±0.05 
0.23±0.04 
0.37±0.05 
0.22±0.04 
0.33±0.05 
0.20±0.04 
0.28±0.05 
0.03 ± 0.02 
0.03 ± 0.02 
0.03 + 0.02 
0.04 ± 0.02 
0.04 ± 0.02 
0.04 ± 0.02 
137 
Table-15: Analysis of SCE, after treatment with hydrocortisone 
and flavonoids in vitro with and without metabolic 
activation. 
Treatment 
Hydrocortisone 
50iJ.g/ml 
Hydrocortisone 
+ Flavonoids 
Hyd + Fo 
Hyd + Fi 
Hyd + F2 
Hyd + F3 
Control 
Normal + F2 
Normal 
DMS0(5^g/ml) 
S^ 
.2 
'•4-' 
3 
Q 
48 
48 
48 
48 
48 
48 
48 
48 
.a c 
^ > 
<U '-P 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
• ^ 0 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
235 
315 
210 
252 
195 
220 
175 
195 
180 
200 
77 
90 
85 
105 
90 
115 
Range 
2 -
1-
1-
2 -
1-
1-
1-
2-
1-
1-
0-
0-
0-
0-
0-
0-
-11 
11 
-10 
-12 
-10 
-9 
-10 
-12 
-10 
-9 
-6 
-6 
-5 
-7 
-5 
-6 
SCE/ 
Cell + SE 
4.70 + 1.20 
6.30 ±1.25 
4.20 + 0.80 
5.04 + 1.20 
3.90"+0.50 
4.40 ±1.00 
3.50 ±0.50 
3.90 ±0.75 
3.60 ±0.50 
4.00 ± 1.00 
1.54 ±0.14 
1.80 ±0.14 
1.70 ±0.14 
2.14 ±0.20 
1.80 ±0.14 
2.30 ±0.20 
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Table-16: Analysis of cell cycle kinetics after treatment With 
hydrocortisone and flavonoids in vitro with and without 
metabolic activation. 
Tre;atment 
Hydrocortisone 
50|j.g/ml 
Hydrocortisone 
+ FJ'avonoids 
Hyd + Fo 
Hyd + F, 
Hyd + F2 
Hyd + F3 
Control 
Normal + F2 
Normal 
DMSO (5|iig/ml) 
0 
0 
C/2 
1> 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
Percent cell in 
Ml 
57 
59 
53 
56 
51 
54 
48 
51 
50 
50 
42 
43 
44 
M2 
40 
36 
38 
37 
37 
38 
37 
40 
39 
42 
39 
41 
40 
M3 
03 
05 
09 
07 
12 
08 
15 
09 
11 
08 
19 
16 
16 
Replication 
Index 
(RI) 
1.46 
1.46 
1.56 
1.51 
1.61 
1.54 
1.67 
1.58 
1.61 
1.58 
1.77 
1.73 
1.72 
2*3 Chi 
square 
Test 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
NotSignificant 
Significant 
Significant 
Significant 
NotSignificant 
Normal 
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Table - 17: Analysis of chromosomal aberration (CA) after treatment 
with C.P and carotenoids in in vitro. 
Treatments 
Cone/ml 
Cvclophosphami 
de C.P (1 * 10"^ ) 
C.P + Cao 
C.P + Ca, 
C.P + Ca2 
C.P + Cas 
Control 
Normal + Cai 
Normal 
DMS0(5^g/ml) 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
72 
T3 
0) 
O 
a 
+-> 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
3.00 
3.00 
3.00 
Percent 
aberration 
metaphase 
g 
21.00 
38.00 
40.00 
17.50 
32.00 
34.00 
15.50 
29.50 
31.50 
14.00 
28.00 
29.50 
13.00 
29.50 
30.50 
2.50 
3.00 
3.50 
19.00 
35.00 
35.00 
16.00 
29.00 
31.00 
14.00 
27.50 
28.00 
13.00 
26.00 
26.50 
12.00 
27.00 
27.50 
1.50 
2.00 
3.00 
Types of 
Aberration (%) 
S 
o 
Q 
23.50 
44.00 
43.00 
19.50 
38.50 
33.50 
18.00 
34.50 
30.50 
16.50 
32.00 
29.00 
16.00 
33.00 
29.00 
1.50 
2.00 
2.50 
B 
o 
00 
O 
O 
10.50 
22.00 
18.00 
9.50 
19.50 
16.50 
9.00 
17.50 
15.00 
8.00 
16.00 
13.50 
8.50 
16.00 
14.00 
0.50 
0.50 
1.00 
+-> 
o H 
35.00 
66.00 
61.00 
29.00 
58.00 
50.00 
27.00 
52.00 
45.50 
24.50 
48.00 
42.50 
24.50 
49.00 
43.00 
2.00 
2.50 
3.50 
Aberration / 
cell ± SE 
0.35 ±0.04 
0.66 ± 0.09 
0.61 ±0.09 
0.29 ± 0.04 
0.58 ±0.09 
0.50 + 0.06 
0.27 ± 0.04 
0.52 ±0.06 
0.46 ± 0.06 
0.25 ± 0.04 
0.48 ± 0.06 
0.43 ± 0.06 
0.25 ± 0.04 
0.49 ± 0.06 
0.43 ± 0.06 
0.02 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
Cao: - caronoids T'. cone. Q.\M ; cap 2"^* cone. 0.5 \M. 
Ca2 - 3'^ cone . 0.6)iM and Ca3- 4* . Cone. 0.8|iM. 
DMSO : - Dimathyl Sulphoxide . 
S.E : - Standard Error. Significant at P < 0.05 
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Table - 18: Analysis of C.A after treatment with C.P and carotenoids 
in presence with or without metabolic activation in vitro. 
Treatments 
CYclophospl:^ ami 
de C.P(1 * 10"^  
M) 
C.P+Carotenoids 
C.P + Cao 
C.P + Cai 
C.P + Ca2 
C.P + Ca3 
Control 
Normal + Ca2 
Normal 
DMSO (5|ig/ml) 
C2 
.2 
> 
o 
o 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
T3 
c3 
0 
00 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Percent 
aberration 
Metaj 
36.00 
40.50 
29.00 
33.50 
27.50 
31.50 
25.00 
29.00 
24.50 
30.00 
2.00 
3.50 
2.50 
4.00 
3.20 
4.50 
3hase 
X 
32.00 
37.50 
26.50 
31.50 
25.00 
29.50 
23.50 
27.00 
23.00 
27.50 
1.50 
2.00 
2.00 
3.00 
2.50 
3.00 
Types oi 
Aberration (%) 
T 3 
0 
33.50 
38.00 
27.50 
33.00 
26.00 
31.50 
24.50 
29.50 
25.00 
30.00 
1.50 
2.00 
2.00 
3.00 
3.00 
3.50 
D 
a 0 
CO 
0 6 0 
0 
17.50 
23.00 
15.00 
19.50 
14.00 
18.50 
12.50 
16.50 
13.00 
17.50 
0.00 
0.50 
0.50 
0.75 
1.00 
1.00 
0 
H 
51.00 
61.00 
42.50 
52.50 
40.00 
50.00 
37.00 
46.00 
38.00 
47.50 
1.50 
2.50 
2.50 
3.75 
4.00 
4.50 
Aberration / 
cell ± SE 
0.51 ±0.07 
0.61+0.07 
0.43 ± 0.06 
0.53 ±0.07 
0.40 ± 0.06 
0.50 ± 0.07 
0.37 ±0.06 
0,46 ± 0.06 
0 38 + 006 
0.48 ± 0.06 
0.02 ±0.01 
0.03 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
0 04 + 0 01 
0.05 ±0.01 
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Table - 19: Analysis of SCE after treatment with C.P and carotenoids 
in vitro with and without metabolic activation. 
Treatment 
C yclopho sphamide 
C.P(lxlO"^M) 
C.P+carotenoids. 
C.P + Cao 
C.P + Cai 
C.P + Ca2 
C.P + Cas 
ConiTol 
Normal + ca2 
Normal 
DMSO (5|ig/ml) 
S^  
o 
Q 
48 
48 
48 
48 
48 
48 
48 
48 
S^  c 
-5 o 
O • rj 
-s ^ 
ci > 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
CO 
2 on 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
340 
380 
280 
330 
270 
310 
256 
300 
260 
280 
80 
87 
96 
Range 
2-11 
2 - 1 1 
2 - 1 1 
1-11 
0 - 1 0 
1-11 
2 - 1 1 
1-11 
0 - 1 0 
1-11 
0 - 9 
0 - 8 
0 - 6 
SCE/Cell+ SE 
6.80±1.30 
7.60 ±1.30 
5.60 ±1.20 
6.60 ±1.30 
5.40 ±1.20 
6.20 ±1.20 
5.12 ±1.00 
6.00 ±1.20 
5.20 ±1.00 
5.60 ±1.20 
1.60 ±0.14 
1.74 ±0.14 
1.92 ±0.14 
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Table - 20: Analysis of cell cycle kinetics after treatment with C.P and 
carotenoids in in vitro with and without metabolic activation. 
Treatment 
Cyclophosphamide 
C.P (1 X IQ-^ M) 
C.P+carotenoids. 
C.P + Cao 
C.P + Ca, 
C.P + Ca2 
C.P + Ca3 
Control 
Normal + ca2 
Normal 
DMSO (Si^g/ml) 
(- Ve Control.) 
^3 
O 
o 
13 U 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
3 C! 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
Percent cell 
Ml 
65 
66 
63 
63 
60 
61 
58 
59 
58 
58 
31 
33 
34 
M2 
33 
32 
33 
32 
35 
33 
37 
34 
38 
34 
55 
54 
50 
in 
M3 
02 
02 
04 
05 
05 
06 
05 
07 
04 
08 
14 
13 
16 
Replication 
Index 
(RI) 
1.37 
1.37 
1.41 
1.42 
1.45 
1.45 
1.47 
1.48 
1.46 
1.50 
1.83 
1.80 
1.82 
2*3 Chi square 
Test 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Normal 
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Table - 21: Analysis of CA after treatment with C.P and Vitamins of 
B - complex invitro. 
Treatments 
Cyclophosphami 
de C.P (1x10" 
' M ) 
1 
C.P + Vit.B 
Complex 
C.P + Elo 
C.P + B, 
C.P + Bz 
C.P + B;, 
Control 
NormaK B2 
Normal 
DMSO (5|ig/ml) 
^ 
03 
Q 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
72 
03 
0 
m 
o3 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
3.00 
3.00 
3.00 
Percent 
aberration 
metaf 
0 
C 
21.50 
38.00 
40.00 
18.70 
33.50 
34.50 
17.00 
31.50 
32.00 
16.00 
29.00 
30.00 
16.50 
30.50 
32.00 
2.50 
3.00 
3.50 
)hase 
19.50 
35.50 
33.00 
17.50 
30.00 
30.00 
16.00 
28.50 
29.00 
14.50 
26.50 
27.00 
15.50 
27.00 
29.00 
2.00 
2.00 
2.50 
Types of 
Aberration (%) 
T3 
•a TO 
0 
23.00 
42.50 
40.00 
19.50 
37.50 
35.00 
17.50 
34.50 
32.50 
15.00 
31.00 
29.50 
16.00 
31.00 
30.00 
1.50 
2.00 
2.50 
(U 
0 
CO 
0 a 
0 
10.0 
22.00 
20.50 
9.00 
18.50 
18.00 
8.50 
17.00 
17.00 
7.50 
15.50 
16.00 
8.00 
17.00 
16.00 
0.50 
1.00 
1.00 
c3 
0 
H 
33.00 
64.50 
60.50 
28.50 
56.00 
53.00 
26.00 
51.50 
49.50 
22.50 
46.50 
45.50 
24.00 
48.00 
46.00 
2.00 
3.00 
3.50 
Aberration / 
cell ± SE 
0.33 + 0.04 
0.65 ±0.09 
0.61 ±0.09 
0.29 ± 0.04 
0.56 ±0.07 
0.53 ± 0.07 
0.26 ± 0.04 
0.52 ± 0.07 
0.50 ± 0.07 
0.23 ± 0.04 
0.47 ± 0.06 
0.46 ± 0.06 
0.24 ± 0.04 
0.48 ±0.06 
0.46 ± 0.06 
0.02 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
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Table - 22: Analysis of C.A after treatment with C.P and vitamins of 
B - complex in presence of metabolic activation in vitro. 
Treatments 
Cyclophosphami 
de C.P (1x10'^ 
M) 
C.P + VitB 
Complex 
C.P + Bo 
C.P + B, 
C.P + B2 
C.P + B3 
Control 
Normal + B2 
Normal 
DMSO (5iig/ml) 
0 
-t-> 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
c 
0 
+-> 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Percent 
aberration 
Metaj 
••5 a 
36.00 
40.50 
32.00 
35.50 
30.00 
33.00 
28.50 
30.50 
29.00 
31.50 
2.00 
4.00 
2.30 
4.50 
3.30 
4.50 
3hase 
c 
• .-< 
d 
0 
x: 
32.00 
37.50 
29.00 
33.00 
28.00 
31.50 
26.00 
28.50 
26.00 
28.00 
1.50 
3.00 
1.70 
3.00 
1.70 
3.50 
Types of 
Aberration (%) 
a 
0 
0 
33.50 
38.00 
30.50 
34.50 
29.00 
31.50 
27.50 
29.00 
28.50 
29.50 
1.50 
3.00 
1.30 
3.50 
2.00 
3.50 
a 
0 
on 
0 a 
0 
17.50 
23.50 
15.50 
20.00 
15.00 
18.50 
13.50 
16.50 
14.00 
16.50 
0.00 
0.00 
0.30 
0.00 
0.00 
0.00 
13 
0 
H 
51.00 
61.50 
46.00 
54.50 
44.00 
5,0.00 
41.00 
45.50 
42.50 
46.00 
1.50 
3.00 
1.60 
3.50 
2.00 
3.50 
Aberration / 
Cell ± SE 
0.51 ±0.07 
0.61 ±0.07 
0.46 ± 0.05 
0.55 + 0.07 
0.44 ± 0.05 
0.50 ±0.07 
0.41 ±0.05 
0 46 + 0 OS 
0.43 + 0.05 
0.46 ± 0.05 
0.02 ±0.01 
0.03 ±0.01 
0.02 ±0.01 
0.04 ±0.01 
0.02 ±0.01 
0.04 ±0.01 
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Table - 23: Analysis of SCE after treatment with C.P and Vitamins of 
B-complex in vitro with and without metabolic activation. 
Treatment 
Cyclophosphamide 
C.P(lxlO"^M) 
C.P+Vit Bcomplex 
C.P + Bo 
C.P + B, 
C.P + B2 
C.P + B3 
Control 
Normal + B2 
Normal 
DMS0(5^g/ml) 
S; 
.2 
Q 
48 
48 
48 
48 
48 
48 
48 
48 
2 c 
^ • 2 
B .> 
S cd 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
< 2 C/3 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
350 
390 
310 
330 
300 
310 
270 
290 
285 
300 
82 
88 
95 
Range 
1-10 
1-10 
2 - 1 1 
2-12 
1-11 
1-11 
1-10 
1-10 
1-10 
1-10 
0 - 5 
0 - 5 
0 - 6 
SCE /Cell + SE 
7.00 + 1.30 
7.80 ±1.30 
6.20±1.20 
6.60 ±1.20 
6.00 ±1.20 
6.20 ±1.20 
5.40 ±1.00 
5.80 ±1.00 
5.70 ±1.00 
6.00 ±1.20 
1.64 ±0.14 
1.76 ±0.14 
1.90 ±0.14 
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Table - 24: Analysis of cell cycle kinetics after treatment with C.P and 
vitamins of B-complex in vitro with and without metabolic 
activation. 
Treatment 
Cyclophosphamide 
C.P (1 X lO'^ M) 
C.P+Vit 
Bcomplex 
C.P + Bo 
C.P + Bi 
C.P + B2 
C.P + B3 
Control 
Normal + B2 
Normal 
DMS()(5^g/ml) 
d > 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
; - i 
0 
0 
U 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
Percent cell in 
Ml 
62 
66 
60 
64 
58 
62 
54 
60 
56 
61 
32 
34 
35 
M2 
35 
30 
36 
31 
38 
33 
40 
34 
36 
33 
55 
50 
49 
M3 
03 
04 
04 
05 
04 
05 
06 
06 
08 
06 
13 
16 
16 
0 
1.41 
1.38 
1.44 
1.41 
1.46 
1.43 
1.52 
1.46 
1.52 
1.45 
1.81 
1.82 
1.81 
2*3 Chi square 
Test 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Normal 
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Table - 25: Analysis of CA after treatment with C.P and ascorbic acid 
in vitro. 
TreELtments 
Cvclophosphami 
de C.P (1x10-^ 
M) 
C.P + Vit - C 
C.P + Co 
C.P + Ci 
C.P + C, 
C.P + C;, 
Control 
Normal + ci 
Normal 
DMS0(5^g/ml) 
(- Ve Control.) 
d 
o 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
72 
T3 
o 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
3.00 
3.00 
3.00 
Perc 
aberr 
Metaj 
60 
23.00 
39.00 
40.00 
19.50 
33.00 
33.00 
17.50 
31.50 
31.00 
15.50 
29.00 
28.00 
14.00 
26.50 
25.50 
2.00 
2.30 
3.30 
,ent 
ation 
3hase 
% Br 
20.00 
35.00 
34.00 
17.50 
31.00 
31.50 
15.00 
28.00 
28.50 
13.50 
27.00 
25.50 
12.00 
24.50 
23.50 
1.00 
1.60 
1.00 
Types of 
Aberration (%) 
-T3 
-t-> 
s 1 
22.00 
44.00 
4.00 
18.50 
40.50 
40.00 
16.50 
38.50 
38.00 
15.00 
36.50 
35.50 
13.50 
33.00 
31.50 
1.00 
1.30 
2.00 
S 
o 
o 
a 
o 
O 10.00 
24.00 
21.00 
9.00 
19.50 
18.00 
8.00 
18.00 
16.00 
7.50 
16.00 
13.50 
7.00 
14.50 
12.50 
0.50 
2.30 
3.00 
13 
-t-> 
o H 
32.00 
68.00 
66.00 
27.50 
60.00 
8.00 
24.50 
56.50 
54.00 
22.50 
52.50 
49.00 
20.50 
47.50 
44.00 
Aberration / 
cell ± SE 
0.32 ±0.04 
0.68 ±0.09 
0.66 ± 0.09 
0.28 ± 0.04 
0.60 ± 0.09 
0.58 ± 0.06 
0.25 ± 0.04 
0.57 ±0.09 
0.54 ±0.09 
0.23 ± 0.04 
0.53 ±0.09 
0.49 ± 0.07 
0.21 ±0.04 
0.48 ± 0.07 
0.44 ±0.07 
0.02 ±0.01 
0.02 ±0.01 
0.03 ±0.01 
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Table - 26: Analysis of CA after treatment with C.P and vitamin C in 
presence of metabolic activation in vitro. 
Treatments 
Cvclophosphami 
deC.PflxlO"^ 
M) 
C.P+VitC 
C.P + Co 
C.P + Ci 
C.P + C;, 
C.P + C:, 
Control 
Normal - C2 
Normal 
DMSO (5|ig/ml) 
.2 
' • 4 — > 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
0 
en 
+-> 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Percent 
aberr 
Meta 
C 
h—I 
35.00 
39.00 
28.50 
32.50 
27.00 
30.00 
24.50 
28.00 
25.00 
27.50 
2.00 
3.00 
2.50 
4.00 
3.50 
4.50 
ation 
Dhase 
GO 
.S 
X 
W 
31.50 
36.50 
25.00 
29.00 
23.50 
26.50 
20.00 
24.50 
22.50 
25.00 
1.50 
2.00 
2.00 
3.00 
2.00 
3.50 
Types oj 
Aberration (%) 
B 0 
32.00 
37.00 
26.50 
30.00 
25.00 
28.00 
22.00 
26.50 
22.00 
27.00 
1.50 
2.00 
1.50 
3.00 
2.50 
3.50 
a 
0 
m 
0 
B 
0 
17.00 
22.00 
14.00 
17.50 
13.50 
16.00 
12.00 
14.50 
13.00 
15.00 
0.00 
0.00 
0.30 
0.50 
0.50 
0.50 
0 
H 
49.00 
59.00 
40.50 
47.50 
38.50 
44.00 
34.00 
41.00 
35.00 
42.00 
1.50 
2.00 
1.80 
3.50 
3.00 
4.00 
Aberration/ 
Cell ± SE 
0.49 ±0.06 
0.59 ±0.07 
0.41 ±0.06 
0.48 ± 0.06 
0.39 ±0.06 
0.44 ± 0.06 
0.34 ±0.06 
0.41 ±0.06 
0.35 ±0.06 
0.42 ± 0.06 
0.02 ±0.01 
0.02 ±0.01 
0.02 ±0.01 
0.04 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
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Table - 27: Analysis of SCE after treatment with C.P and ascorbic 
acid in vitro. With and without the presence of metabolic 
activation at 48h durations. 
Treatment 
Cyclophosphamide 
C.P(lxlO"^M) 
C.P+ Vit. C. 
C.P + Co 
C.P + Ci 
C.P -^  C2 ' 
C.P + C3 
Conti'ol 
Normal + ca2 
Norm.al 
DMSO (5^g/ml) 
^ 
^ 
0 
Q 
48 
48 
48 
48 
48 
48 
48 
48 
.a c 
0 - 2 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-'-' is 
fll TO 
2 00 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
320 
360 
250 
290 
230 
270 
215 
250 
200 
245 
75 
80 
90 
Range 
2-12 
2 - 1 3 
1-11 
2 - 1 1 
1-10 
1-10 
0 - 9 
1-10 
0 - 9 
1-11 
0 - 6 
0 - 5 
0 - 5 
SCE /Cell ±SE 
6.40 + 1.20 
7.20+1.30 
5.00 ±1.00 
5.80+1.20 
4.60 ±1.00 
5.40 ±1.20 
4.30 ±0.75 
5.00+1.00 
4.00 ± 0.75 
4.90 ±1.00 
1.50±0.15 
1.60 ±0.15 
1.80 ±0.15 
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Table- 28: Analysis of cell cycle kinetics after treatment with C.P and 
ascorbic acid in vitro, with and without the presence of 
metabolic activation at 48 h duration. 
Treatm(;nt 
Cyclophosphamide 
C.P (1 X 10"'M) 
C.P+ Vit C 
C.P + Co 
CP + Ci 
C.P + C2 
C.P + C3 
Control 
Normal + Cj 
Normal 
DMS0(5(ig/ml) 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
- 0 
D 
i-i 
0 
0 
00 
IS 
U 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
Percent cell in 
Ml 
64 
66 
60 
61 
56 
57 
50 
53 
48 
50 
32 
33 
35 
M2 
30 
30 
34 
34 
37 
37 
41 
41 
43 
24 
55 
50 
52 
M3 
04 
04 
06 
05 
07 
06 
09 
06 
09 
08 
13 
17 
13 
Replication 
Index 
(RI) 
1.40 
1.38 
1.46 
1.44 
1.51 
1.49 
1.59 
1.53 
1.61 
1.58 
1.81 
1.84 
1.78 
2*3 Chi 
square test 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Normal 
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Table-29: Analysis of C.A after treatment with C.P and flavonoids 
in vitro. 
Treatments 
Cvclophosphami 
de 
C.P(1 xlO'^M 
C.P+Flavonoids 
C.P + Fo 
C.P + F, 
C.P + F. 
C.P + F3 
Control 
Normal + F2 
Normal 
DMS0(5|ig/ml) 
0 
. 1 — ( 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
72 
T3 
• ( -> 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
Pere 
aberr 
Metai 
3 TO 
^ ISO 
1—1 
23.50 
40.00 
39.00 
20.50 
35.50 
35.00 
19.00 
33.00 
32.50 
18.00 
31.00 
30.00 
18.50 
32.00 
30.00 
2.50 
3.00 
3.50 
cent 
ation 
Dhase 
21.00 
36.00 
34.50 
19.00 
33.00 
31.50 
17.50 
31.00 
29.00 
16.00 
29.50 
28.00 
16.50 
30.00 
28.50 
2.00 
2.50 
3.00 
Types of 
Aberration (%) 
a 
0 
0 
22.50 
43.00 
41.00 
19.50 
36.50 
36.50 
19.00 
33.00 
32.50 
17.50 
30.00 
30.50 
17.00 
31.00 
30.00 
2.00 
2.50 
2.50 
S 0 
0 
s 
0 
u 
11.00 
23.00 
20.00 
10.00 
19.50 
17.50 
9.50 
18.00 
16.50 
9.00 
17.00 
14.50 
9.00 
17.50 
15.00 
0.50 
1.00 
1.00 
0 H 
33.50 
66.00 
61.00 
29.50 
56.00 
54.00 
28.50 
51.00 
49.00 
26.50 
47.00 
45.00 
26.00 
48.50 
45.00 
2.50 
3.50 
3.50 
Aberration / 
cell + SE 
0.34 ±0.04 
0.66 ±0.09 
0.61 ±0.09 
0.30 ±0.04 
0.56 ±0.07 
0.54 ±0.07 
0.29 ± 0.04 
0.51 ±0.07 
0.49 ± 0.07 
0.27 ± 0.04 
0.47 ± 0.07 
0.45 ± 0.07 
0.26 ± 0.04 
0.49 ± 0.07 
0.45 ± 0.07 
0.03 ±0.01 
0.04 ±0.01 
0.04 ±0.01 
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Table - 30: Analysis of C.A after treatment with C.P and flavonoids in 
presence with or without metabolic activation in vitro. 
Treatments 
Cyclophosphami 
de 
C.P(lxlO-^M 
C.P +FIavonoids 
C.P + Fo 
C.P + Fi ' 
C.P + F2 
C.P + F3 
Control 
Normal + F2 
Normal 
DMS0(5(xg/ml) 
C 
0 
> 
0 
0 
X) 
+-> 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+SQ 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
0 
• • - ' 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Perecent 
aberration 
Meta 
p — 1 
36.00 
40.50 
31.00 
34.50 
29.50 
31.50 
28.00 
30.00 
27.50 
29.00 
2.50 
3.00 
3.00 
4.00 
3.50 
4.50 
phase 
X 
32.50 
38.00 
28.50 
33.00 
27.00 
29.00 
26.00 
27.00 
26.50 
26.50 
1.50 
2.00 
2.50 
3.00 
2.00 
3.50 
r Types of 
Aberration (%) 
td 
a 
0 
33.00 
38.00 
28.00 
34.00 
25.50 
31.50 
24.00 
29.50 
25.00 
28.00 
1.50 
2.00 
2.50 
3.00 
2.50 
3.00 
(D 
0 
0 
a 0 
0 
18.00 
23.50 
16.50 
20.00 
15.00 
18.00 
13.50 
16.50 
13.00 
16.00 
0.50 
0.50 
0.50 
0.50 
0.50 
0.50 
Id 
+-> 
0 
H 
51.00 
61.50 
44.50 
54.00 
40.50 
49.50 
37.50 
46.00 
38.00 
44.00 
2.00 
2.50 
3.00 
3.50 
3.00 
3.50 
Aberration / 
cell ± SE 
0.51 ±0.06 
0.62 ± 0.07 
0.45 + 0.06 
0.54 ±0.07 
0.41 ±0.06 
0.50 ± 0.06 
0.38 ±0.06 
0.46 + 0.06 
0.38 ±0.06 
0.44 ± 0.06 
0.03 ±0.01 
0.04 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
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Table - 31: Analysis of SCE after treatment with C.P and flavonoid in 
vitro. 
Treatment 
Cyclophosphamide 
C.P(1 * 1 0 - ' M ) 
C.P+ Flavonoids. 
C.P + Fo 
C.P + Fi 
C.P + F2 
C.P + F3 
Control 
Normal + F2 
Normal 
DMSO (5^g/ml) 
S^ 
c 
.2 
Q 
48 
48 
48 
48 
48 
48 
48 
48 
2 d 
^ • 2 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
00 
J3 "-o 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
310 
375 
260 
310 
240 
290 
220 
280 
210 
285 
72 
82 
95 
Range 
2-12 
1-12 
1-10 
1-10 
1-10 
1-11 
2-12 
2 - 1 2 
0 - 9 
0 - 1 0 
0 - 6 
0 - 5 
0 - 8 
SCE / Cell 
±SE 
620 ±1.20 
7.50 ±1.30 
5.20 ±1.00 
6.20 ±1.20 
4.80 ±1.00 
5.80 ±1.20 
4.40 ± 0.75 
5.60 ±1.20 
4.20 ± 0.75 
5.70 ±1.20 
1.44 ±0.14 
1.64 ±0.14 
1.90 ±0.14 
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Table-32; Analysis of cell cycle kinetics after treatment with C.P 
and flavonoids in vitro, with and without the presence of 
metabolic activation at 48 h duration. 
Treatment 
Cyclophosphamide 
C.P(lxlO"^M) 
C.P+ Flavonoid. 
C.P + Fo 
C.P + F, 
C.P + F2 
C.P + F3 
Control 
Normal + F2 
Normal 
DMSO (Sjig/ml) 
0 c" 
.—1 0 
^ 0 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
Xi 
u 
0 
0 
00 
U 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
Percent cell in 
Ml 
62 
67 
60 
65 
59 
62 
57 
60 
58 
60 
37 
39 
40 
M2 
35 
31 
36 
31 
35 
33 
37 
35 
37 
34 
50 
46 
48 
M3 
03 
02 
04 
04 
06 
05 
06 
05 
05 
06 
13 
15 
12 
Replication 
Index 
(RI) 
1.41 
1.35 
1.44 
1.39 
1.47 
1.43 
1.49 
1.45 
1.47 
1.46 
1.76 
1.76 
1.72 
2*3 Chi 
square 
Test 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Normal 
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Table-33: Analysis of CA after treatment with C.P and along with 
carotenoids and vitamins of B - complex in vitro. 
Treatments 
Cvclophosphami 
de C.P (1x10"^) 
C.P+ 
carotenoids+ 
Vit B complex. 
C.P + Ca,+ Bi 
C.P + Ca2+ B2 
C.P + Ca2+ B2 
C.P + Ca, 4-Bi 
Control 
Normal 
DMSO (5)ig/ml) 
c 
.2 
u 
Q 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
c 
c 
0 
<U 
K3 
a 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
3.00 
3.00 
Per 
aben 
Meta 
00 
22.00 
39.50 
40.00 
17.00 
30.00 
31.00 
14.50 
24.50 
25.50 
15.50 
26.50 
27.00 
14.50 
26.00 
26.50 
2.25 
3.25 
Dent 
ation 
phase 
.S 
x 
19.50 
34.25 
33.50 
15.00 
26.50 
25.50 
12.50 
21.25 
21.50 
13.50 
23.50 
22.50 
13.00 
22.50 
22.00 
1.50 
1.00 
Types of 
Aberration (%) 
B 
0 
23.00 
42.00 
45.00 
17.50 
32.00 
34.50 
15.00 
26.00 
28.50 
15.50 
28.50 
27.50 
15.00 
27.50 
29.50 
1.50 
2.00 
B 
0 
0 
S 
0 
7.00 
22.00 
22.33 
5.50 
17.00 
17.00 
4.50 
14.00 
14.50 
5.00 
15.00 
15.50 
5.00 
14.50 
15.00 
0.50 
0.75 
Id 
+-> 
0 H 
30.00 
64.00 
67.33 
23.00 
49.00 
51.50 
19.50 
40.00 
43.00 
20.50 
43.50 
43.00 
20.00 
42.00 
44.50 
2.00 
2.75 
Aberration / 
cell ± SE 
0.30 ±0.03 
0.64 ± 0.09 
0.67 ±0.09 
0.23 ± 0.03 
0.49 ± 0.06 
0.52 ± 0.06 
0.20 ± 0.03 
0.40 ± 0.06 
0.43 ± 0.06 
0.21 ±0.03 
0.44 ± 0.06 
0.43 ± 0.06 
0.20 ± 0.03 
0.42 ± 0.06 
0.45 ± 0.06 
0.02 ±0.01 
0.03 ±0.01 
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Table-34: Analysis of C.A after treatment with C.P along with 
carotenoids and Vitamins of B - Complex in presence with 
or without metabolic activation in vitro. 
Treatments 
Cyclophosphamide 
C.P(lxlO'^M 
C.P+ 
carotenoids+ 
Vit B complex. 
C.P + Cai+B, 
C.P + Ca2+ B2 
C.P + Ca2+ B2 
C.P + Cai+B, 
Control 
Normal 
DMSO (5p.g/ml) 
c 
03 
_> 
0 
"o 
• » - ' 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-0 
03 
D 
0! 
a 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Per 
aben 
Meta 
3 03 
32.75 
40.50 
24.00 
29.50 
20.75 
26.00 
23.00 
28.50 
22.50 
27.50 
2.50 
3.50 
3.20 
4.50 
:ent 
ation 
phase 
m 
30.25 
39.50 
22.50 
28.00 
19.50 
24.50 
21.50 
27.00 
20.00 
26.00 
1.50 
2.00 
1.50 
3.50 
Types of 
Aberration (%) 
T3 
0 
29.33 
37.50 
21.50 
27.50 
19.00 
24.50 
20.50 
25.50 
19.00 
25.00 
1.50 
2.50 
2.00 
3.50 
a 
0 
a 0 
19.67 
23.50 
14.50 
14.50 
12.50 
15.00 
13.50 
16.00 
14.00 
16.00 
0.30 
0.00 
0.50 
0.00 
13 
0 
H 
49.00 
61.00 
36.00 
42.00 
31.50 
39.50 
34.00 
41.50 
33.00 
41.00 
1.80 
2.50 
2.50 
3.50 
Aberration / 
cell ± SE 
0.49 ±0.06 
0.61 ±0.07 
0.36 ±0.06 
0.42 ± 0.06 
0.32 ± 0.06 
0.40 ±0.06 
0.34 ± 0.06 
0.42 ± 0.06 
0.33 ±0.06 
0.41 ±0.06 
0.02 ±0.01 
0.03 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
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Table-35: Analysis of SCE after treatment with C.P along with 
' carotenoids and vitamins of B-Complex in vitro. With and 
without the presence of metabolic activation at 48 h 
duration. 
Treatment 
Cyclophosphamide 
C.P(lx 10"'M) 
C.P+ carotenoids+ 
Vit B complex. 
C.P + Ca, +Bi 
C.P + Ca2+ B2 
C.P + Ca2+ B2 
C.P + Cai+B, 
Control 
Normal 
DMSO (5|^g/ml) 
^ 
.2 
u 
Q 
48 
48 
48 
48 
48 
48 
48 
2 d 
TO > 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
C/5 
5 -o 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
372 
395 
268 
286 
250 
246 
261 
274 
255 
266 
75 
78 
Range 
2-12 
3 - 1 3 
2-12 
2 - 1 2 
1-11 
1-11 
1-11 
1-11 
0 - 1 0 
2 - 1 2 
0 - 5 
0 - 6 
SCE/Cell 
±SE 
7.44 ±1.26 
7.82 + 1.30 
5.36 ±1.00 
5.72 ±1.00 
5.00 ±1.00 
4.92 ±1.00 
5.22 ±1.00 
5.48 ±1.00 
5.10 ±1.00 
5.32 ±1.00 
1.50±0.12 
1.56 ±0.12 
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Table-36: Analysis of cell cycle kinetics after treatment with C.P 
along with carotenoids and vitamins of B-Complex in 
vitro. With and without the presence of metabolic 
activation. 
Treatment 
Cyclophosphamide 
C.P (1 X 10"^ M) 
C.P+ carotenoids+ 
Vit B complex. 
C.P + Ca,+ Bi 
C.P + Ca2+ B2 
C.P + Ca2+ B2 
C.P + Ca,+Bi 
1 
Control 
Normal 
DMSO (5|ig/ml) 
CO :> 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-0 
0 
0 
GO 
13 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
Percent eel] 
Ml 
65 
66 
58 
57 
50 
50 
52 
54 
53 
52 
34 
33 
M2 
30 
29 
36 
37 
42 
42 
41 
39 
40 
41 
55 
54 
in 
M3 
05 
05 
06 
06 
08 
08 
07 
07 
07 
07 
11 
13 
Replication 
Index 
(RI) 
1.40 
1.39 
1.48 
1.49 
1.58 
1.58 
1.55 
1.53 
1.54 
1.55 
1.77 
1.80 
2*3 Chi square 
Test 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Normal 
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Table - 37: Analysis of CA after treatment with C.P, carotenoids and 
ascorbic acid in different combination in vitro. 
Treatments 
Cvclophosphami 
de C.P(lx 10"^  
M) 
C.P+Carotenoids 
+ Vit-C 
C.P + Cai+C, 
C.P + Ca2+C2 
CP + C a n Q 
C.P + Ca2-HC3 
Control 
Normal + Zi 
Normal 
DMS0(5|ig/ml) 
-C 
.2 
Q 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
(U 
55 "d 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
3.00 
3.00 
Percent 
aberration 
meta 
23.00 
38.00 
40.00 
17.50 
29.50 
30.00 
14.25 
23.50 
24.50 
15.50 
25.50 
27.50 
16.00 
27.00 
28.00 
2.30 
3.50 
3hase 
20.00 
33.00 
33.50 
15.50 
25.00 
25.50 
12.50 
20.00 
20.50 
14.00 
22.50 
22.00 
14.00 
23.00 
23.50 
1.80 
1.50 
Types of 
Aberration (%) 
24.00 
40.00 
45.00 
18.50 
31.00 
34.00 
14.50 
24.50 
27.00 
16.00 
27.00 
30.00 
17.50 
28.00 
31.50 
1.30 
2.00 
00 
O 
p S 
7.00 
20.50 
22.50 
6.00 
15.50 
17.50 
5.00 
13.00 
14.50 
5.00 
15.00 
15.50 
5.50 
14.50 
16.00 
0.70 
0.50 
'3 
4-" 
o 
H 
31.00 
60.00 
67.50 
24.50 
46.50 
51.50 
19.50 
37.50 
41.50 
21.00 
42.00 
45.50 
23.00 
42.00 
47.50 
2.00 
2.50 
Aberration / 
cell ± SE 
0.31 ±0.03 
0.61 ±0.06 
0.68 ± 0.09 
0.25 ± 0.03 
0.47 ± 0.04 
0.52 ±0.06 
0.20 ± 0.03 
0.38 ±0.03 
0.42 ± 0.04 
0.21 ±0.03 
0.42 ± 0.04 
0.46 ± 0.04 
0.23 ± 0.03 
0.43 ± 0.04 
0.48 ± 0.04 
0.02 ±0.01 
0.03 ±0.01 
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Table - 38: Analysis of C.A after treatment with C.P, carotenoids and 
ascorbic acid in presence of metabolic activation (S9 -
mix) in vitro. 
Treatments 
Cyclophosphami 
de_ C.P (1x10' ' 
M) 
C.P+Carotenoids 
+ Vit - C 
C.P + Cai+Ci 
C.P + Ca2+C2 
C.P + Ca,-C2 
C.P + Ca2,Ci 
Control 
Normal 
DMSO (5|^g/ml) 
c 
0 
0 
'o 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
c3 
0 
(U 
GO 
OH 
4-' 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Per 
aben 
meta 
*—< 
33.00 
41.00 
25.50 
31.00 
20.00 
25.50 
22.50 
28.00 
23.50 
29.00 
2.70 
4.00 
3.50 
4.50 
cent 
•ation 
phase 
x: 
30.00 
40.00 
23.00 
29.50 
18.00 
24.00 
20.00 
26.50 
21.00 
27.50 
1.70 
2.50 
1.70 
3.00 
Types of 
Aberration (%) 
a 
0 
0 
29.50 
36.50 
23.00 
28.50 
18.50 
22.50 
19.50 
24.50 
20.50 
26.50 
1.50 
3.00 
2.50 
3.00 
a 
0 
on 
0 a 0 
19.50 
23.50 
16.00 
18.00 
12.00 
14.50 
14.00 
15.50 
13.00 
16.50 
0.50 
0.00 
0.50 
0.50 
•13 
0 
49.00 
60.00 
39.00 
46.50 
30.50 
37.00 
33.50 
40.00 
33.50 
43.00 
2.00 
3.00 
3.00 
3.50 
Aberration / 
Cell ± SE 
0.49 + 0.06 
0.60 ± 0.07 
0.39 ±0.06 
0.47 ± 0.06 
0.31 ±0.06 
0.37 ±0.06 
0.34 ±0.06 
0.40 ± 0.06 
0.34 ± 0.06 
0.43 ± 0.06 
0.02 ±0.01 
0.03 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
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Table-39: Analysis of SCE after treatment with C.P , carotenoids 
and ascorbic acid in different combination in vitro. With 
and without the presence of metabolic activation at 48 h 
durations. 
Treatment 
Cyclophosphamide 
C.P(lxlO"^M) 
C.P+Carotenoids+ 
Vit-C 
C.P + Ca,+C, 
C.P + Ca2+C2 
C.P + Ca, + C2 
C.P + Ca2+Ci 
1 
Control 
Normal 
DMSO (5)ig/ml) 
S^ 
0 
48 
48 
48 
48 
48 
48 
48 
.3^  c 
0 . 2 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
1/1 
S CO 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
350 
360 
235 
235 
210 
200 
230 
215 
245 
240 
84 
89 
Range 
2-11 
2-11 
2 - 1 2 
2 - 1 2 
1-10 
1-12 
1-10 
0-10 
2 - 1 2 
1-11 
0 - 5 
0 - 6 
SCE/Cell 
+ SE 
7.00 ±1.29 
4.70 ±1.00 
4.70 ±1.00 
4.10 ±1.00 
4.00 ±0.75 
4.60 ±1.00 
4.30 ±1.00 
4.90 ±1.00 
4.80 ±1.00 
1.68±0.11 
1.78 ±0.12 
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Table- 40: Analysis of cell growth kinetics after treatment with C.P 
carotenoids and ascorbic acid in different combination in 
vitro. With and without the presence of metabolic 
activation at 48 h durations. 
Treatment 
Cyclophosphamide 
C.P(lxlO-^M) 
C.P+Carotenoids+ 
Vit-C 
C.P + Ca,+Ci 
C.P + Ca2+C2 
C.P + Ca, + C2 
C.P + Ca2+C, 
Control 
Normal 
DMSO (5|ig/ml) 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
u 0 0 
13 
U 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
Percent cell 
Ml 
66 
68 
55 
54 
49 
50 
52 
52 
53 
53 
32 
34 
M2 
30 
29 
39 
40 
41 
41 
41 
41 
42 
40 
52 
54 
in 
M3 
04 
06 
06 
10 
09 
07 
07 
05 
07 
16 
12 
Replication 
Index 
(RI) 
1.38 
1.51 
1.52 
1.61 
1.59 
1.55 
1.55 
1.52 
1.54 
1.84 
1.78 
2*3 Chi 
square 
Test 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Normal 
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Table-41: Analysis of CA after treatment with C.P along with 
vitamins of B-Complex and vitamin C in vitro. 
Treatments 
Cvclophosphami 
de C.P (1x10-^) 
C.P+VitBcomple 
X 
+Vit C. 
C.P + B, + Ci 
C.P + B2+C2 
C.P + B1 + C2 
C.P + B2+C1 
Control 
Normal 
DMS0(5^g/ml) 
3; 
c 
.2 
Q 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
73 
0 
D 
§^  
• ( -> 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
3.00 
3.00 
Per 
aben 
meta] 
-3 TO 
0 
1—1 
24.00 
38.00 
39.00 
16.25 
26.50 
27.00 
13.50 
21.50 
22.00 
16.00 
25.00 
25.50 
16.50 
25.00 
27.00 
2.00 
2.50 
cent 
ation 
3hase 
19.00 
33.00 
35.00 
13.00 
23.00 
24.00 
10.50 
19.00 
20.00 
12.50 
21.50 
22.50 
13.00 
23.50 
23.50 
1.50 
1.00 
Types of 
Aberration (%) 
-0 
a 0 
23.00 
41.50 
45.00 
15.50 
28.00 
30.00 
13.00 
23.00 
24.50 
15.00 
27.00 
29.50 
15.00 
27.00 
28.50 
1.50 
2.50 
a 
0 
(Zl 
0 a 
0 
6.00 
20.00 
22.00 
4.50 
13.50 
15.00 
3.50 
11.00 
12.50 
5.00 
13.00 
14.50 
4.50 
13.00 
14.00 
0.70 
0.50 
13 
29.00 
61.50 
67.00 
20.00 
41.50 
45.00 
16.50 
34.00 
37.00 
20.00 
40.00 
44.00 
19.50 
40.00 
42.50 
2.20 
3.00 
Aberration / 
Cell ± SE 
0.29 ± 0.03 
0.62 ± 0.09 
0.67 ± 0.09 
0.20 ± 0.03 
0.42 ± 0.06 
0.45 ± 0.06 
0.17 ±0.03 
0.34 ± 0.04 
0.37 ±0.04 
0.20 ±0.03 
0.40 ± 0.06 
0.44 ± 0.06 
0.20 ±0.03 
0.40 ± 0.06 
0.43 ± 0.06 
0.02 ±0.01 
0.03 ±0.01 
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Table - 42: Analysis of C.A after treatment with C.P along with 
vitamins of B-complex and vitamin C in presence with or 
without metabolic activation in vitro. 
Treatments 
Cvclophosphami 
de_ C.P (1x10"^ 
M) 
C.P+VitBcomple 
X 
+Vit C. 
C.P + B, + C, 
C.P + B2+ C2 
c.p + Bi + c;2 
C.P + B2+C1 
Control 
Normal 
DMSO (5|ig/ml) 
0 
> 
• M 
'0 
x> 
• 4 - " 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
T3 
cd 
0 
00 
OH 
-t-i 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Per 
aben 
meta 
l-H 
32.50 
37.50 
23.00 
27.50 
19.50 
23.00 
21.00 
25.50 
22.50 
26.50 
2.70 
3.70 
3.50 
4.00 
cent 
ation 
)hase 
X 
30.50 
39.00 
21.50 
26.00 
18.00 
22.00 
20.00 
23.50 
20.50 
25.00 
1.30 
2.30 
1.50 
3.00 
Types of 
Aberration (%) 
0 
30.00 
38.00 
21.00 
27.00 
18.00 
22.50 
19.50 
25.00 
20.50 
24.00 
1.70 
2.70 
2.50 
3.50 
B 0 
0 
a 
18.00 
22.00 
13.00 
15.50 
11.00 
13.00 
12.00 
14.50 
12.50 
15.00 
0.30 
0.30 
0.00 
0.50 
"3 
• I - ' 
0 H 
48.00 
60.00 
34.00 
42.50 
29.00 
35.50 
31.50 
39.50 
33.00 
39.00 
2.00 
3.00 
2.50 
4.00 
Aberration/ 
Cell ± SE 
0.48 + 0.06 
0.60 ± 0.07 
0.34 ±0.04 
0.43 ± 0.06 
0.29 ± 0.04 
0.36 ±0.04 
0.32 ±0.04 
0.40 ± 0.04 
0.33 ±0.04 
0.39 ±0.04 
0.02 ±0.01 
0.03 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
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Table-43: Analysis of SCE after treatment with C.P along with 
vitamins of B - Complex and vitamin C in vitro. With 
and without the presence of metabolic activation at 48 h 
durations. 
Treatment 
CYclophosphamide 
C.P (1 X 10"^ M) 
C.P+VitBcomplex 
+Vit C. 
C.P + Bi + C, 
C.P + B2+ C2 
C.P + B,+ C2 
C.P + B2+C, 
Control 
Normal 
DMSO (5(ig/ml) 
^ 
.2 
Q 
48 
48 
48 
48 
48 
48 
48 
y d 
^ • 2 
ra > 
(U +3 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
1/1 
P3 S 
-t-> C 
2 V3 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
370 
385 
240 
245 
219 
215 
234 
235 
237 
240 
72 
76 
Range 
2-12 
1-11 
1-10 
1-11 
2 - 1 2 
1-11 
1-10 
0-10 
1-10 
0-10 
0 - 6 
0 - 6 
SCE / Cell 
±SE 
7.40 + 1.25 
7.60 ±1.30 
4.80 ±1.00 
4.90 ±1.00 
4.38 ±1.00 
4.30 ±1.00 
4.68 + 1.00 
4.70 ±1.00 
4.74 + 1.00 
4.80 ±1.00 
1.44 ±0.12 
1.52±0.12 
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Table - 44: Analysis of ciell kinetics after treatment with C.P along 
with vitamins of B - complex and vitamin C in vitro. 
With and without the presence of metabolic activation at 
48h durations. 
Treatment 
Cyclophosphamide 
C.P(lxlO'^M) 
C.P+VitBcomplex 
+Vit C. 
C.P + B,+ Ci 
C.P + B2+ C2 
C.P + B, + C2 
C.P + B2+C, 
Control 
Normal 
DMSO (5)ig/ml) 
.a G 
0-2 
^ 03 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
0 
0 
00 
200 
200 
t 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
Percent eel] 
Ml 
65 
67 
53 
52 
48 
45 
50 
49 
51 
51 
34 
33 
M2 
30 
28 
40 
39 
41 
45 
41 
42 
40 
41 
56 
55 
in 
M3 
05 
05 
07 
09 
11 
10 
9 
09 
9 
10 
10 
12 
1.40 
1.38 
1.54 
1.57 
1.63 
1.65 
1.59 
1.60 
1.58 
1.57 
1.76 
1.79 
2x3 Chi square 
Test 
Significant 
Significant 
Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
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Table - 45: Analysis of A after treatment with C.P along with vitamin 
C and flavonoids in vitro. 
Treatments 
Cyclophosphami 
de C.P (1x10'^) 
C.P+Vit C. + 
Flavonoid 
C.P + Ci + Fi 
C.P + C2+ F2 
C.P + C1 + F2 
C.P + C2+F1 
Control 
Normal 
DMS0(5^ig/ml) 
2^ 
' • ( - < 
Q 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
a 0 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
3.00 
3.00 
Percent 
aberration 
metaphase 
» — 1 
22.50 
38.00 
39.00 
15.50 
26.00 
27.00 
13.50 
24.50 
25.00 
14.50 
25.00 
26.00 
14.00 
24.00 
25.00 
2.70 
3.50 
x: 
19.00 
33.00 
35.00 
13.00 
22.50 
24.00 
12.00 
20.50 
22.50 
13.00 
24.00 
23.50 
12.00 
23.00 
22.50 
1.80 
2.00 
Types of 
Aberration (%) 
6 
0 
23.00 
40.00 
46.00 
15.50 
27.50 
31.50 
14.00 
25.00 
28.00 
15.00 
26.00 
30.00 
13.50 
25.50 
29.00 
2.00 
2.50 
B 0 
0 
B 0 
M 
u 
7.00 
18.50 
22.50 
5.00 
12.50 
15.50 
4.50 
11.50 
14.50 
5.00 
14.50 
15.50 
5.00 
13.50 
15,00 
0.00 
0.50 
0 H 
30.00 
58.50 
68.50 
20.50 
40.00 
47.00 
18.50 
36.50 
42.50 
20.00 
40.50 
45.50 
18.50 
39.00 
44.00 
2.00 
3.00 
Aberration / 
Cell ± SE 
0.30 ±0.04 
0.59 + 0.09 
0.69 ±0.10 
0.21 ±0.04 
0.40 ±0.04 
0.47 ± 0.06 
0.19 ±0.03 
0.37 ±0.04 
0.43 ± 0.06 
0.20 ± 0.03 
0.41 ±0.06 
0.46 ± 0.06 
0.19 ±0.03 
0.39 ± 0.04 
0.44 ± 0.06 
0.02 ±0.01 
0.03 ±0.01 
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Table-46: Analysis of C.A after treatment with C.P along with 
vitamins C and Flavonoids in presence with or 
without metabolic activation in vitro. 
Treatments 
Cyclophosphami 
de C.P (1 X 10-^  
M) 
C.P+Vit C. + 
Flavonoids 
C.P + C , + F , 
C.P + C2+F2 
C.P + C,+ F2 
C.P + C2+F1 
Control 
Normal 
DMSO (5|ag/ml) 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
cd 
0 
to 
1/3 
a 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Per 
aberi 
meta 
G 
33.00 
41.50 
23.00 
29.50 
20.50 
25.50 
22.50 
28.00 
21.50 
27.00 
2.50 
3.00 
2.70 
4.50 
cent 
•ation 
3hase 
30.50 
38.50 
21.00 
28.00 
19.00 
24.00 
20.00 
26.00 
20.00 
25.00 
1.50 
2.00 
1.30 
3.00 
Types of 
Aberration (%) 
73 
• ( - ' 
0 
u 
31.00 
37.00 
21.50 
29.00 
19.50 
23.00 
21.00 
25.50 
20.50 
24.00 
1.70 
2.50 
2.00 
2.70 
0 
a 0 
B 0 
0 
19.50 
24.00 
14.50 
17.00 
12.50 
15.00 
14.00 
16.00 
12.50 
16.00 
0.30 
0.00 
0.70 
1.30 
13 
50.50 
61.00 
36.00 
46.00 
32.00 
38.00 
35.00 
41.50 
33.00 
40.00 
2.00 
2.50 
2.70 
4.00 
Aberration / 
Cell ± SE 
0.51 ±0.06 
0.61 ±0.07 
0.36 ± 0.04 
0.46 ± 0.06 
0.32 ± 0.04 
0.38 ± 0.04 
0.35 ±0.04 
0.42 ± 0.06 
0.33 ± 0.04 
0.40 ± 0.04 
0.02 ±0.01 
0.03 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
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Table-47: Analysis of SCE after treatment with C.P along with 
vitamin C and flavonoids in vitro. With and without the 
presence of metabolic activation at 48h durations. 
Treatment 
Cvclophosphamide 
C.P(lxlO'^M) 
C.P+VitC.+ 
Flavonoids 
C.P + C,+Fi 
C.P + C2+ F2 
C.P + C1 + F2 
C.P + C2+F, 
Control 
Normal 
DMSO (5(ig/ml) 
^ 
.2 
Q 
48 
48 
48 
48 
48 
48 
48 
^ c 
^ • 2 
TO > 
S cd 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
ca S 
Hi R3 
5 0 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
376 
383 
256 
269 
222 
230 
250 
259 
244 
247 
77 
82 
Range 
1-
2-
1-
1-
2-
1-
2-
0-
0-
0-
0-
0-
11 
-12 
-10 
11 
-12 
-11 
-12 
-10 
-10 
-10 
-6 
-7 
SCE/Cell 
+SE 
7.52 + 1.24 
7.66 ±1.30 
5.12 ±1.00 
5.30 ±1.00 
4.44 ±1.00 
4.60 ±1.00 
5.00 ±1.00 
5.18 ±1.00 
4.88 + 1.00 
4.94 ±1.00 
1.54±0.12 
1.64 ±0.12 
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Table - 48: Analysis of cell cycle kinetics after treatment with C.P 
along with vitamin C and flavonoids in vitro. With and 
without the presence of metabolic activation at 48h 
durations. 
Treatment 
Cvclophosphamide 
C . P ( 1 X 1 0 ' ' M ) 
C.P+Vit C. + 
Flavonoids 
C.P + Ci+F, 
C.P + C2+F2 
C.P + C,+F2 
C.P + C2+F1 
Control 
Normal 
DMSO (5|ig/ml) 
1 
CO > 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
T3 
0 
00 
13 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
Percent cell 
Ml 
65 
67 
52 
54 
46 
47 
49 
50 
48 
49 
32 
34 
M2 
33 
31 
43 
41 
45 
44 
44 
43 
44 
43 
55 
50 
in 
M3 
02 
02 
05 
05 
09 
09 
07 
07 
08 
08 
13 
16 
^ ^ 
1.37 
1.35 
1.53 
1.51 
1.63 
1.62 
1.58 
1.57 
1.60 
1.59 
1.81 
1.82 
2x3 Chi square 
Test 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Normal 
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Table-49: Analysis of CA after treatment with C.P along with 
carotenoids and flavonoids in vitro. 
Treatments 
Cvclophosphami 
de C.P (1x10"^) 
C.P+ cartenoids. 
+Flavonoids 
C.P + Ca, + Fi 
C.P + Ca2+ F2 
C.P + Ca, + F2 
C.P + Ca2+Fi 
Control 
Normal 
DMSO (5|ag/ml) 
c 
.2 
'-t-> 
u 
Q 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
0 
(U 
on 
2 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
Per 
aben 
meta] 
3 TO 
23.00 
37.50 
38.00 
17.50 
28.50 
29.00 
15.00 
23.50 
24.50 
17.00 
27.00 
27.50 
16.00 
26.50 
27.00 
2.50 
3.00 
:ent 
ation 
phase 
W) 
W 
18.50 
32.00 
33.00 
14.00 
24.00 
26.00 
12.00 
21.50 
21.50 
14.00 
23.00 
24.00 
13.00 
22.50 
23.50 
1.70 
1.50 
Types of 
Aberration (%) 
3 
' • ( - ' 
B 
0 
u 
22.00 
40.50 
44.00 
16.50 
30.50 
33.00 
14.00 
26.00 
28.50 
16.00 
29.50 
32.00 
15.50 
28.50 
31.00 
1.70 
2.00 
B 0 
00 0 
B 
0 
6.00 
20.50 
23.00 
5.00 
15.50 
17.50 
4.00 
13.50 
15.00 
4.50 
15.00 
17.00 
4.50 
14.50 
16.00 
0.30 
1.00 
1 — ( 
0 
H 
28.00 
61.00 
67.00 
21.50 
46.00 
50.50 
18.00 
39.50 
43.50 
20.50 
44.50 
49.00 
20.00 
43.00 
47.00 
2.00 
3.00 
Aberration / 
Cell ±SE 
0.28 ±0.03 
0.61 ±0.09 
0.67 ±0.09 
0.22 ± 0.03 
0.46 ± 0.06 
0.51 ±0.06 
0.18 ±0.03 
0.40 ± 0.06 
0.44 ± 0.06 
0.21 ±0.03 
0.45 ± 0.06 
0.49 ± 0.06 
0.20 ± 0.03 
0.43 ± 0.06 
0.47 ± 0.06 
0.02 ±0.01 
0.03 ±0.01 
172 
Table-50: Analysis of C.A after treatment with C.P along with 
carotenoids and flavonoids in presence with or without 
metabolic activation in vitro. 
Treatments 
Cvclophosphami 
de_ C.P (1x10"^ 
M) 
C.P+ cartenoids. 
+Flavonoids 
C.P + Cai + F, 
C.P + Ca2+F2 
C.P + Ca,+ F2 
C.P + Ca2+Fi 
Control 
Normal 
DMSO (5)ig/ml) 
c 
0 
..—( 
' • ( - > 0 
"o 
X) 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-0 
o 
0 
CO 
D 
- t - l 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Per 
aben 
Meta 
c 
1 — I 
33.00 
41.00 
25.00 
31.00 
21.50 
26.50 
24.00 
29.50 
23.00 
29.00 
2.80 
3.00 
3.00 
4.50 
3ent 
ation 
phase 
31.00 
40.00 
23.50 
30.00 
20.00 
25.00 
22.50 
28.00 
22.00 
28.00 
1.50 
2.00 
1.50 
2.50 
Types of 
Aberration (%) 
0 
30.00 
38.00 
22.50 
28.50 
19.50 
23.50 
22.00 
27.50 
21.00 
27.00 
1.70 
2.50 
2.00 
3.00 
(U 
a 0 
a 
0 
20.00 
24.00 
15.00 
18.00 
13.00 
15.50 
14.50 
17.50 
14.00 
17.00 
0.30 
0.50 
1.00 
0.50 
13 
0 
H 
50.00 
62.00 
37.50 
46.50 
32.50 
39.00 
36.50 
45.00 
35.00 
44.00 
2.00 
3.00 
3.00 
3.50 
Aberration/ 
Cell ± SE 
0.50 ±0.06 
0.62 + 0.07 
0.38 ±0.06 
0.47 ± 0.06 
0.33 ± 0.06 
0.39 ±0.06 
0.37 ±0.06 
0.45 ± 0.06 
0.35 ±0.06 
0.44 ± 0.06 
0.02 ±0.01 
0.03 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
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Table-51: Analysis of SCE after treatment with C.P along with 
carotenoids and flavonoids in vitro. With and without the 
presence of metabolic activations. 
Treatment 
Cyclophosphamide 
C.P (1 X IQ-^ M) 
C.P+ cartenoids. 
+Flavonoids 
C.P + Cai + F] 
C.P + Ca2+ F2 
C.P + Cai + F2 
C.P + Ca2+Fi 
Control 
Normal 
DMSO (5^g/ml) 
^ 
0 
48 
48 
48 
48 
48 
48 
48 
0 c 
0 • •-< 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
0) 
t/2 
a, 2 
+-» c 
p<5 00 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
376 
386 
282 
290 
241 
247 
270 
282 
260 
270 
74 
78 
Range 
2-
2-
1-
1-
1-
1-
2-
0-
2 -
0-
0-
0-
-12 
-12 
-11 
-11 
-11 
-11 
-12 
-10 
-12 
-lU 
-5 
-6 
SCE / Cell 
+SE 
7.52 ±1.24 
7.72 ±1.30 
5.64 ±1.00 
5.80 ±1.00 
4.82 ±1.00 
4.94 ±1.00 
5.40 ±1.00 
5.64+1.00 
5.20 + 1.00 
5.40 ±1.00 
1.48 ±0.12 
1.56 ±0.12 
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Table-52: Analysis of cell cycle kinetics after treatment with C.P 
along with carotenoids and flavonoids in vitro. With 
and without the presence of metabolic activation at 48h 
durations. 
Treatment 
Cyclophosphamide 
C.P(lxlO"^M) 
C.P+ cartenoids. 
+Flavonoids 
C.P + Ca,+F] 
C.P + Ca2+F2 
C.P + Cai + F2 
C.P + Ca2+ Fi 
Control 
Normal 
DMSO (5)ig/ml) 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-a 
>-, 
0 
0 
00 
• — I 
u 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
Percent cell in 
Ml 
68 
66 
58 
56 
50 
50 
54 
54 
52 
52 
35 
34 
M2 
29 
31 
37 
39 
43 
42 
40 
40 
42 
41 
55 
54 
M3 
03 
03 
05 
05 
07 
08 
06 
06 
06 
07 
10 
12 
.2 2 
1.35 
1.37 
1.47 
1.49 
1.57 
1.58 
1.52 
1.52 
1.54 
1.55 
1.75 
1.78 
2x3 Chi square 
Test 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Significant 
Normal 
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Table-53: Analysis of CA after treatment with C.P along with 
vitamins of B-complex and flavonoids in vitro. 
Treatments 
1 
Cvclophosphami 
de C.P (1x10' 
C.P+ Vit 
B Complex 
+Flavonoids 
C.P + Bi + F, 
C.P + B2+ F2 
C.P + B1+F2 
C.P + B2+F1 
Control 
Normal 
DMS0(5ng/ml) 
0 
• ( - > 
a 
u 
Q 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
Per 
aben 
meta] 
23.00 
37.00 
39.00 
17.00 
27.00 
28.50 
14.50 
23.50 
25.00 
16.00 
25.50 
26.50 
15.50 
24.50 
26.00 
2.50 
3.50 
:ent 
ation 
phase 
X 
20.50 
33.50 
34.00 
15.00 
24.50 
25.00 
13.00 
21.50 
21.50 
14.00 
23.00 
23.50 
13.50 
22.50 
23.00 
1.50 
2.00 
Types of 
Aberration (%) 
0 
21.50 
37.50 
45.00 
16.00 
27.50 
33.00 
13.50 
24.00 
28.50 
15.00 
25.00 
31.00 
14.50 
25.00 
30.00 
1.80 
2.50 
B 0 
S 
0 
M 
u 
7.00 
19.50 
22.50 
5.50 
14.50 
16.50 
4.50 
12.50 
14.50 
5.00 
13.00 
15.50 
5.00 
13.00 
15.00 
0.50 
0.50 
0 
H 
28.50 
57.00 
67.50 
21.50 
42.00 
49.50 
18.00 
36.50 
43.00 
20.00 
38.00 
46.50 
19.50 
38.00 
45.00 
2.30 
3.00 
Aberration / 
Cell ±SE 
0.29 ± 0.04 
0.57 ±0.08 
0.68 ±0.09 
0.22 ± 0.04 
0.42 ± 0.06 
0.50 ±0.08 
0.18 ±0.03 
0.37 ±0.04 
0.43 ± 0.06 
0.20 ± 0.03 
0.38 ±0.04 
0.47 ± 0.06 
0.20 ± 0.03 
0.38 ±0.06 
0.45 ± 0.06 
0.02 ±0.01 
0.03 ±0.01 
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Table-54. Analysis of C.A after treatment with C.P along with 
vitamins of B-complex and flavonoids in presence with 
or without metabolic activation in vitro. 
Treatments 
Cyclophosphami 
de C.P (1x10-^ 
M) 
C.P+ Vit 
B complex 
+Flavonoids 
C.P + B, + F, 
C.P + B2+ F2 
C.P + B,+F2 
C.P + B2+F, 
Control 1 
Normal 
DMSO (5|ig/ml) 
-S9. 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
^ on 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Percent 
aberration 
Metaphase 
0 
^5 bfi 
33.50 
42.00 
24.50 
31.00 
21.00 
26.00 
23.00 
29.50 
22.50 
28.00 
2.50 
3.50 
3.50 
4.50 
0 w 
^ 01) 
31.00 
40.50 
22.50 
29.00 
19.50 
25.00 
21.00 
27.50 
20.50 
27.00 
1.50 
2.00 
2.00 
2.50 
Types of Aberration 
(%) 
+-< 
B 
0 
u 3 
32.00 
37.50 
23.50 
27.50 
20.00 
23.50 
22.00 
25.50 
21.50 
25.00 
2.00 
3.00 
2.50 
3.50 
0 
S 
U 0 
19.00 
23.00 
14.00 
17.00 
12.00 
14.50 
13.00 
16.00 
12.50 
15.50 
0.00 
0.00 
1.00 
0.50 
"13 
0 
H 
51.00 
60.50 
37.50 
44.50 
32.00 
38.00 
35.00 
41.50 
34.00 
40.50 
2.00 
3.00 
3.50 
4.00 
Aberration / 
Cell ± SE 
0.51 ±0.06 
0.61 ±0.08 
0.38 ±0.06 
0.45 ± 0.06 
0.32 ±0.06 
0.38 ±0.06 
0.35 ±0.06 
0.42 ± 0.06 
0.34 ± 0.06 
0.41 ±0.06 
0.02 ±0.01 
0.03 ±0.01 
0.04 ±0.01 
0.04 ±0.01 
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Table-55: Analysis of SCE after treatment with C.P along with 
vitamins of B-complex and flavonoids in vitro. With and 
without the presence of metabolic activation at 48h 
durations. 
Treatment 
Cyclophosphamide 
C.P(lxlO'^M) 
C.P+ Vit 
B complex 
+Flavonoids 
C.P + Bi+Fi 
C.P + B2+F2 
C.P + B,+F2 
C.P + B2+F1 
Control 
Normal 
DMSO (5|ig/ml) 
S; 
d 
0 
Q 
48 
48 
48 
48 
48 
48 
48 
^ G 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
C/5 
5 0 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
Total 
SCE 
367 
391 
268 
286 
228 
243 
250 
266 
243 
258 
82 
86 
Range 
2-12 
1-11 
1-11 
2 - 1 2 
1-11 
0 - 1 0 
2 - 1 2 
1-11 
2 - 1 2 
1-10 
0 - 6 
0 - 7 
SCE / Cell 
±SE 
7.34 ±1.26 
7.82 + 1.30 
5.36 ±1.00 
5.72 ±1.00 
4.56 ±1.00 
4.86 ±1.00 
5.00 ±1.00 
5.32 + 1.00 
4.86 ±1.00 
4.16 ±1.00 
1.64 ±0.12 
1.72±0.12 
178 
Table - 56: Analysis of cell cycle kinetics after treatment with C.P along 
with vitamins of B-complex and flavonoids in vitro. With and 
without the presence of metabolic activation at 48h durations. 
Treatmerit 
Cvclophosphamide 
C.P(lxlO-^M) 
C.P+VitB complex 
+Flavonoids 
C.P + B,+Fi 
C.P + B2+ F2 
C.P + B1+F2 
C.P + B2+F1 
3 c 
-2 ^ 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
Control 
Normal 
DMS0(5^g/ml) 
T3 
0 
0 
U 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
Percent cell in 
Ml 
66 
67 
53 
56 
47 
49 
50 
52 
49 
50 
35 
35 
M2 
30 
29 
41 
39 
44 
43 
42 
42 
43 
43 
52 
54 
M3 
04 
04 
06 
05 
09 
08 
08 
06 
08 
07 
13 
11 
1.38 
1.37 
1.53 
1.49 
1.62 
1.59 
1.58 
1.54 
1.59 
1.57 
1.78 
1.76 
2x3 Chi square 
Test 
Significant 
Significant 
Significant 
Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
Not Significant 
Normal 
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Table-57: Effective percentage in lowering of clastogency when 
treated separately. 
Antigenotoxic 
Agents. 
Carotenoids. 
Flavonoids. 
B-Complex. 
Vit-C. 
H] 
Highest 
value. 
54.00 
55.00 
52.50 
52.00 
f'drocortisone 
Lowest 
value. 
36.75 
43.00 
40.00 
38.50 
Percent 
reduction 
value. 
32.00 
22.00 
24.00 
26.00 
Cyclophosphamide 
Highest 
value. 
61.00 
61.00 
60.50 
66.00 
Lowest 
value. 
42.50 
45.00 
45.50 
44.00 
Percent 
reduction 
value. 
30.30 
26.20 
25.00 
33.30 
Table 58: Effective percentage in lowering of clastogency with S9-
mix, when treated separately. 
Antigenotoxic 
Agents. 
Carotenoids. 
Flavonoids. 
B-Complex. 
Vi t -C. 
Hydrocortisone 
Highest 
value. 
41.00 
41.00 
41.00 
42.00 
Lowest 
value. 
30.30 
27.00 
28.00 
28.00 
Percent 
reduction 
value. 
25.6 
34.1 
31.7 
33.3 
Cyclophosphamide 
Highest 
value. 
61.0 
61.0 
59.0 
61.50 
Lowest 
value. 
46.0 
45.5 
41.0 
44.0 
Percent 
value. 
24.5 
25.4 
30.5 
28.4 
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Table-59: Effective percentage in lowering of SCE when treated 
separately. 
Antigenotoxic 
Agents. 
Carotenoids. 
Flavonoids. 
B-Complex. 
Vi t -C. 
Hydrocortisone 
Highest 
value. 
230 
220 
205 
235 
Lowest 
value. 
170 
165 
142 
175 
Percent 
reduction 
value. 
26.0 
25.0 
30.7 
25.5 
Cyclophosphamide 
Highest 
value. 
340 
310 
350 
320 
Lowest 
value. 
256 
210 
270 
200 
Percent 
value. 
24.7 
28.0 
37.5 
32.2 
Table-60: Effective percentage in lowering of SCE when treated 
separately with metabolic activation. 
Antigenotoxic 
TAgents. 
Carotenoids. 
Flavonoids. 
B-Complex. 
Vi t -C. 
Hydrocortisone 
Highest 
value. 
300 
315 
371 
332 
Lowest 
value. 
200 
195 
230 
257 
Percent 
reduction 
value. 
33.3 
38.0 
38.0 
22.5 
Cyclophosphamide 
Highest 
value. 
380 
375 
390 
360 
Lowest 
value. 
280 
280 
290 
245 
Percent 
value. 
26.3 
25.3 
25.6 
31.9 
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Table -61: Effective percentage in lowering of clastogeny in different 
combination of antigenotoxicity agents against C.P 
induced genotoxicity in absence and presence of S9 - mix. 
Combination 
Carotenoids+B-Complex 
Carotenoids+Vit C 
Carotenoids+ Flavonoid 
B-Complex+ Vit C. 
B-Complex+ Flavonoid 
Flavonoid+ Vit C. 
Highest 
value. 
-S9 
49.0 
49.0 
50.0 
48.0 
51.0 
50.5 
+S9 
61 
60 
62 
60 
60.5 
61 
Lowest value. 
-S9 
31.5 
30.5 
15.0 
29.0 
32.0 
32.0 
+S9 
39.5 
37.0 
18.0 
35.5 
38.0 
38.0 
Percent 
reduction. 
-S9 
35.7 
37.7 
30.0 
29.0 
32.0 
32.0 
+S9 
35.2 
38.3 
35.3 
40.8 
37.1 
37.7 
Table-62: Effective percentage in lowering of SCE when treated in 
different combination of antigenotoxic agents an absence 
as well as in presence of metabolic activation. 
Combinations. 
Carotenoids+B-Complex 
Carotenoids+Vit C 
Carotenoids+ Flavonoid 
B-Complex+ Vit C. 
B-Complex+ Flavonoid 
Flavonoid+ Vit C. 
Highest 
value. 
-S9 
372 
350 
376 
370 
367 
376 
+S9 
372 
350 
386 
365 
391 
383 
Lowest value. 
-S9 
250 
210 
241 
219 
228 
222 
+S9 
246 
235 
247 
215 
243 
230 
Percent 
reduction. 
-S9 
32.7 
40.0 
35.9 
40.8 
37.8 
40.9 
+S9 
33.8 
32.8 
36.0 
41.0 
37.8 
39.9 
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Table-63: Percentage enhancement of R.I after treatment with 
antigenotoxic agents in separately in Hydrocortisone and 
C.P induced genotoxicity. 
Antigenotoxic 
Agents. 
Carotenoids. 
Flavonoids. 
B-Complex. 
V i t - C . 
Hydrocortisone 
Highest 
R.I 
1.63 
1.67 
1.68 
1.68 
Lowest 
R.I 
1.48 
1.46 
1.46 
1.51 
Percent 
change 
10.1 
14.3 
15.0 
11.2 
Cyclophosphamide 
Highest 
R.I 
1.47 
1.49 
1.52 
1.61 
Lowest 
R.I 
1.37 
1.41 
1.37 
1.40 
Percent 
change. 
7.29 
5.6 
10.9 
15.0 
Table-64: Percent enhancement of R.I when treated in different 
combination with and without S9 - mix. 
Combinations 
Carotenoids+B-
Complex 
Carotenoids+Vit C 
Carotenoids+ 
Flavonoid 
B-Complex^ Vit C. 
B-Complex+ 
Flavonoid 
Flavonoid+ Vit C 
Highest 
R.I 
1.58 
1.61 
1.57 
1.63 
1.62 
1.63 
S9 
Lowest 
R.I 
1.40 
1.38 
1.35 
1.40 
1.38 
137 
Percent 
change. 
12.8 
16.6 
16.2 
16.4 
17.3 
18.9 
+S9 
Highest 
R.I 
1.58 
1.59 
1.58 
1.65 
1.59 
1.62 
Lowest 
R.I 
1.39 
1.35 
1.37 
1.38 
1.37 
1.35 
Percent 
change. 
13.7 
17.7 
15.3 
17.5 
16.0 
20.0 
Table-65. Different test chemicals and their effect in reducing various 
types of aberrations 
Treatment 
Control 
Hyd 
Hyd+Ca 
Hyd+B-
complex 
Hyd+C 
Hyd+flav. 
S9 
mix 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
-S9 
+S9 
Total 
Metaphase 
scored 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Total 
Abnormal 
cells 
(%) 
12(4) 
12(6) 
72(24) 
58(29) 
57(19) 
52(26) 
60(20) 
54(27) 
51(170 
40(20) 
58(19) 
54(27) 
Aberrations (%) 
chromatid type chromosome type Total 
g c c/c del ib tf t gcc/cdel ibtft 
02 0 0 0 0 2 02 0 0 0 02 4 
0 30 0 0 0 3 0 5 0 0 0 05 8 
2 16 5 1 0 130 0102 1 0 015 45 
2 20 6 11 0 36 2 12 2 1 1 1 21 57 
1 12 3 1 0 121 0 9 11 1 0 14 34 
1 15 4 1 0 024 1 8 1 1 0 1 13 37 
1 14 4 0 0 123 0 8 2 0 0 0 12 35 
0 16 5 1 0 027 1 7 1 1 1 012 39 
0113 0 0 0 17 0 7 10 0 0 9 26 
014 4 0 1 0 23 0 7 1 0 0 0 8 31 
113 4 0 0 0 22 0 6 1 0 0 0 7 29 
0 15 4 0 1 0 24 1 9 1 0 1 013 37 
Abbreviations- g; gaps, c; breaks, c/c; exchanges, del; deletion, ib; isochromatid breaks, tf; 
terminal fragment, t; total. Hyd; hydrocortisone. Ca; carotenoids. C; vitamin C. flav; flavonoidi 
one exchange implies two breaks. 
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Fig.l (Photo-A): Antigenotoxic effects of carotenoids in C.P induced 
chromosomal aberration, sliowing cell with 
chromosome breaks and chromatid gaps. 
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Fig. 2 (Photo-B): Antigenotoxic effects of flavonoids in C.P induced 
chromosomal aberration, showing cell with chromosome 
breaks and chromatid gaps 
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Fig. 3 (Photo-C): Antigenotoxic effects of vitamin C in C.P induced 
chromosomal aberration, siiowing cell with terminal 
deletion. 
Fig. 4(Photo-D): Antigenotoxic effects of vitamin B-complex in C.P induced 
cliromosomal aberration, showing cell with chromosome 
exchanges 
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Fig. 5 (Photo-E) Combined antigenotoxic effects of vitamin C and 
carotenoids in C.P induced chromosomal aberration 
showing cell with chromatid break. 
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Fig 6 (Photo-F): Combined antigenotoxic effects of vitamin C and 
flavonoids in C.P induced chromosomal aberration showing 
cell with chromatid exchanges. 
Fig 7 (Photo-G) :Combined antigenotoxic effects of vitamin B-complex and 
C in C.P induced ciiromosomal aberration showing cell 
with dicentric. 
Fig 8 (Photo-H): Combined antigenotoxic effects of carotenoids and 
flavonoids in C.P induced chromosomal aberration 
sliowing cell with extreme chromosome shortening with 
chromosome segregation. 
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Fig 9 (Photo-J) :Combined antigenotoxic effects of vitamin B-complex and 
flavonoids in C.P induced chromosomal aberration 
showing cell towards the condition of multiple anomalies. 
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Fig. 10 (Photo-K): Combined antigenotoxic effects of vitamin C and 
carotenoids in C.P induced chromosomal aberration 
showing sister chromatid exchanges (Ml stage) 
Fig. ] 1 (Photo-M): Combined antigenotoxic effects of vitamin C and 
flavonoids in C.P induced chromosomal aberration 
showing sister chromatid exchanges (M2stage) 
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Fig. 12 (Photo-N): Antigenotoxic effects of vitamin C in C.P induced 
chromosomal aberration, showing sister chromatid exchanges. 
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Amelioration of genotoxic damage by certain phytoproducts in 
human lymphocyte cultures. 
Md Sultan Ahmad, Sheeba* and Mohd. Afzal. 
Section of Genetics, Department of Zoology, Aligarh Muslim University, 
Aligarh-202002, India 
Abstract: -
The antigenotoxic effect of some phytoproducts like carotenoid (B-
carotene), curcumin, ascorbic acid and flavonoid (genistein) was 
demonstrated on the genotoxicity induced by hydrocortisone. Human 
lymphocyte cultures were studied for the induction of chromosomal 
aberrations, sister chromatid exchanges and effect on cell cycle kinetics 
with or without the presence of metabolic activation (Sg mix). The 
phytoproducts were studied in two most effective doses viz. carotenoid 
(0.5 |LiM, 0.7 laM), curcumin (15j^ M 25|aM), ascorbic acid (60fiM, 80)aM) 
and flavonoid (25|aM, 40|iM) in 24, 48 and 72 hr cultures and they were 
found to reduce chromosomal aberrations, sister chromatid exchange 
and increase replication index. The present study showed that the 
ascorbic acid and curcumin were more effective than carotenoid and 
flavonoid, though, all provide protection against the genotoxicity of 
hydrocortisone. 
Abbreviations: CA, chromosomal aberration; SCE, sister chromatid 
exchange; Rl, replication index; Hyd, hydrocortisone (138 ^M); DMSO, 
Dimethyl sulphoxide (64 ^M); Cai, carotenoid (0.5 ^M); Ca2, carotenoid 
(0.7 laM); Cui, curcumin (15 |j,M); Cu2, curcumin (25 ^M); Ci, ascorbic 
acid (60 |iM); C2, ascorbic acid (80 ^M); Fi, flavonoid (25 ^M); F2, 
flavonoid (40 )iM). 
*Corresponding author. 
E-mail address: sheeba_2003_00@yahoo.co.in (Sheeba) 
Keywords: Phytoproducts, Hydrocortisone, Chromosomal aberrations. Sister 
chromatid exchanges. Replication index. 
1. Introduction 
Steroids are active biological agents that function as natural hormones, chemical 
ligands, and precursors for endogenous synthesis of other chemicals. Steroidal 
hormones and their synthetic derivatives perform their function by forming 
steroid receptor complex that bind with DNA and influence gene expression [1]. 
Despite of the therapeutic uses, there are many reports indicating their 
mutagenic, carcinogenic, clastogenic, and teratogenic effects [2]. 
Hydrocortisone is a potent steroidal drug, which is used therapeutically for a 
number of reasons. It is a potent glucocorticoid used primarily for ameliorating 
severe inflammation, allergic reaction, in shock syndrome neoplasia and adrenal 
insufficiency. Hydrocortisone induces chromosomal aberrations, sister chromatid 
exchanges and cell cycle kinetics in human lymphocyte cultures with and without 
metabolic activation [3-4]. Some phytoproducts act as antioxidants and free 
radical scavengers and thus act as anticarcinogen and anticlastogen. Curcumin, 
ascorbic acid and flavonoids are best-known antimutagens used in in vivo animal 
models. 
Carotenoids, specially p - carotene, is used as protective agent against 
mutagenesis. Several epidemiological studies have indicated that increased 
intake of foods, rich in carotenoids, is related to a reduced incidence of various 
types of cancers [5-8]. 
Curcumin (diferuioylmethane) is the major constituent of turmeric, a spice used 
in Indian dishes, which is isolated from the rhizomes of the curcuma longa linn. It 
has shown ant carcinogenic properties in animal and cell models. It has been 
reported to inhibit tumors of skin, fore stomach and colon in animals [9-12] and 
mammary tumor genesis in rats [13]. The anti-inflammatory and antioxidant 
properties of curcumin are known for a long time [14]. Ascorbic acid has been 
shown to posses antimutagenic and anticiastogenic properties against a number 
of chemicals in variety of systems including man [15-18] 
Flavonoids have been reported possess clinical and antitumorigenic properties 
[19-20]. In addition to the beneficial properties, in vitro data have indicated that 
some dietary compounds such as genistein at high concentrations produce 
cytotoxicity. 
In the present study, we have evaluated the antigenotoxic properties of these 
phytoproducts at two different doses against hydrocortisone-induced 
genotoxicity. 
2. Materials and methods 
2.1. Chemicals 
Chemicals 
1 .Hydrocortisone 
2. Carotenoid (B-carotene) 
3. Curcumin 
4. Ascorbic acid 
5. Flavonoid (genistein) 
6. DMSO 
Doses/ml 
138 ^ M 
0.5 ^M, 0.7 ^ M 
15^M,25^M. 
60 ^M, 80 i^M 
25 ^M, 40 ^ M 
64|iM 
Source 
Sigma, St. Louis, MO 
Sigma, St. Louis, MO 
Sigma, St. Louis, MO 
Xoche India Ltd. 
Sigma, St. Louis, MO 
Sigma, St. Louis, MO 
2.2. Chromosomal aberration analysis 
Metaphase chromosome analysis for the detection of CAs was performed by 
using the technique of Moorehead et.al. [21]. Human lymphocyte cultures were 
set by adding 0.5 ml of whole blood (from two adult and healthy donors, 
occupationally not exposed to mutagens) to 4.5 ml of RPMI 1640 (Gibco, USA), 
antibiotics (Penicillin and streptomycin 100 lU/ml each; Hoechst) and L. 
Glutamine (1 mM; Gibco, USA). Lymphocytes were stimulated by adding 0.1 ml 
of phytohaemagglutinin - M (PHA - M, Gibco). The culture were incubated at 
37"C with 5% CO2 for 72 hours in dark. Hydrocortisone at a final concentration of 
138 nM was added at 0 hour and kept for 24, 48 and 72 hours of duration, which 
served as positive control. Subsequently, carotenoid, curcumin, ascorbic acid and 
flavonoid were added in their respective concentrations along with hydrocortisone 
and the cultures were kept for 24, 48 and 72 hours. Ascorbic acid was obtained 
from synthetic sodium salt of L - ascorbic acid manufactured by Roche India Ltd 
with trade name Redoxon. Solutions of Carotenoids, curcumin and flavonoids 
were prepared in DMSO and prepared at two different concentrations as shown 
above. These chemicals were added separately in parallel cultures along with 
hydrocortisone. 
In the metabolic activation experiments two different concentrations of 
carotenoid, curcumin, ascorbic acid flavonoid and single concentration of 
hydrocortisone were treated along with S9 mix (0.8 ml) in cultures. Liver S9 
fraction was prepared from Swiss albino healthy rats (wistar strain) each weighing 
about 200g. The rats were given 0.1% of phenobarbitone (Img/ml) in drinking 
water for one week for the induction of liver enzymatic activities. The Sg mix 
was freshly prepared as per the standard procedures of Maron and Ames [22]. The 
animals were sacrificed and livers were obtained immediately. The liver slices 
were carefully homogenized at 4°C in 25 JJ,M phosphate buffer (pH 7.2) 
containing 27 |iM KCl and 2\[iM MgCb. The homogenate was centrifugated at 
4°C for 10 min at 9000 rpm. The supernatant (Sg) was stored at - 194°C until 
used. The S9 fraction was complemented by the addition of 5 |aM NADP and 10 
^M glucose -6- phosphate just before use. After 6 hours of incubation the cells 
were collected by centrifugation and the pellets were washed twice in prewarmed 
(37°C) medium to remove the drug and S9 mix and reincubated for 24 hours in 
fresh medium supplemented with antibiotic and fetal calf serum. Parallel 
cultures receiving same concentrations of different phytoproducts for similar 
treatment duration without S9 mix were simultaneously set for comparison. 
Colchicine (0.20 |ig/ml, Micro lab) was added to the cultures, 2.5 hours prior to 
harvesting. The cells were collected by centrifugation (10 min, 1200 rpm), hypo 
tonic treatment (0.075 KCl) was given for 10-12 min at BV'^ C and the recollected 
cells after centrifiigation were fixed in methanol: acetic acid (3:1). For 
metabolic activation experiments, DMSO and hydrocortisone were used as 
negative and positive controls, respectively. Preparation of slides, staining and 
scanning was done under code. A total of 300 well - spread metaphases were 
analysed per treatment per duration for all types of chromatid and chromosome 
type of aberrations. Aberrations were scored as per Hundal et al [23] and Bali et 
al [3]. 
2.3. Sister chromatid exchange analysis 
Analysis of SCE was carried out following the fluorescent plus Giemsa technique 
[24-25]. The cells in the cultures were exposed to 5-bromo-2 - deoxyuridine 
(BrdU 2p,g/ml; Sigma) after 24 hours of initiation of culture. The test compounds 
with same concentrations as in the case of CA analysis were added together with 
the BrdU. To minimize photolysis of Brdu another 48 hours cultures were 
maintained in the dark. Hydrocortisone (50^g/mI) and DMSO (5^g/ml) were 
used as positive and negative controls respectively. 
For SCE analysis in the presence of metabolic activation system, the phytoproducts 
along with S9 mix were added into the cultures after 48 hours of its initiation and 
reincubated at 37°C. After 90min. of this pulse treatment the cells were spun 
down and the supernatant discarded. The cells were washed twice to remove 
any traces of the steroid, phytoproducts and the liver metabolites. Finally the cell 
pellets were resuspended in fresh medium supplemented with fetal calf serum, 
antibiotics and BrdU, and kept for another 24 hours in the dark at 37°C. For 
comparison parallel cultures without S9-mix were also set simultaneously. 
One day old slides were stained in Hoechst 33258 stain (Sigma 0.5 iig/ml), exposed 
to UV lamp (254nm) for 30 min. and incubated in 2X SSC (0.3 M NaCl, 0.03M 
Sodium citrate; pH 7.0) at 60°C for 90 min and stained for sister chromatids. 
The slides were coded prior to scoring and 50 well- spread metaphase cells were 
scanned per concentration and the number of exchange scored [3,23]. 
2.4. Cell cycle kinetics 
Cells undergoing l''(Mi), 2"'' (M2) and 3'^ '^  (M3) metaphase divisions were 
detected with BrdU - Harlquin technique for differential staining of metaphase 
chromosome [26] by studying 200 metaphases for each concentration and 
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duration. The replication index (RI), an indirect measure of studying cell cycle 
progression, was calculated by applying the following formula [27] 
R l = Mixi+M2x2+M3x3 
100 
2.5. Slatistical analysis 
Student's two-tailed "t" test was used for calculating the statistical significance in 
CAs and SCEs, where as 2x3 chi- square test (x )^ was used to analyze the cell 
cycle kinetics. The level of significance was tested from standard statistical tables 
of Fisher and Yates [28]. 
3. Results 
The results of different treatments of the phytoproducts along with their respective 
controls are shown in table - 1 . 
3.T Analysis of chromosomal aberrations 
Cultures treated with hydrocortisone showed a high frequency of chromosomal 
aberrations i.e. (0.19, 0.21 and 0.54) per cell for three different durations (24,48 and 
72hr) of cultures when compared with controls (P<0.05). 
Vitamin C was most effective in reducing chromosomal aberrations amortg the 
phytoproducts used (Fig. 1). It reduced CAs by 32.5 % at 72 hr duration at a 
concentration of 80 |aM. The data obtained from the treatments of Vit C along with 
hydrocortisone were (0.13, 0.14 and 0.38) CAs per cell at the concentration of 60pM 
while (0.13,0.14and 0.35) CAs per cell at 80iaM concentration for 24,48 and 72 hr of 
durations respectively. 
The second most effective phytoproduct was curcumin. It reduced the CAs by 29 % at a 
concentration of 25 ^M in 72 hr cultures. With hydrocortisone, curcumin produced 
0.14,0.16 and 0.40 aberrations per cell at 15 jiM. where as it-produced 0.14,0.15 and 
0.30 aberrations at 25 \iM concentrations at culture durations of 24,48 and 72 hr 
respectively. 
Carotenoid and flavonoid were not much effective in reduction of CAs at tested 
concentrations. Carotenoid reduced CAs by 24 % at 0.7 |.iM and 19.16 % at 0.5 [iM 
concentration in 72 hr cultures. 
Flavonoid reduced CAs by 19.16 and 16.80 % at 40 ^M and 25 yM concentrations 
respectively. Reduction in CAs was dose dependent up to a certain concentration in all 
the phytoproducts tested. None of the phytoproducts reduced the chromosomal 
aberrations to the normal level. 
Similar trends were observed when treated with metabolic activation system (Fig 2). 
3.2 Analysis of sister chromatid exchanges 
Figure 3 &4 show the effect of ascorbic acid, curcumin, carotenoid and flavonoid in 
reducing SCE. Vit C was found to be most effective in reducing SCEs. It reduced SCEs 
about 33% at 80 i^M and 32% at 60 \xM concentration in 48 hr cultures. The SCEs 
produced by hydrocortisone was 4.40 per cell. When treated with Vit C along with 
hydrocortisone, the value of SCE decreased to 3.00 and 2.86 per cell at two different 
doses when time was kept constant at 48 hr. Curcumin was the next most effective 
phytoproduct which reduced the SCE level by 29.54% and 27.27% at two respective 
doses (15 ^M &25 fiM). The values per cell were 3.20 and 3.10 when treated along with 
hydrocortisone. 
The data obtained for carotenoid at 0.5 yM & 0.7 jaM was 3.52 and 3.30 per cell 
respectively and for flavonoid these values were 3.60 and 3.50 at 25 i^ M and 40 ^M 
respectively. Trends were similar with increasing effects when treated in the presence of 
metabolic activation system (Fig. 4). 
3.3. Analysis of cell cycle kinetics 
The replication indices were 1.48 for hydrocortisone and (1.60, 16.3), (1.64, 1.67), 
(1.70, 1.70) and (1.58, 1.61) for along with carotenoid (0.5 [iM & 0.7 |aM). 
curcumin (15 )LIM & 25 fiM), ascorbic acid (60 jiM &80 |JM) and flavonoid (25 
|uM & 40 |uM) respectively. These values were 1.47, (1.58, 1.60), (1.60,1.63), 
(1.64,1.65) and (1.54,1.59) in the presence of metabolic activation. We 
observed that all the phytoproducts are capable of increasing the RL Vit C at 
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concentrations 60 ^M & 80 |iM and curcumin at 25 )iM were capable of 
increasing it up to the level of normal (Table-2). Similar trends were observed 
with metabolic activation system (Table-3). 
4. Discussion 
4.1. The studies presented above lead to the follownng major conclusions: 
1. Curcumin, carotenoid, flavonoid and vit C are able to protect the genotoxic 
damage in human lymphocyte cultures. 
2. Vit C and curcumin are more effective in comparison to carotenoid and flavonoid. 
3. The order of activity noted was: vit C > curcumin > carotenoid > flavonoid. 
4. None of the above chemicals can completely reverse the genotoxic effects of 
hydrocortisone to normal level for SCE and CA. 
5. Ascorbic acid and curcumin is able to increase RI up to normal level. 
In earlier reports, it has been shown that hydrocortisone, used therapeutically 
for a number of reasons, induced CA and SCE in human lymphocyte cultures in 
presence or, in absence of metabolic activation system [29]. Its frequent usage 
may, therefore, produce significant genotoxic damage. Thus, the present study 
aimed to test the efficiency of different phytoproducts in preventing genotoxicity 
produced by hydrocortisone. 
Our resuhs indicate that the anticlastogenic action of the phytoproducts, used 
in the present study, increase up to a maximum level at their respective 
concentration, after which this effect was not observed. Therefore, we selected 
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two most- effective dosage of each phytoproduct and worked out in two different 
conditions i.e. in presence and absence of S9 mix. 
Curcumin tias been reported to possess antiproliferative and antioxidant 
property in human tumor cell cultures to prevent cancer in many animal models 
[30-32]. Thus, the use of curcumin or its related compounds in the diet can 
potentially decrease the susceptibility to cancer causing agents. Our findings also 
support this view. It decreases CA, SCE and enhances RI in hydrocortisone-
induced genotoxicity in human lymphocytes in vitro. This may be one of the 
reasons for the lower incidence of prostate cancer seen in Asians. 
The bioavailibility of curcumin has been shown to be low. Oral dosing of 
humans with 4 to 8 grams of curcumin showed plasma levels of about 0.41 to 
1.75 )iM. Such low plasma levels may not cause optimal chemo preventive 
effects. However, organs like liver and colon, which are more prominently 
exposed to curcumin and where its bioavailability is high, it can exert its local 
effects. The bioavailability of the metabolites of curcumin is of much therapeutic 
value [33]. However toxicologically, it is relatively inert and does not appear to 
be toxic to either animals or humans even at high doses [34]. Previous literature 
suggests that due to its insolubility, it cannot be administered intravenously. 
Though, there is one study in which the curcumin has been administered 
intravenously for the first time in animal model [35}. However, further studies are 
required to clarify the current aspect. Ascorbic acid has been shown to possess 
anti mutagenic and ant carcinogenic properties against number of chemicals. The 
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present study also suggests that vit C lowers the CA and SCE and enhances RI. It 
has been shown to exert genotoxic effects in certain system [36]. Wayner et.al 
[37] have shown the ant oxidation of ascorbic acid apart from its free radical 
trapping property. In this study we use only milder dosage of ascorbic acid 
eliciting its anticlastogenic effects in lymphocyte. 
Carrot juice, and probably P - carotene has been reported to have an inhibitory effect on 
the genotoxic activity of CP, possibly, by interfering with the enzymatic 
processes of its action [38,39]. Another mechanism of antimutagenesis 
proposed for (3 - carotene is through its antioxidant and free redical 
scavenging activity [40]. Plasma level of 0.4 \xM of [i - carotene has been 
correlated with reduced risk of various cancers [41]. The present study showed 
that p - carotene lower the CA, SCE and increase RI but the effect is poor. 
Flavonoid (genistein) may act as free radical scavenger and therefore, might react with 
carcinogenic metabolites before they reach the DNA and damage occurs. 
Genistein was reported to inhibit multiplication of numerous neoplastic cells, 
including those in breast [42]. In this study, genistein lower the values of CA, 
SCE and increases RI in hydrocortisone-induced genotoxicity, in the absence 
and in the presence of metabolic activation in culture. 
Above phytoproducts increase RI, especially ascorbic acid and curcumin enhances RI 
up to the normal level. This shows that administration of vit C and curcumin can 
revert the cell antiproliferative effects of hydrocortisone. 
14 
These results support the concept that the phytoproducts used in the present study may 
be used as chemo preventive agents in ameliorating the genotoxicity induced by 
steroidal drugs and other mutagens. Thus, these and other phytoproducts may be 
used as model for chemo preventive drug and may be exploited commercially 
for pharmaceutical purposes. 
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Table 1. Analysis of chromosomal aberrations after treatment with different 
phytoproducts in hydrocortisone induced cultures: 
Treatments 
Jlydrocortisone 
138 ^ iM 
Hyd+Ca, (0.5^M) 
Hyd+Ca2 (OJ^M) 
Hyd+Cui(15^M) 
Hyd +Cu2 (25|iM) 
Hyd+C, (60HM) 
C/2 
3 
O 
c 
_o 
0 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
24 
48 
T3 
1^ 
0 
EX 
• ) - ' 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
% Aberrations 
Metaphase 
DO 
16.00 
23.00 
39.70 
13.00 
18.50 
32.00 
12.00 
17.25 
30.00 
11.50 
17.00 
29.00 
11.33 
16.33 
28.33 
11.00 
16.00 
00 
W DO 
15.00 
20.00 
38.33 
12.00 
17.00 
29.50 
11.00 
15.00 
29.00 
10.50 
15.00 
28.00 
10.66 
14.25 
27.33 
10.35 
14.00 
Types 
(%) 
-0 
B 0 
0 
13.33 
12.70 
23.90 
10.50 
10.50 
19.00 
10.00 
9.50 
18.00 
10.00 
9.50 
17.50 
9.50 
9.00 
17.00 
9.00 
8.70 
of aberration 
0 
0 
S 0 
•^ 9, U S 
6.00 • 
8.33 
30.70 
5.00 
6.50 
24.70 
4.50 
6.50 
23.00 
4.35 
6.00 
22.50 
4.25 
6.00 
22.00 
4.00 
5.50 
13 
0 
19.33 
21.03 
54.40 
15.50 
17.00 
43.70 
14.50 
16.00 
41.00 
14.35 
15.50 
40.00 
13.75 
15.00 
39.00 
13.00 
14.20 
Aberrations /cell 
± Standard erroi 
0.19 ±0.03 
0.21 ±0.03 
0.54 ±0.05 
0.16 ±0.03 
0.17 ±0.03 
0.44 ± 0.05 
0.15 ±0.03 
0.16 ±0.03 
0.41 ± 0.05 
0.14 ±0.03 
0.16 ±0.03 
0.40 ±0.05 
0.14 ±0.03 
0.15 ±0.03 
0.39 ±0.03 
0.13 ±0.03 
0.14 ±0.03 
22 
Hyd +C2 (80|aM) 
Hyd +F, (25^M) 
Hyd +F2 (40^M) 
Control (DDH2O) 
DMSO 64 ^M 
72 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
27.50 
10.50 
15.00 
26.00 
13.33 
19.00 
33.00 
13.00 
18.50 
32.00 
2.80 
3.30 
26.00 
10.00 
13.50 
25.00 
12.50 
17.00 
32.00 
12.00 
17.00 
29.00 
2.00 
2.50 
16.50 
9.00 
8.50 
15.70 
11.00 
10.50 
19.70 
10.50 
10.50 
19.00 
1.70 
2.00 
21.30 
4.00 
5.30 
19.50 
5.00 
7.00 
25.50 
5.00 
6.50 
24.50 
1.00 
1.00 
37.70 
13.00 
13.80 
35.20 
16.00 
17.50 
45.20 
15.50 
17.00 
43.50 
2.70 
3.00 
0.38 + 0.03 
0.13 + 0.03 
0.14 ±0.03 
0.35 ±0.03 
0.16 ±0.03 
0.18 ±0.03 
0.45 ± 0.05 
0.16 ±0.03 
0.17 ±0.03 
0.44 ± 0.05 
0.03 ±0.01 
0.03 ±0.01 
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Table 2. Analysis of cell cycle kinetics after treatment with different 
phytoproducts in hydrocortisone induced cultures of 48 hours 
Treatment 
Hydrocortisone 
(138 ^M) 
Hyd+ Cai 
Hyd+Ca2 
Hyd+ Cui 
Hyd+Cu2 
Hyd+ C, 
Hyd+C2 
Hyd+ F, 
Hyd+F2 
Normal 
DM SO(-ve control) 
-a 
.—1 k i 
(D O 
200 
200 
200 
-200 
200 
200 
200 
200 
200 
200 
200 
Percent cells ir 
M, 
56 
49 
47 
47 
45 
43 
42 
50 
48 
44 
43 
M2 
40 
42 
43 
42 
43 
44 
45 
42 
43 
40 
37 
1 
M3 
04 
09 
10 
11 
12 
13 
13 
08 
09 
16 
20 
Replication 
Index (Rl) 
1.48 
1.60 
1.63 
1.64 
1.67 
1.70 
1.70 
1.58 
1.61 
1.72 
1.77 
2x3 Chi square 
Test 
Significant 
Significant 
Significant 
Significant 
Not significant 
Not significant 
Not significant 
Significant 
Significant 
Normal 
24 
Table 3, Analysis of cell cycle kinetics after treatment with different 
phytoproducts in hydrocortisone induced cultures of 48 hours in presence of Sg -
mix. 
Treatment 
Hydrocortisone 
(138 ^M) 
Hyd+ Ca, 
Hyd+Ca2 
Hyd +Cui 
Hyd +Cu2 
Hyd+C, 
Hyd+C2 
Hyd+ F| 
Hyd+F2 
Normal 
DM SO (-ve control) 
=2 -a 
o 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
Percent cells in 
M, 
58 
51 
50 
49 
47 
46 
45 
53 
50 
46 
47 
M2 
37 
40 
40 
42 
43 
44 
45 
40 
41 
38 
40 
M3 
05 
09 
10 
9 
10 
10 
10 
07 
09 
16 
13 
Replication 
Index (RI) 
1.47 
1.58 
1.60 
1.60 
1.63 
1.64 
1.65 
1.54 
1.59 
1.70 
1.66 
2x3 Chi square 
Test 
Significant 
Significant 
Significant 
Significant 
Not significant 
Not significant 
Not significant 
Significant 
Significant 
Normal 
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chromosomal aberrations induced by hydrocortisone in 72 h cultures. 
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CURCUMIN AS AN ANTIGENOTOXIC 
AGENT AGAINST NORGESTREL 
INDUCED CHROMOSOMAL 
ABERRATIONS 
MD. SULTAN AHMAD, SHEEBA and M. AFZAL 
Section of Genetics, Department of Zoology, 
Aligarh Muslim University, 
Aligarh-202 002 (U.P.). 
A large number of chemical mutagens find their 
way into human bodies, essentially through drugs and 
constituents of dietary regimens, having little or no 
alternative left thereof. These chemical agents, either 
natural or synthetic, induce changes in genetic material 
either directly or indirectly and thought to contribute to 
the risk of cancer. Most of these chemicals have exhibited 
carcinogenic and mutagenic properties in animal models 
in varieties of short-term tests. Since it is difficult to avoid 
taking these mutagens, a potentially important area of 
research is to develop dietary strategies to prevent the 
genotoxic effects of these chemicals. 
In this regard, authors tested the antigenotoxic action 
of Curcumin (diferuloylmethane) on Norgestrel induced 
genotoxicity in human lymphocyte cultures, with and 
without metabolic activation system (S, mix). 
Chromosomal aberrations (CAs) were taken as parameter 
of genotoxic damage. Norgestrel is a synthetic 
progesterone, widely used as oral contraceptive and shows 
genotoxic effects. The concentrations of Norgestrel used 
were 25ng/ml and 50ng/ml for 48 hr and 72hr. Curcumin 
is a major constituent of turmeric and is isolated from 
Table 1. Effect of Curcumin on chromosomal aberrations induced by Norgestrel in human lymphocyte cultures. 
Treatment 
Norgestrel 
(^g/ml) 
Norgestrel+ 
Curcumin 
Norgestrelf 
Curcumin 
Control 
(-ve control) 
25 
50 
25+C, 
25+C2 
50+C, 
50+C, 
Normal 
DMSO (5\x\lm\) 
(+ve control) 
CP (IxlO-'M) 
Metabolic 
Activation 
-s, 
+s, 
-s, 
+s, 
-s, 
+s, 
-s. 
+s, 
-s, 
+s. 
-s. 
+s, 
-s, 
+s, 
-s, 
+S' 
-s, 
+s, 
1 
Including 
gap 
34.02 
36.00 
40.67 
52.32 
32.60 
35.32 
30.30 
33.80 
31.50 
35.20 
32.00 
36.25 
3.67 
4.00 
4.33 
4.50 
28.67 
32.50 
% Abberation 
Metaphase 
; Excluding 
gap 
32.00 
34.00 
38.00 
43.70 
31.30 
33.75 
29.52 
31.70 
30.00 
32.75 
30.25 
34.72 
2.33 
2.00 
1.67 
2.00 
27.33 
30.55 
Chromatid 
32.00 
34.10 
34.33 
37.25 
27.25 
30.00 
25.50 
27.20 
28.50 
31.75 
27.20 
30.00 
3.00 
3.50 
3.00 
2.50 
39.00 
45.20 
TVpes of 
Abberation% 
Chromosome 
14.00 
14.09 
20.33 
22.50 
16.75 
18.25 
15.00 
17.30 
17.50 
19.25 
17.80 
20.00 
0.33 
0.50 
0.67 
1.00 
27.67 
32.50 
Total 
46.00 
48.21 
54.66 
59.75 
44.00 
48.25 
40.50 
44.50 
46.00 
51.00 
45.00 
50.00 
3.33 
4.00 
3.67 
3.50 
66.67 
77.70 
Abberation/ 
Cell ± SE 
0.14±0.02 
0.15±0.03 
0.55+0.04 
0.60±0.05 
0.44±0.04 
0.48±0,04 
0.41±0.04 
0.45±0.04 
0.46±0.04 
0.51±0.04 
0.45±0.04 
0.50±0.04 
0.03+0.026 
0.04±0.028 
0.04±0.027 
0.04±0.03 
0.67±0.07 
0.78±0.10 
No. of Metaphase Scanned - 300 in all cases; CP : Cyclophosphamide; DMSO : Dimethylsulphoxide. 
C : 15 nM Curcumin; C : 25 \M Curcumin. 
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rhizomes of the Curcuma longa Linn, plant. The median 
antigenotoxicity concentrations for Curcumin in culture 
were 15nM and 25pM for 48hr and 72hr of incubation. 
Dimethylsulphoxide (concentration 5ng/ml) and 
Cyclophosphamide (concentration lxlO"'M) were added 
to the culture as negative and positive control respectively. 
Metaphase chromosome analysis was performed by 
culturing human lymphocytes, following the techniques 
of Moorehead et al. 1960. Cultures were set up by adding 
0.5 ml of whole blood from two healthy adult female 
donors who were occupationally not exposed to mutagens. 
In metabolic activation experiments, different 
concentrations of Norgestrel and Curcumin were treated 
alongwith S, mix (0.8ml) in cultures. Liver S, fractions 
were prepared from Swiss albino rats (Wistar strain) as 
per the standard procedure of Maron & Ames (1983). 
A total of 300 well spread metaphases were analyzed 
per treatment per duration for all types of chromatid and 
chromosome type aberrations. Chromosomal aberrations 
were scored as per Hundal et al. (1997) and Bali et al. 
(1990). Student's two-tailed't' test was used for calculating 
the statistical significance in chromosomal aberrations. 
Results in Table 1 indicate that Curcumin is a potent 
antigenotoxic agent against Norgestrel induced 
chromosomal aberrations. Curcumin when treated in 
different concentrations also showed effective inhibition 
of chromosomal aberrations with metabolic activation 
system. These results support the concept that dietary 
supplement of certain herbal products could reduce the 
risk of cancerous tumors in human beings. 
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Abstract: In earlier reports, hydrocortisone administration to human lymphocytes in culture was shown to cause 
chromosomal aberrations and increased sister chromatid exchanges. With a view to study the ameliorative 
action of some antioxidants against this effect, vitamins C and E were used separately and in combination along 
with hydrocortisone treatment, at different dosage and for different durations, on human lymphocyte cultures. 
The levels of chromosomal aberrations and sister chromatid exchanges were lowered, suggesting a protective 
role of vitamins against genotoxic damage. Administration of vitamins C and E combined appeared to be more 
effective in preventing chromosomal damage than separate administration, demonstrating the additive action of 
these vitamins against steroid-induced genotoxicity. 
Key words: Hydrocortisone, vitamin C, vitamin E, chromosomal aberrations, sister chromatid exchange 
Introduction 
Steroids are active biological agents that function as 
natural hormones, chemical ligands, and precursors for 
endogenous synthesis of other chemicals. Steroidal hor-
mones and their synthetic derivatives perform their func-
tions by forming steroid receptor complexes that bind with 
DNA and influence gene expression [1,2]. In spite of their 
therapeutic use, there are many reports indicating their mu-
tagenic, carcinogenic, clastogenic, and teratogenic effect 
[3]. Hydrocortisone is a potent steroidal drug used thera-
peutically for a number of reasons. It is a potent gluco-
corticoid used primarily for ameliorating severe inflam-
mation, allergic reaction in shock syndromes, neoplasia, 
and adrenal insufficiency [4], Hydrocortisone induces 
chromosomal aberrations and sister chromatid exchanges 
in human lymphocyte chromosomes, with and without 
metabolic activation [5, 6]. Vitamins act as antioxidants 
and free radical scavengers, thereby acting as anticar-
cinogenic, anticlastogenic, and antimutagenic agents. Of 
these, vitamins C and E are among the best known anti-
oxidants used in in vivo animal models [7]. In this paper, 
we present the effects of vitamins C and E on human lym-
phocyte chromosomes treated with hydrocortisone. 
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Materials and Methods 
The details of the experimental design are as follows 
Treatments Dosage 
Controls 
1. Normal blood Nil 
2. Negative control 5 )Jg/mL 
(with DMSO) 
3. Positive control 1 x 1Q-^  M 
(Cyclophosphamide) 
Vitamins used 
4, Ascorbic Acid 
5. a-Tocopherol 
20 |ig/mL, 30 |ig/mL 
l5ng/mL, 20ng/mL 
Hydrocortisone + Vitamins 
6. Hydrocortisone+Ascorbic Acid 25 jag/mL + 20 |ag/mL 
50|ag/mL + 30fig/mL 
7. Hydrocortisone+a-locopherol 25 M-g/mL + 15 |Xg/mL 
50|ig/mL + 20|ig/mL 
Hydrocortisone + Combined Vitamins 
8. Hydrocortisone+Ascorbic Acid + a-tocopherol 
25 |ig/mL + 20 |ig/mL + 15 jig/mL 
50 |j.g/mL+30 )ig/mL + 20 |ig/mL 
Chromosomal aberration analysis 
Steroid treatment effects on metaphase 
Lymphocyte cultures were carried out in TC-199 medium 
(Flow Laboratories) supplemented with 15% fetal calf 
serum (Gibco), antibiotics (penicillin and streptomycin; 
100 lU/mL each, Hoechst) and L-Glutamine (1 mM, Gib-
co). Around 0.5 mL of heparinized whole blood taken from 
two healthy adult male donors (who were known to be oc-
cupationally unexposed) was added to 4 mL each of the 
medium. The lymphocytes were stimulated to divide by 
adding 0.1 mL of phytohemagglutinin - M (PHA M, Mi-
crolab) and incubated at 37°C with 5% CO2 for 72 hours, 
in the dark. Hydrocortisone at a final concentration of 25 
and 50 (a,g/mL, respectively, was added and kept for 24, 
48, and 72 hours of duration each by adding the hydro-
cortisone after 24 and 48 hours after initiation of cultures. 
Dimethylsulfoxide (DMSO; 5 [ig/mL, SRL, Bombay, In-
dia) was added to the simultaneously kept cultures for 72 
hours of incubation as negative control. The positive con-
trol cyclophosphamide (CP; lxIO-''M) was added and 
kept for 24, 48 and 72 hours of incubation. 
Vitamin treatment 
Synthetic sodium salt of L-ascorbic acid manufactured by 
Roche India Ltd., with the trade name Redoxon, was used 
at a concentration of 20 |ig/mL and 30 jig/mL per culture; 
the vitamin was used alone, along with steroid, and also 
concurrently with Vitamin E. 
The source of vitamin E was Ephynal, manufactured 
by Roche Chemicals and Pharmaceuticals, procured from 
the local market. The concentrations were 15 jig/mL and 
20 |ig/niL. The reason for choosing this combination of 
vitamins is that they are generally recommended by physi-
cians in the same qualitative and quantitative combination. 
Metabolic activation 
The same experiment was repeated under metabolic acti-
vation. In this series, six- to 30-hour-old cultures were 
treated with 25 and 50 Hg/mL concentrations of hydro-
cortisone in the presence of rat liver S9 microsomal frac-
tion. Liver S9 fraction was prepared from healthy albino 
rats induced with phenobarbital, and stored in liquid ni-
trogen until use. S9 was freshly prepared for use. The cells 
were collected after centrifugation and the pellets washed 
twice in the prewarmed medium to remove the chemical 
and the Sy mix. The parallel cultures receiving the same 
dose of the drug for similar duration but without S9 mix 
were also set simultaneously for comparison. 
Colchicine treatment (0.20 |J,g/mL, Microlab) was per-
formed prior to harvesting. The cells were recollected by 
centrifugation and fixed in methanol and acetic acid (3:1) 
for preparation of slides. Staining and scanning was done 
under code. A total of 150 well-spread metaphase plates 
were analyzed at treatment durafion for all types of chro-
matid and chromosome type of aberrations. For metabol-
ic activation, only 100 well-spread metaphase plates were 
analyzed. 
Sister Chromatid Exchange Analysis 
Analysis of sister chromatid exchanges (SCEs) was car-
ried out following fluorescent plus Giemsa techniques [8]. 
Cells were exposed to 5-Bromo-2 deoxyuridine (BrdU, 
2 ^g/mL Sigma) 24 hours after culture initiation. The test 
compounds were added together with BrdU, To minimize 
photolysis of BrdU, another set of cultures was maintained 
in the dark for 48 hours. 
For SCE analysis in the presence of metabolic activa-
tion, hydrocortisone plus the S9 mix was added into the 
culture 48 hours after initiation and reincubated at 37°C. 
After 90 minutes of treatment, the cells were spun down 
and the supernatant discarded. The cells were washed 
twice to remove traces of excess steroid and the liver 
metabolites. Finally the cells were resuspended in fresh 
medium supplemented with fetal calf serum, PHA-M, and 
BrdU, and cultured for another 24 hours in the dark at 
37°C. Parallel cultures were also set simultaneously with-
out adding S9 mix. Hoechst stain (0.5 |ig/mL, Sigma) was 
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used along with 10% Giemsa stain for differential stain-
ing of sister chromatids. The slides were coded prior to 
scoring and 50 well-spread metaphase cells were scanned 
per concentration and the number of exchanges scored. 
Hydrocortisone, vitamins plus hydrocortisone, and vita-
min treatments .separately were given as usual. 
Results 
The chromosomal aberrations calculated per cell show 
higher values in the steroid-treated cultures (2.'i and 
50 |ig/mL) at 24, 48, and 72 hours: (0.18.0.19.0.49) and 
(0.33,0.05,0.04) respectively. The values for normal con-
trols and negative controls (DMSO) were lower: 0.02 and 
0.02 aberrations (for 72-hour cullures only). The cyclo-
phosphamide (CP) treated group (positive control) showed 
values of 0.30, 0.41, and 0.68, respectively, for the 24-, 
48-, and 72-hour cultures. The differences between these 
values are statistically significant, showing that the steroid 
increased chromosomal aberrations with increasing dose 
concentration and duration of treatment. 
Vitamin C and E treatments, when admini.stered .sepa-
rately, were associated with values of 0.02 and 0.01 at 
20 |ig/mL and 30 |Jg/mL dosages, respectively for vita-
min E. it comes to 0.02 and 0.01 at 15 |ig/mL and 20 H-g/mL 
respectively for 72 hours culture, there being almost sim-
ilar effect. However, in the case of vitamins and steroids 
administered together, the chromosomal aberration scores 
were lower than those for steroids used alone. For Vita-
min C and hydrocortisone, these values were 0.12, 0.13, 
and 0.34 for different durations at the first concentration 
and 0.23, 0.03, and 0.03 at the second concentration. The 
values for vitamin E and hydrocortisone were slightly 
higher: 0.14,0.14,0.36 at the first concentration and 0.25, 
0.03 and 0.03 at the second concentration. The additive 
effect of vitamins C and E plus hydrocortisone resulted in 
values of 0.11, 0.11, 0.30 at the first concentration and 
0.22, 0.30 and 0.02 at the second concentration. When 
metabolic activation systems were used, we found the 
higher level of aberrations per cell in the presence of the 
Sg mix than cells cultured without the S9 mix, thus show-
ing that vitamins decrease the genotoxic effects of hydro-
cortisone even in the presence of metabolic activafion 
(Fig. 1 and 2). 
Sister Chromatid Exchange 
The number of SCEs in human lymphocytes following 
hydrocortisone treatment were 3.70 and 2.50 at two dif-
ferent concentrations, higher than the normal and DMSO 
control values of 1.70 and 1.80. For CP the exchanges were 
4.50 per cell. Vitamins reduced the SCE levels to 1.60 and 
1.54 (vitamin C) and 1.66 and 1.60 (vitamin E). The cells 
20 
18 
16 
14 
12 
10 
8 
6 
4 
2 
0 
• N 
• He 
D Hc+Vit.C 
aHc+Vit.E 
laHc+Vit.C+Vit.E 
Concentration 1 Concentration 2 
Fii^iiiv I: Additive effects of vitamins on chroniosoiiial aberra-
tion without Si) mix. 
• N 
• He 
a Hc+Vit.C 
Q He+Vit.E 
B Hc+Vit.C+Vit.E 
Concentration 1 Concentration 2 
Figure 2: Additive effects of vitamins on chromosomal aberra-
tion with S9 mix. 
N = Normal 
He = Hydrocortisone 
Hc+Vit.C = Hydrocortisone+Vitamin C 
Hc+Vit.E = Hydrocortisone+Vitamin E 
Hc+Vit.C+Vit.E = Hydrocortisone+Vitamin C+VitaminE 
treated with combined vitamins C and E, plus hydrocor-
tisone at two different concentradons, showed SCE val-
ues of 2.30 and 1.70 respectively. With the S9 mix treat-
ment, the trend is similar: the lowest value of SCE was 
1.50 for vitamin C alone and the highest value for CP was 
6.50. There is thus a distinct effect of vitamins of C and E 
separately and additively in bringing down the SCE lev-
el, the effect being statistically significant (Fig. 3 and 4). 
Discussion 
The field of antirnutagenesis is as old as Norvick and Szi-
lard [9| who developed this idea in their seminal contri-
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Figure 4: Additive effects of vitamins on sister chromatid ex-
change with metabolic activation. 
N = Normal 
He = Hydrocortisone 
Hc + Vit.C = Hydrocortisone + Vitamin C 
Hc+Vit.E = Hydrocortisone + Vitamin E 
Hc + Vit.C+Vit.E = Hydrocortisone + Vitamin C +Vitamin E 
bution to antigenotoxicity assays. Subsequently, mecha-
nisms were suggestedby a number of researchers [10,11]. 
Among antimutagens, vitamins occupy a principal place 
for their anticarcinogenic, anticlastogenic, and antimuta-
genic action, e.g. vitamin A [12, 13], vitamin B complex 
[14], riboflavin [15], thiamine [16] and most conspicu-
ously, vitamin C [13, 17] and vitamin E [18]. The effects 
of vitamins C and E in human lymphocyte chromosomes 
has been reported by Gebhart et al[\9]. Studying the chro-
mosome aberrations in the blood cells of coal tar workers, 
Sram et al [20] and Krishna el a/ [21] reported inhibition 
of sister chromatid exchanges in mice by cyclophos-
phamide and mitomycin treatment. Most of these studies 
show protective action of vitamin C and E against geno-
toxicity [22|. 
Few studies, however, report toxic effects of vitamins 
of C and E at high dosages [23]. Alberts et al [24] report-
ed potentiation of doxorubicin (DXR)-induced toxicity 
due to vitamin E. The conflicting reports in fact are relat-
ed to the mechanism of action and threshold values of both 
aberrations and concentrations of protective substances 
[25]. Most of these vitamins act as free radical scavengers 
and antioxidants [26, 27]. Wayner et al [28] have shown 
the antioxidation of vitamin C itself, apart from its radi-
cal trapping antioxidant property. Vitamin C increases pro-
duction of hydroxy! radicals for formation of hydrogen 
peroxide \'ia the Fenton reaction [23]. Our study uses on-
ly milder doses of vitamin C, eliciting its anticlastogenic 
effect in lymphocytes. The synergistic action of vitamins 
C and E has also been reported by Niki et al [29] and by 
Niki [30]. Lack of synergistic effect, however, has been 
reported by Renner [31] in combating genotoxicity. 
It has been suggested that ascorbic acid reduces toco-
pheroxyl radicals in vitro and thereby regenerates vitamin 
E. The tocopheroxyl radicals are produced by scavenging 
of free radicals by vitamin E during normal metabolism. 
This mechanism of tocopherol regeneration also links sol-
uble ascorbic acid to the protection of membranes against 
free radical damage. A synergistic relationship between 
ascorbic acid and vitamin E in vitro has been reported by 
Niki etal [32]. and Packer era/ [33]. Mulholland and Strain 
[34] have found little effect of large doses of alpha-toco-
pherol and ascorbic acid supplement action in young 
healthy volunteers using total radical trapping antioxidant 
potential (TRAP) levels in plasma. The lack of response, 
they argued, might in fact be due to high levels of dietary 
antioxidants already in the diet. Our study shows an ad-
ditive effect, rather than synergistic effect, which has been 
also noted by Loebitz et al [35]. Burton et al [36] have al-
so found a negligible effect studied in vivo, in the case of 
nonoxidatively stressed guinea pigs. The synergistic ac-
tion of tocopherol and ascorbic acid however resulted in 
an increase in total radical trapping antioxidant potential 
(TRAP) levels. Vitamin C is known to stimulate 7-hy-
droxylation of lipids and cholesterol rings, thus enhanc-
ing their biodegradation [37]. Most of these studies were 
performed in vivo in animal models. Our study empha-
sizes the additive action of these vitamins in human 
lymphocytes, with chroinosomal aberrations and SCE as 
genetic end points, and hence it may be suggested that 
these vitamins be used as antidotes to steroid-induced 
genotoxicity during hydrocortisone therapy. 
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